FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Kerbauy, LN
   Kerbauy, MN
   Bautzer, V
   Chapchap, EC
   de Mattos, VRP
   da Rocha, JDA
   Esteves, I
   Kutner, JM
   Kerbauy, FR
   Ribeiro, AAF
   Machado, CM
   Hamerschlak, N
   Santos, FPD
AF Kerbauy, Lucila Nassif
   Kerbauy, Mariana Nassif
   Bautzer, Vivien
   Chapchap, Eduardo Cerello
   Pinto de Mattos, Vinicius Renan
   Agnol da Rocha, Juliana Dall'
   Esteves, Iracema
   Kutner, Jose Mauro
   Kerbauy, Fabio Rodrigues
   Feitosa Ribeiro, Andreza Alice
   Machado, Clarisse Martins
   Hamerschlak, Nelson
   de Souza Santos, Fabio Pires
TI Severe hemorrhagic cystitis caused by the BK polyomavirus is associated
   with decreased survival post-allogeneic hematopoietic stem cell
   transplantation
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE allogeneic stem cell transplantation; BK virus reactivation; hemorrhagic
   cystitis; mortality
ID RISK-FACTORS; VIRUS-INFECTION; URINE SAMPLES; JC VIRUS; CIDOFOVIR;
   BLOOD; DNA; REACTIVATION; NEPHROPATHY; PREVENTION
AB Background BK polyomavirus reactivation can occur following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and may lead to hemorrhagic cystitis (BKPyV-HC). We hypothesized that development of BKPyV-HC is associated with increased mortality post allo-HSCT. Methods We retrospectively reviewed data on 133 adult patients (>= 18 years old) who underwent allo-HSCT from 2007 until 2014 at Hospital Israelita Albert Einstein in Sao Paulo, Brazil. Results Thirty-six patients presented with BKPyV-HC after a median time of 42 days, with a 1-year cumulative incidence probability of 28.9% (95% CI 21.5%-36.7%). In a multivariate Cox model, risk factors for development of BKPyV-HC included younger age, male sex, development of grade 2-4 acute graft-versus-host disease and recipients of umbilical cord blood grafts. Development of grade 3-4 BKPyV-HC (but not grade 1-2) was associated with a decreased overall survival (OS) in a multivariate Cox model (hazard ratio [HR] 7.51, P < 0.0001) and an increased risk of TRM (HR 3.66, P < 0.0001). Grade 3-4 BKPyV-HC was also associated with an increased risk of relapse that did not reach statistical significance (HR 3.01, P = 0.07). Median overall survival (OS) post-BKPyV-HC was 4.7 months, and cidofovir had no impact on survival. Conclusion Development of BKPyV-HC appears to be associated with decreased survival following allo-HSCT.
C1 [Kerbauy, Lucila Nassif; Kerbauy, Mariana Nassif; Bautzer, Vivien; Chapchap, Eduardo Cerello; Pinto de Mattos, Vinicius Renan; Agnol da Rocha, Juliana Dall'; Esteves, Iracema; Kutner, Jose Mauro; Kerbauy, Fabio Rodrigues; Feitosa Ribeiro, Andreza Alice; Hamerschlak, Nelson; de Souza Santos, Fabio Pires] Hosp Israelita Albert Einstein, Ctr Hematol & Oncol Familia Dayan Daycoval, Dept Hematol & Stem Cell Transplantat, Ave Albert Einstein 627-701,Bloco A,3o Subsolo, Sao Paulo, SP, Brazil.
   [Machado, Clarisse Martins] Hosp Israelita Albert Einstein, IIEP, Sao Paulo, Brazil.
   [Machado, Clarisse Martins] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
RP Santos, FPD (corresponding author), Hosp Israelita Albert Einstein, Ctr Hematol & Oncol Familia Dayan Daycoval, Dept Hematol & Stem Cell Transplantat, Ave Albert Einstein 627-701,Bloco A,3o Subsolo, Sao Paulo, SP, Brazil.
EM santos.fabio2@einstein.br
RI Kerbauy, Mariana/AAW-6720-2020
OI Kerbauy, Mariana Nassif/0000-0002-4441-9212
CR Abudayyeh A, 2016, AM J TRANSPLANT, V16, P1492, DOI 10.1111/ajt.13635
   Abudayyeh A, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12632
   Aksenova M, 2015, PEDIATR TRANSPLANT, V19, pE29, DOI 10.1111/petr.12411
   APPERLEY JF, 1987, TRANSPLANTATION, V43, P108, DOI 10.1097/00007890-198701000-00024
   ARTHUR RR, 1986, NEW ENGL J MED, V315, P230, DOI 10.1056/NEJM198607243150405
   BEDI A, 1995, J CLIN ONCOL, V13, P1103, DOI 10.1200/JCO.1995.13.5.1103
   Behzad-Behbahani A, 2004, J CLIN VIROL, V29, P224, DOI 10.1016/S1386-6532(03)00155-0
   Bogdanovic G, 2004, J CLIN MICROBIOL, V42, P5394, DOI 10.1128/JCM.42.11.5394-5396.2004
   Cesaro S, 2013, BONE MARROW TRANSPL, V48, P809, DOI 10.1038/bmt.2012.247
   Cesaro S, 2018, J ANTIMICROB CHEMOTH, V73, P12, DOI 10.1093/jac/dkx324
   Cesaro S, 2009, CLIN INFECT DIS, V49, P233, DOI 10.1086/599829
   CHESTERS PM, 1983, J INFECT DIS, V147, P676, DOI 10.1093/infdis/147.4.676
   COX DR, 1972, J R STAT SOC B, V34, P187
   DROLLER MJ, 1982, UROLOGY, V20, P256, DOI 10.1016/0090-4295(82)90633-1
   Dropulic LK, 2008, BONE MARROW TRANSPL, V41, P11, DOI 10.1038/sj.bmt.1705886
   Egli A, 2009, J INFECT DIS, V199, P837, DOI 10.1086/597126
   GARDNER SD, 1971, LANCET, V1, P1253
   Gilis L, 2014, BONE MARROW TRANSPL, V49, P664, DOI 10.1038/bmt.2013.235
   GOUDSMIT J, 1982, J MED VIROL, V10, P91, DOI 10.1002/jmv.1890100203
   Hayden RT, 2015, TRANSPL INFECT DIS, V17, P234, DOI 10.1111/tid.12364
   Hirsch HH, 2003, LANCET INFECT DIS, V3, P611, DOI 10.1016/S1473-3099(03)00770-9
   Hwang YY, 2013, BONE MARROW TRANSPL, V48, P745, DOI 10.1038/bmt.2012.215
   Kondo M, 1998, BONE MARROW TRANSPL, V22, P995, DOI 10.1038/sj.bmt.1701482
   Kwon HJ, 2013, TRANSPL INFECT DIS, V15, P569, DOI 10.1111/tid.12136
   Latouche A, 2005, BIOMETRICAL J, V47, P807, DOI 10.1002/bimj.200410152
   Lee SS, 2015, KOREAN J INTERN MED, V30, P212, DOI 10.3904/kjim.2015.30.2.212
   Leung AYH, 2001, BLOOD, V98, P1971, DOI 10.1182/blood.V98.6.1971
   Lunde LE, 2015, BONE MARROW TRANSPL, V50, P1432, DOI 10.1038/bmt.2015.162
   Peterson L, 2016, INFECTION, V44, P483, DOI 10.1007/s15010-016-0872-4
   Philippe M, 2016, BIOL BLOOD MARROW TR, V22, P723, DOI 10.1016/j.bbmt.2015.12.009
   Ramos E, 2009, TRANSPLANTATION, V87, P621, DOI 10.1097/TP.0b013e318197c17d
   Reploeg MD, 2001, CLIN INFECT DIS, V33, P191, DOI 10.1086/321813
   Ruggeri A, 2015, TRANSPL INFECT DIS, V17, P822, DOI 10.1111/tid.12455
   Silva LD, 2010, HAEMATOL-HEMATOL J, V95, P1183, DOI 10.3324/haematol.2009.016758
   Sorror ML, 2014, J CLIN ONCOL, V32, P3249, DOI 10.1200/JCO.2013.53.8157
   Therneau T.M., 2000, MODELING SURVIVAL DA
   Uhm J, 2014, BONE MARROW TRANSPL, V49, P1528, DOI 10.1038/bmt.2014.181
   Verghese PS, 2009, PEDIATR TRANSPLANT, V13, P913, DOI 10.1111/j.1399-3046.2008.01069.x
   Wong ASY, 2007, CLIN INFECT DIS, V44, P830, DOI 10.1086/511863
NR 39
TC 2
Z9 2
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD OCT
PY 2019
VL 21
IS 5
AR e13101
DI 10.1111/tid.13101
EA AUG 2019
PG 8
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA JF4KI
UT WOS:000479865200001
PM 31054192
DA 2020-12-15
ER

PT J
AU de Souza, ABC
   da Silva, PM
   Silva, GF
   Simioni, AJ
   Zanetti, LP
   Moreno, JRD
   de Oliveira, LCS
   Colturato, I
   Franceschi, FLD
   dos Santos, ACF
   Adati, EM
   de Souza, MP
   Colturato, VAR
   Machado, CM
AF de Souza, Anna Beatriz C.
   da Silva, Paula Moreira
   Silva, Gustavo Fernandes
   Simioni, Anderson Joao
   Zanetti, Lilian Perilio
   Do Prado Moreno, Juliana R.
   de Oliveira, Leila Cibele S.
   Colturato, Iago
   de Souza Franceschi, Fernada Leite
   Ferrari dos Santos, Ana Claudia
   Adati, Elen Monteiro
   de Souza, Mair Pedro
   Rensi Colturato, Vergilio Antonio
   Machado, Clarisse Martins
TI RSV infection in HSCT recipients: Experience from one single center
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 45th Annual Meeting of the
   European-Society-for-Blood-and-Marrow-Transplantation (EBMT)
CY MAR 24-27, 2019
CL Frankfurt, GERMANY
SP European Soc Blood & Marrow Transplantat
C1 [de Souza, Anna Beatriz C.; da Silva, Paula Moreira; Silva, Gustavo Fernandes; Simioni, Anderson Joao; Zanetti, Lilian Perilio; Do Prado Moreno, Juliana R.; de Oliveira, Leila Cibele S.; Colturato, Iago; de Souza Franceschi, Fernada Leite; Ferrari dos Santos, Ana Claudia; Adati, Elen Monteiro; de Souza, Mair Pedro; Rensi Colturato, Vergilio Antonio; Machado, Clarisse Martins] Amaral Carvalho Fdn, Jau, Brazil.
   [Machado, Clarisse Martins] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUL
PY 2019
VL 54
SU 1
MA P412
BP 410
EP 411
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA JA3GL
UT WOS:000487707800511
DA 2020-12-15
ER

PT J
AU Yoshikawa, FSY
   Pietrobon, AJ
   Branco, ACCC
   Pereira, NZ
   Oliveira, LMD
   Machado, CM
   Duarte, AJD
   Sato, MN
AF Yamada Yoshikawa, Fabio Seiti
   Pietrobon, Anna Julia
   Calvielli Castelo Branco, Anna Claudia
   Pereira, Natalli Zanete
   da Silva Oliveira, Luanda Mara
   Machado, Clarisse Martins
   da Silva Duarte, Alberto Jose
   Sato, Maria Notomi
TI Zika Virus Infects Newborn Monocytes Without Triggering a Substantial
   Cytokine Response
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Zika virus; flavivirus; viral entry receptors; newborn; monocytes
ID PATTERN-RECOGNITION RECEPTORS; CLEC5A; CELLS; ACTIVATION; EXPRESSION;
   TARGET
AB Zika virus (ZIKV) is a clinically important flavivirus that can cause neurological disturbances in newborns. Here, we investigated comparatively the outcome of in vitro infection of newborn monocytes by ZIKV. We observed that neonatal cells show defective production of interleukin 1 beta, interleukin 10, and monocyte chemoattractant protein 1 in response to ZIKV, although they were as efficient as adult cells in supporting viral infection. Although CLEC5A is a classical flavivirus immune receptor, it is not essential to the cytokine response, but it regulates the viral load only in adult cells. Greater expression of viral entry receptors may create a favorable environment for viral invasion in neonatal monocytes. We are the first to suggest a role for CLEC5A in human monocyte infectivity and to show that newborn monocytes are interesting targets in ZIKV pathogenesis, owing to their ability to carry the virus with only a partial triggering of the immune response, creating a potentially favorable environment for virus-related pathologies in young individuals.
C1 [Yamada Yoshikawa, Fabio Seiti; Pietrobon, Anna Julia; Calvielli Castelo Branco, Anna Claudia; Pereira, Natalli Zanete; da Silva Oliveira, Luanda Mara; da Silva Duarte, Alberto Jose; Sato, Maria Notomi] Univ Sao Paulo, Fac Med, Inst Med Trop, Lab Invest Dermatol & Imunodeficiencias, Sao Paulo, Brazil.
   [Pietrobon, Anna Julia; Calvielli Castelo Branco, Anna Claudia; Pereira, Natalli Zanete; Sato, Maria Notomi] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, Sao Paulo, Brazil.
   [Machado, Clarisse Martins] Univ Sao Paulo, Inst Med Trop, Lab Virol, Sao Paulo, Brazil.
RP Sato, MN (corresponding author), Univ Sao Paulo, Sch Med, Inst Trop Med, Lab Dermatol & Immunodeficiencies, LIM-56,Ave Dr Eneas de Carvalho Aguiar 500,3rd Fl, BR-05403000 Sao Paulo, Brazil.
EM marisato@usp.br
RI da Silva Oliveira, Luanda Mara/E-7273-2013; Sato, Maria N/C-1196-2012;
   Yoshikawa, Fabio Seiti Yamada/F-3049-2014; Pereira, Natalli
   Zanete/U-7291-2019; Sato, Maria N/C-2853-2012
OI da Silva Oliveira, Luanda Mara/0000-0003-0903-8219; Sato, Maria
   N/0000-0002-7911-1824; Yoshikawa, Fabio Seiti
   Yamada/0000-0002-6112-7107; Pereira, Natalli Zanete/0000-0002-8875-9470;
   Pietrobon, Anna Julia/0000-0002-7969-8119
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2016/16840-6, 2016/09764-1]
FX This work was supported by the Sao Paulo Research Foundation (grants
   2016/16840-6 and 2016/09764-1).
CR Aarreberg LD, 2018, MBIO, V9, DOI 10.1128/mBio.00342-18
   Castillo JA, 2019, ARCH IMMUNOL THER EX, V67, P27, DOI 10.1007/s00005-018-0525-7
   Bakker ABH, 1999, P NATL ACAD SCI USA, V96, P9792, DOI 10.1073/pnas.96.17.9792
   Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008
   Bordi L, 2017, ADV EXP MED BIOL, V972, P61, DOI 10.1007/5584_2016_187
   Chen ST, 2008, NATURE, V453, P672, DOI 10.1038/nature07013
   Chen ST, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00356-3
   Chen ST, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002655
   Cheung R, 2011, J CLIN INVEST, V121, P4446, DOI 10.1172/JCI57682
   Dasari P, 2011, PEDIAT ALLERG IMM-UK, V22, P221, DOI 10.1111/j.1399-3038.2010.01091.x
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Foo SS, 2017, NAT MICROBIOL, V2, P1558, DOI 10.1038/s41564-017-0016-3
   Gaidt MM, 2016, IMMUNITY, V44, P833, DOI 10.1016/j.immuni.2016.01.012
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Henao-Mejia J, 2012, NAT IMMUNOL, V13, P321, DOI 10.1038/ni.2257
   Jiao QJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027646
   Jurado KA, 2017, NAT MICROBIOL, V2, P1460, DOI 10.1038/s41564-017-0049-7
   Kim SY, 2017, PHARMACEUTICALS-BASE, V10, DOI 10.3390/ph10020044
   Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009
   Lo YL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166474
   Lum FM, 2018, MSPHERE, V3, DOI [10.1128/mSphereDirect.00120-18, 10.1128/mspheredirect.00120-18]
   Mavigner M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao6975
   McGrath-Morrow SA, 2018, J BIOL CHEM, V293, P11772, DOI 10.1074/jbc.RA118.003589
   Michlmayr D, 2017, NAT MICROBIOL, V2, P1462, DOI 10.1038/s41564-017-0035-0
   Naveca FG, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760170542
   Nazmi A, 2014, VIRUS RES, V185, P32, DOI 10.1016/j.virusres.2014.03.013
   Neal JW, 2014, J INFECTION, V69, P203, DOI 10.1016/j.jinf.2014.05.010
   Netea MG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000661
   Nikitina E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092821
   Normann E, 2010, AM J REPROD IMMUNOL, V63, P66, DOI 10.1111/j.1600-0897.2009.00767.x
   Nowakowski TJ, 2016, CELL STEM CELL, V18, P591, DOI 10.1016/j.stem.2016.03.012
   Patel AA, 2017, J EXP MED, V214, P1913, DOI 10.1084/jem.20170355
   Perry H, 2017, BRIT MED BULL, V124, P157, DOI 10.1093/bmb/ldx038v1
   Plato A, 2015, SEMIN IMMUNOPATHOL, V37, P97, DOI 10.1007/s00281-014-0462-4
   ROTH P, 1992, J PEDIATR-US, V121, P285, DOI 10.1016/S0022-3476(05)81205-3
   Shan C, 2018, CELL HOST MICROBE, V24, P12, DOI 10.1016/j.chom.2018.05.021
   Slavica L, 2013, J LEUKOCYTE BIOL, V94, P1003, DOI 10.1189/jlb.1212617
   Sun XM, 2017, CELL REP, V21, P3471, DOI 10.1016/j.celrep.2017.11.087
   Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002
   Tappe D, 2016, MED MICROBIOL IMMUN, V205, P269, DOI 10.1007/s00430-015-0445-7
   Teng OIE, 2017, J VIROL, V91, DOI 10.1128/JVI.01813-16
   Torrentes-Carvalho A, 2009, MEM I OSWALDO CRUZ, V104, P1091, DOI 10.1590/S0074-02762009000800005
   Valero N, 2014, VIRAL IMMUNOL, V27, P151, DOI 10.1089/vim.2013.0123
   Waldorf KMA, 2018, NAT MED, V24, P368, DOI 10.1038/nm.4485
   Walter LT, 2018, MOL NEUROBIOL, V55, P1620, DOI 10.1007/s12035-017-0442-5
   Wang WB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02645-3
   Watson AA, 2011, J BIOL CHEM, V286, P24208, DOI 10.1074/jbc.M111.226142
   Wu MF, 2013, BLOOD, V121, P95, DOI 10.1182/blood-2012-05-430090
   Zhang Y, 2012, J LEUKOCYTE BIOL, V91, P189, DOI 10.1189/jlb.1010591
NR 50
TC 3
Z9 3
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 1
PY 2019
VL 220
IS 1
BP 32
EP 40
DI 10.1093/infdis/jiz075
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA IS7UF
UT WOS:000482354100007
PM 30785182
DA 2020-12-15
ER

PT J
AU Sabaini, CS
   Siminone, AJ
   da Silva, PM
   Zanetti, LP
   de Oliveira, LCS
   Souza, MDE
   Moreno, JP
   Franceschi, FS
   Colturato, I
   Souza, MP
   Colturato, VR
   Machado, CM
AF Sabaini, Carlos S.
   Siminone, Anderson J.
   da Silva, Paula M.
   Zanetti, Lilian P.
   de Oliveira, Leila C. S.
   de Oliveira e Souza, Marina
   Moreno, Juliana P.
   Franceschi, Fernanda S.
   Colturato, Iago
   Souza, Mair P.
   Colturato, Vergilio R.
   Machado, Clarisse M.
TI Influenza A and B infection are clinically similar in HSCT recipients
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 44th Annual Meeting of the
   European-Society-for-Blood-and-Marrow-Transplantation (EBMT)
CY MAR 18-21, 2018
CL Lisbon, PORTUGAL
SP European Soc Blood & Marrow Transplantat
C1 [Sabaini, Carlos S.; Siminone, Anderson J.; da Silva, Paula M.; Zanetti, Lilian P.; de Oliveira, Leila C. S.; de Oliveira e Souza, Marina; Moreno, Juliana P.; Franceschi, Fernanda S.; Colturato, Iago; Souza, Mair P.; Colturato, Vergilio R.; Machado, Clarisse M.] Amaral Carvalho Fdn, HSCT Program, Jahu, Brazil.
   [Machado, Clarisse M.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD SEP
PY 2018
VL 53
SU S
MA P570
BP 567
EP 568
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA JA3ES
UT WOS:000487702805114
DA 2020-12-15
ER

PT J
AU Colturato, I
   Moreno, JP
   Zanetti, LP
   de Oliveira, LCS
   Franceschi, FS
   Sabaini, CS
   dos Santos, ACF
   da Silva, PM
   de Souza, MP
   Colturato, VR
   Machado, CM
AF Colturato, Iago
   Moreno, Juliana P.
   Zanetti, Lilian P.
   de Oliveira, Leila C. S.
   Franceschi, Fernanda S.
   Sabaini, Carlos S.
   dos Santos, Ana Claudia F.
   da Silva, Paula M.
   de Souza, Mair P.
   Colturato, Vergilio R.
   Machado, Clarisse M.
TI Revisiting viral surveillance in haploidentical stem cell
   transplantation (haploSCT). A case-control study
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 44th Annual Meeting of the
   European-Society-for-Blood-and-Marrow-Transplantation (EBMT)
CY MAR 18-21, 2018
CL Lisbon, PORTUGAL
SP European Soc Blood & Marrow Transplantat
C1 [Colturato, Iago; Moreno, Juliana P.; Zanetti, Lilian P.; de Oliveira, Leila C. S.; Franceschi, Fernanda S.; Sabaini, Carlos S.; dos Santos, Ana Claudia F.; de Souza, Mair P.; Colturato, Vergilio R.; Machado, Clarisse M.] Amaral Carvalho Fdn, HSCT Program, Jahu, Brazil.
   [da Silva, Paula M.] Amaral Carvalho Fdn, HSCT, Jahu, Brazil.
   [Machado, Clarisse M.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD SEP
PY 2018
VL 53
SU S
MA P592
BP 585
EP 586
PG 2
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA JA3ES
UT WOS:000487702806002
DA 2020-12-15
ER

PT J
AU Campos, SV
   Souza, ACM
   Mello, LS
   Pereira, BBS
   Machado, CM
AF Campos, Silvia Vidal
   Souza, Ana Carolina M.
   Mello, Liliane S.
   Pereira, Barbara B. S.
   Machado, Clarisse M.
TI Cut-Off of COBAS (R) Ampliprep/COBAS (R) Taqman (R) CMV Test in
   Transplant Recipients Receiving Intermittent Ganciclovir (GCV)
   Prophylaxis
SO TRANSPLANTATION
LA English
DT Meeting Abstract
CT 27th International Congress of the Transplantation-Society (TTS)
CY JUN 30-JUL 05, 2018
CL Madrid, SPAIN
SP Transplantat Soc, Soc Espanola Trasplante, Soc Madrilena Trasplante
C1 [Campos, Silvia Vidal; Mello, Liliane S.] Sao Paulo Med Sch, Heart Inst Os, Lung Transplant Grp, Sao Paulo, Brazil.
   [Souza, Ana Carolina M.; Pereira, Barbara B. S.; Machado, Clarisse M.] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD JUL
PY 2018
VL 102
SU 7
MA C393.1
BP S98
EP S98
DI 10.1097/01.tp.0000542694.21180.a0
PG 1
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA GT5IP
UT WOS:000444541200163
DA 2020-12-15
ER

PT J
AU Darrigo, LG
   Carvalho, AMD
   Machado, CM
AF Darrigo, Luiz Guilherme, Jr.
   de Sant'Anna Carvalho, Alexandre Machado
   Machado, Clarisse Martins
TI Chikungunya, Dengue, and Zika in Immunocompromised Hosts
SO CURRENT INFECTIOUS DISEASE REPORTS
LA English
DT Review
DE Chikungunya; Zika; Dengue; Transplantation; Immunocompromised hosts;
   Arboviruses
ID VIRUS TRANSMISSION; TRANSPLANT RECIPIENTS; BLOOD-DONATIONS; LIVING
   DONOR; INFECTION; OUTBREAK; BRAZIL; AMERICA; VIREMIA; REGION
AB Purpose of Review Describe the characteristics of chikungunya, dengue, and Zika in transplant recipients and immunocompromised hosts.
   Recent Findings Stem cell/bone marrow grafts, organs, and blood transfusions can transmit CHIKV/DENV/ZIKV infections, which are clinically similar, resembling influenza-like illness. Laboratory confirmation is necessary. In the acute phase, RT-PCR is preferred. DENV and ZIKV serology may cross-react. Delayed engraftment and extended viruria is observed in ZIKV+/HSCT recipients, while longer viremia is observed in DENV+/HSCT patients. Arbovirus persistence in organ tissues is generally unknown. Vaccine development is in early stages for CHIKV/ZIKV. No data is available to recommend the licensed DENV vaccine in transplant recipients.
   Summary In endemic areas, the assessment of epidemiological risk is mandatory. Donor deferral for 120 days in suspected or confirmed ZIKV+ has been recommended, while CHIKV+ donors should wait 30 days. No deferral is recommended for DENV+ donors. CHIKV/DENV/ZIKV tests should be included in the differential of febrile neutropenia and other transplant syndromes. Reassessment of DENV serology is urgently needed. Prospective studies are necessary to determine the impact of CHIKV/DENV/ZIKV in this special population.
C1 [Darrigo, Luiz Guilherme, Jr.] Univ Sao Paulo, Ribeirao Preto Med Sch, Bone Marrow Transplant Unit, Ribeirao Preto, SP, Brazil.
   [de Sant'Anna Carvalho, Alexandre Machado; Machado, Clarisse Martins] Univ Sao Paulo, Inst Trop Med, Virol Lab, Av Dr Eneasde de Carvalho Aguiar 470,2nd Floor, BR-05403000 Sao Paulo, SP, Brazil.
   [Machado, Clarisse Martins] Amaral Carvalho Fdn, HSCT Program, Jahu, SP, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Inst Trop Med, Virol Lab, Av Dr Eneasde de Carvalho Aguiar 470,2nd Floor, BR-05403000 Sao Paulo, SP, Brazil.; Machado, CM (corresponding author), Amaral Carvalho Fdn, HSCT Program, Jahu, SP, Brazil.
EM clarimm@usp.br
RI Darrigo Junior, Luiz/A-2686-2019; JUNIOR, LUIZ GUILHERME
   DARRIGO/AAH-1776-2019
OI Darrigo Junior, Luiz/0000-0001-6007-8908; JUNIOR, LUIZ GUILHERME
   DARRIGO/0000-0001-6007-8908
CR Abdelnabi R, 2017, CURR OPIN VIROL, V24, P25, DOI 10.1016/j.coviro.2017.03.016
   Alfaro A, 2016, DENGUE GUIDELINES PA
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P609
   Appassakij H, 2014, TRANSFUSION, V54, P1945, DOI 10.1111/trf.12575
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Barzon L, 2017, EXPERT OPIN BIOL TH, V17, P1185, DOI 10.1080/14712598.2017.1346081
   Basile K, 2017, PATHOLOGY, V49, P698, DOI 10.1016/j.pathol.2017.08.002
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760
   Burt FJ, 2012, LANCET, V379, P662, DOI 10.1016/S0140-6736(11)60281-X
   Collucci C, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4560
   Couderc T, 2012, J INFECT DIS, V206, P851, DOI 10.1093/infdis/jis296
   Cox J, 2012, J VIROL, V86, P7637, DOI 10.1128/JVI.00534-12
   da Cunha RV, 2017, MEM I OSWALDO CRUZ, V112, P523, DOI 10.1590/0074-02760170044
   de Oliveira WK, 2016, MMWR-MORBID MORTAL W, V65
   Pereira BBSD, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12721
   Dias LL, 2012, TRANSFUSION, V52, P1667, DOI 10.1111/j.1537-2995.2012.03729.x
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Faria NR, 2016, PLOS CURRENTS OUTBRE
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Felix AC, 2017, J MED VIROL, V89, P1477, DOI 10.1002/jmv.24789
   Fernandes Paula Frassinetti Castelo Branco Camurca, 2017, World J Transplant, V7, P57, DOI 10.5500/wjt.v7.i1.57
   Gasperina DD, 2015, TRANSPL INFECT DIS, V17, P876, DOI 10.1111/tid.12453
   Girao ES, 2017, TRANSPL P, V49, P2076, DOI 10.1016/j.transproceed.2017.07.004
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Guilarde AO, 2008, J INFECT DIS, V197, P817, DOI 10.1086/528805
   Gupta RK, 2016, J CLIN EXP HEPATOL, V6, P59, DOI 10.1016/j.jceh.2016.01.005
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Heald-Sargent T, 2017, PEDIATR ANN, V46, pE428, DOI 10.3928/19382359-20171025-01
   Ikejezie J, 2017, AM J TRANSPLANT, V17, P1681, DOI 10.1111/ajt.14333
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Jimenez A, 2017, TRANSFUSION, V57, P2077, DOI 10.1111/trf.14252
   Keasey SL, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00036-17
   Kee ACL, 2010, EMERG INFECT DIS, V16, P1038, DOI 10.3201/eid1606.091115
   Kuehnert MJ, 2016, MMWR-MORBID MORTAL W, V65, P627, DOI 10.15585/mmwr.mm6524e2
   Lemant J, 2008, CRIT CARE MED, V36, P2536, DOI 10.1097/CCM.0b013e318183f2d2
   Levi JE, 2015, TRANSFUSION, V55, P961, DOI 10.1111/trf.12944
   Linnen JM, 2008, TRANSFUSION, V48, P1355, DOI 10.1111/j.1537-2995.2008.01772.x
   Machado CM, 2017, BLOOD ADV, V1, P624, DOI 10.1182/bloodadvances.2016003285
   Machado CM, 2016, TRANSPLANT INFECT, P129
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   Magnani DM, 2017, J VIROL, V91, DOI 10.1128/JVI.00867-17
   Mansuy JM, 2017, EMERG INFECT DIS, V23, P863, DOI 10.3201/eid2305.161631
   Mathew AJ, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0680-7
   McCarthy MK, 2016, FUTURE MICROBIOL, V11, P331, DOI 10.2217/fmb.15.147
   Morens DM, 2014, NEW ENGL J MED, V371, P885, DOI 10.1056/NEJMp1408509
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Nasim A, 2013, TRANSPL INFECT DIS, V15, P516, DOI 10.1111/tid.12114
   Nhan TX, 2014, EMERG INFECT DIS, V20, P1773, DOI 10.3201/eid2010.141060
   Nogueira ML, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14047
   Pandey N, 2015, ARCH VIROL, V160, P1463, DOI 10.1007/s00705-015-2410-6
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Petersen LR, 2012, TRANSFUSION, V52, P1647, DOI 10.1111/j.1537-2995.2011.03529.x
   Pierrotti LC, 2017, INT J INFECT DIS, V64, P96, DOI 10.1016/j.ijid.2017.09.009
   Powers AM, 2007, J GEN VIROL, V88, P2363, DOI 10.1099/vir.0.82858-0
   Prazeres J, 2016, BRAZIL JAMA OPHTHALM, V134, P529, DOI [10.1001/jamaophthalmol.2016.0267, DOI 10.1001/JAMA0PHTHALM0L.2016.0267]
   Punzel M, 2014, EMERG INFECT DIS, V20, P1366, DOI 10.3201/eid2008.140508
   Qing M, 2009, ANTIMICROB AGENTS CH, V53, P3226, DOI 10.1128/AAC.00189-09
   Raboni SM, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12700
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Rigau-Perez Jose G., 2001, American Journal of Tropical Medicine and Hygiene, V64, P67
   ROBINSON M C, 1955, Trans R Soc Trop Med Hyg, V49, P28, DOI [10.1016/0035-9203(57)90022-6, 10.1016/0035-9203(55)90080-8]
   Sabino EC, 2016, J INFECT DIS, V213, P694, DOI 10.1093/infdis/jiv326
   Salvador FS, 2015, TRAVEL MED INFECT DI, V2015, P1
   Schwartzmann PV, 2017, MAYO CLIN PROC, V92, P460, DOI 10.1016/j.mayocp.2016.12.019
   Shirley DAT, 2017, PEDIATR CLIN N AM, V64, P937, DOI 10.1016/j.pcl.2017.03.012
   Shukla S, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01685
   Silveira FP, 2016, J HEART LUNG TRANSPL, V35, P560, DOI 10.1016/j.healun.2016.03.010
   Simkins J, 2017, AM J TRANSPLANT
   Siu R, 2016, NEUROLOGY, V87, P1623, DOI 10.1212/WNL.0000000000003038
   Slavov SN, 2017, TRANSFUSION, V57, P2897, DOI 10.1111/trf.14322
   Styczynski J, 2017, BONE MARROW TRANSPL, V52, P1345, DOI 10.1038/bmt.2017.145
   Tan FLS, 2005, NEPHROL DIAL TRANSPL, V20, P447, DOI 10.1093/ndt/gfh601
   Thiery G, 2016, INTENS CARE MED, V42, P1485, DOI 10.1007/s00134-016-4364-x
   U. S. Department of Health and Human Services, 2016, REV REC RED RISK ZIK
   UNOS, 2016, GUID ORG DON TRANSPL
   US Department of Health and Human Services, 2016, GUID ZIK VIR ORG PRO
   Wang YM, 2016, ANTIVIR RES, V135, P81, DOI 10.1016/j.antiviral.2016.10.003
   Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
   Weerakkody RM, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-016-0428-y
   Weerakkody Ranga Migara, 2014, J Med Case Rep, V8, P378, DOI 10.1186/1752-1947-8-378
   WHO, 2009, DENG GUID DIAGN TREA
   WHO PAHO, 2017, DENG CAS AM, V2017, P1
   Wichmann O, 2017, VACCINE, V35, P5535, DOI 10.1016/j.vaccine.2017.08.066
   World Health Organization, 2016, WHO POS PAP JUL 2016, V30
NR 87
TC 13
Z9 14
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3847
EI 1534-3146
J9 CURR INFECT DIS REP
JI Curr. Infect. Dis. Rep.
PD APR
PY 2018
VL 20
IS 4
AR 5
DI 10.1007/s11908-018-0612-2
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA GB4RR
UT WOS:000429048900002
PM 29551005
OA Other Gold, Green Published
DA 2020-12-15
ER

PT J
AU da Silva, PM
   Simione, AJ
   Sona, BF
   Colturato, L
   Mauad, LMQ
   dos Santos, ACF
   Machado, CM
   Possani, VD
   Franceschi, FLD
   Sabaini, CS
   Colturato, VAR
   De Souza, MP
AF da Silva, Paula Moreira
   Simione, Anderson Joao
   Sona, Bruna Fernanda
   Colturato, Lag
   Queiroz Mauad, Lenira Maria
   Ferrari dos Santos, Ana Claudia
   Machado, Clarisse Martins
   Possani, Valquiria de Cassia
   de Souza Franceschi, Fernanda Leite
   Sabaini, Carlos Sitta
   Colturato, Vergilio A. R.
   De Souza, Mair Pedro
TI Use of Adhesive Tags as a Facilitating Tool in the Data Report of
   Chronic Gvhd in a HSCT Center Lacking Electronic Medical Records
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT Blood and Marrow Transplantion Tandem Meetings of the
   Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR) /
   American-Society-for-Blood-and-Marrow-Transplantation (ASBMT)
CY FEB 21-25, 2018
CL Salt Lake City, UT
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [da Silva, Paula Moreira; Simione, Anderson Joao; Sona, Bruna Fernanda; Colturato, Lag; Queiroz Mauad, Lenira Maria; Ferrari dos Santos, Ana Claudia; Possani, Valquiria de Cassia; de Souza Franceschi, Fernanda Leite; Sabaini, Carlos Sitta; Colturato, Vergilio A. R.; De Souza, Mair Pedro] Hosp Amaral Carvalho, BMT, Jahu, Brazil.
   [Machado, Clarisse Martins] Univ Sao Paulo, Sch Med, Trop Med, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2018
VL 24
IS 3
SU 1
MA 122
BP S108
EP S108
PG 1
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA FW7CE
UT WOS:000425476000126
DA 2020-12-15
ER

PT J
AU Palmieri, M
   Martins, VAD
   Sumita, LM
   Tozetto-Mendoza, TR
   Romano, BB
   Machado, CM
   Pannuti, CS
   Brandao, TB
   Ribeiro, ACP
   Correa, L
   Braz-Silva, P
AF Palmieri, Michelle
   de Oliveira Martins, Victor Adriano
   Sumita, Laura Masami
   Tozetto-Mendoza, Tania Regina
   Romano, Bruna Baraldi
   Machado, Clarisse Martins
   Pannuti, Claudio Sergio
   Brandao, Thais Bianca
   Prado Ribeiro, Ana Carolina
   Correa, Luciana
   Braz-Silva, Paulo Henrique
TI Oral shedding of human herpesviruses in patients undergoing
   radiotherapy/chemotherapy treatment for head and neck squamous cell
   carcinoma
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Human herpesviruses; Oral mucositis; Radiotherapy; Squamous cell
   carcinoma
ID HERPES-SIMPLEX-VIRUS; RECEIVING RADIOTHERAPY; CANCER-PATIENTS; MUCOSAL
   INJURY; LASER THERAPY; MUCOSITIS; INFECTION; PREVENTION; DNA;
   IDENTIFICATION
AB Opportunistic infections may affect the oral mucosa of patients undergoing radio/chemotherapy through exacerbation of oral mucositis. The aim of this study is to evaluate the oral shedding of all eight human herpesviruses and its possible association with oral mucositis.
   In this prospective cohort study, we analyzed oral rinse samples, collected weekly, from 20 patients during radiotherapy treatment. Serologic status to HSV1 and HSV2, EBV, CMV, and VZV in three different periods was performed by ELISA assay. PCR and enzymatic digestion was performed to detect HSV1, HSV2, EBV, CMV, VZV, HHV6, HHV7, and HHV8. Oral mucositis was evaluated according to the WHO criteria.
   Oral shedding of EBV, HHV6, and HHV7 was observed in all weeks of radiotherapy. Considering the episodes of shedding, the highest frequency was found in patients with EBV excretion (55.0%). No virus reactivation was observed by serological analysis. EBV oral shedding frequency was significantly higher than that of other viruses and showing a positive correlation with oral mucositis grade >= 2.
   There was a positive correlation between EBV oral shedding and oral mucositis grade >= 2, particularly after 3 weeks of radiotherapy, a period in which the severity of mucositis was statistically higher. These findings allow us to infer that the local inflammatory environment in mucositis grade >= 2 is more favorable for EBV replication.
   Mucositis is a frequent and important side effect of radio/chemotherapy treatment. Understanding the possible participation of viruses in the mechanism of this condition is important to develop strategies for treatment and prevention.
C1 [Palmieri, Michelle; de Oliveira Martins, Victor Adriano; Romano, Bruna Baraldi; Correa, Luciana; Braz-Silva, Paulo Henrique] Univ Sao Paulo, Sch Dent, Div Pathol, Dept Stomatol, Ave Prof Lineu Prestes,2227 Cidade Univ, BR-05508000 Sao Paulo, SP, Brazil.
   [Sumita, Laura Masami; Tozetto-Mendoza, Tania Regina; Machado, Clarisse Martins; Pannuti, Claudio Sergio; Braz-Silva, Paulo Henrique] Univ Sao Paulo, Inst Trop Med, Virol Lab, Ave Dr Eneas Carvalho Aguiar,470-Jd Amer, BR-05403000 Sao Paulo, SP, Brazil.
   [Brandao, Thais Bianca; Prado Ribeiro, Ana Carolina] Inst Canc Estado Sao Paulo Octavio Frias Oliveira, Div Dent, Ave Dr Arnaldo,251 Cerqueira Cesar, BR-01246000 Sao Paulo, SP, Brazil.
RP Braz-Silva, P (corresponding author), Univ Sao Paulo, Sch Dent, Div Pathol, Dept Stomatol, Ave Prof Lineu Prestes,2227 Cidade Univ, BR-05508000 Sao Paulo, SP, Brazil.
EM pbraz@usp.br
RI Ribeiro, Ana Carolina Prado/AAE-9336-2019; Correa, Luciana/H-3875-2012;
   Corr\\xc3\\xaaa, Luciana/U-3166-2019; Braz-Silva, Paulo
   Henrique/O-4344-2014; Brandao, Thais Bianca/H-4151-2018
OI Ribeiro, Ana Carolina Prado/0000-0002-0127-7998; Correa,
   Luciana/0000-0002-5774-0750; Braz-Silva, Paulo
   Henrique/0000-0002-1842-9521; Brandao, Thais Bianca/0000-0001-9128-3138
FU Conselho Nacional de Desenvolvimento Tecnologico (CNPq)National Council
   for Scientific and Technological Development (CNPq) [443004/2014-5];
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/04303-5,
   2015/03906-6]
FX The authors would like to thank financial support from Conselho Nacional
   de Desenvolvimento Tecnologico (CNPq; grant no. 443004/2014-5 and
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; grants no.
   2012/04303-5 and no. 2015/03906-6.)
CR AMBINDER RF, 1985, J CLIN MICROBIOL, V21, P353, DOI 10.1128/JCM.21.3.353-356.1985
   Andrews N, 2001, AUST DENT J, V46, P88, DOI 10.1111/j.1834-7819.2001.tb00562.x
   Bello-Silva MS, 2010, PHOTOMED LASER SURG, V28, P135, DOI 10.1089/pho.2008.2458
   Biganzoli P, 2010, J MED VIROL, V82, P1679, DOI 10.1002/jmv.21880
   Braz-Silva PH, 2006, DIAGN CYTOPATHOL, V34, P24, DOI 10.1002/dc.20380
   CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879
   Chen YK, 2011, EUR J CLIN MICROBIOL, V30, P753, DOI 10.1007/s10096-010-1148-z
   de Carvalho RR, 2010, LASER MED SCI, V25, P397, DOI 10.1007/s10103-009-0717-9
   de Lima AG, 2012, INT J RADIAT ONCOL, V82, P270, DOI 10.1016/j.ijrobp.2010.10.012
   Dougal G, 2013, CLIN EXP DERMATOL, V38, P713, DOI 10.1111/ced.12069
   Eduardo CD, 2014, LASER MED SCI, V29, P1517, DOI 10.1007/s10103-013-1311-8
   Eduardo CD, 2012, LASER MED SCI, V27, P1077, DOI 10.1007/s10103-011-1019-6
   Epstein JB, 2002, ORAL SURG ORAL MED O, V94, P712, DOI 10.1067/moe.2002.127585
   Fang FM, 2008, INT J RADIAT ONCOL, V72, P356, DOI 10.1016/j.ijrobp.2007.12.054
   JENSEN AB, 1994, ACTA ONCOL, V33, P487, DOI 10.3109/02841869409083923
   Johansson J, 2004, RADIOTHER ONCOL, V72, P129, DOI 10.1016/j.radonc.2004.03.018
   Johnson G, 2000, J CLIN MICROBIOL, V38, P3274, DOI 10.1128/JCM.38.9.3274-3279.2000
   Krause CE, 2015, ANAL BIOANAL CHEM, V407, P7239, DOI 10.1007/s00216-015-8873-1
   KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k
   Lalla RV, 2008, DENT CLIN N AM, V52, P1
   Correia AVL, 2015, SUPPORT CARE CANCER, V23, P2105, DOI 10.1007/s00520-014-2558-8
   Magalhaes IM, 2010, MEM I OSWALDO CRUZ, V105, P925, DOI 10.1590/S0074-02762010000700015
   Melkos A B, 2003, Clin Oral Investig, V7, P113, DOI 10.1007/s00784-003-0209-4
   Mohammed FF, 2012, HEAD NECK-J SCI SPEC, V34, P985, DOI 10.1002/hed.21848
   Mosel DD, 2011, ORAL DIS, V17, P550, DOI 10.1111/j.1601-0825.2011.01788.x
   Moslemi D, 2016, RADIOTHER ONCOL, V120, P13, DOI 10.1016/j.radonc.2016.04.001
   Sanchez PJM, 2012, PHOTOMED LASER SURG, V30, P37, DOI 10.1089/pho.2011.3076
   Nicolatou-Galitis O, 2006, SUPPORT CARE CANCER, V14, P753, DOI 10.1007/s00520-005-0006-5
   Nicolatou-Galitis O, 2001, J ORAL PATHOL MED, V30, P471, DOI 10.1034/j.1600-0714.2001.030008471.x
   Oakley C, 1997, ORAL SURG ORAL MED O, V84, P272, DOI 10.1016/S1079-2104(97)90342-5
   Parvathaneni U, 2012, J ONCOL, V2012, DOI 10.1155/2012/597467
   Pinheiro RD, 2013, REV SOC BRAS MED TRO, V46, P15, DOI 10.1590/0037-868217172013
   REDDING SW, 1990, ORAL SURG ORAL MED O, V69, P578, DOI 10.1016/0030-4220(90)90239-O
   Roizman Bernard, 1993, P1
   Ruping MJGT, 2011, SUPPORT CARE CANCER, V19, P1211, DOI 10.1007/s00520-010-0940-8
   Scully C, 2004, HEAD NECK-J SCI SPEC, V26, P77, DOI 10.1002/hed.10326
   Seoudi N, 2015, J ORAL MICROBIOL, V7, DOI 10.3402/jom.v7.27156
   Sonis SL, 2002, CRIT REV ORAL BIOL M, V13, P380, DOI 10.1177/154411130201300502
   Sonis ST, 2004, CANCER-AM CANCER SOC, V100, P1995, DOI 10.1002/cncr.20162
   Stona Priscila, 2014, Int J Clin Pediatr Dent, V7, P140, DOI 10.5005/jp-journals-10005-1252
   Tolentino ED, 2011, J APPL ORAL SCI, V19, P448, DOI 10.1590/S1678-77572011000500003
   Trotti A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8
   Tsao SW, 2012, SEMIN CANCER BIOL, V22, P137, DOI 10.1016/j.semcancer.2012.02.004
   van der Beek MT, 2012, BONE MARROW TRANSPL, V47, P1222, DOI 10.1038/bmt.2012.2
   Wagner EK, 1994, PATHOGENICITY HUMAN, P210
   Ward KN, 2005, J CLIN VIROL, V32, P183, DOI 10.1016/j.jcv.2004.11.008
   Yamamoto Y, 2014, J MED VIROL, V86, P505, DOI 10.1002/jmv.23782
   Zanin T, 2010, PHOTOMED LASER SURG, V28, P233, DOI 10.1089/pho.2008.2242
NR 48
TC 4
Z9 4
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1432-6981
EI 1436-3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD SEP
PY 2017
VL 21
IS 7
BP 2291
EP 2301
DI 10.1007/s00784-016-2022-x
PG 11
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA FD9CI
UT WOS:000407820000018
PM 27966015
DA 2020-12-15
ER

PT J
AU Pereira, BBSD
   Darrigo, LG
   Costa, TCD
   Felix, AC
   Simoes, BP
   Stracieri, AB
   da Silva, PM
   Mauad, M
   Machado, CM
AF de Souza Pereira, Barbara Brito
   Darrigo Junior, Luiz Guilherme
   de Mello Costa, Thalita Cristina
   Felix, Alvina Clara
   Simoes, Belinda P.
   Stracieri, Ana Beatriz
   da Silva, Paula Moreira
   Mauad, Marcos
   Machado, Clarisse M.
TI Prolonged viremia in dengue virus infection in hematopoietic stem cell
   transplant recipients and patients with hematological malignancies
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE dengue virus; hematological malignancies; HSCT; immunocompromised
   patients; prolonged viremia
ID HEMORRHAGIC-FEVER; SHOCK SYNDROME; DONOR; TRANSMISSION; DIAGNOSIS;
   SERIES; ADULTS
AB Fever, skin rash, headache, and thrombocytopenia are considered hallmarks of dengue infection. However, these symptoms are frequently observed in infectious and non-infectious complications of hematopoietic stem cell transplant recipients and oncohematological patients. Thus, laboratory confirmation of dengue is relevant for prompt intervention and proper management of dengue in endemic and non-endemic regions. Because no prospective study of dengue has been conducted in these populations, the actual morbidity and mortality of dengue is unknown. In the present series, we describe five cases of dengue in patients living in endemic areas, emphasizing the prolonged course of the disease and the occurrence of prolonged viremia.
C1 [de Souza Pereira, Barbara Brito; Felix, Alvina Clara; Machado, Clarisse M.] Univ Sao Paulo, Virol Lab, Inst Trop Med, Sao Paulo, Brazil.
   [Darrigo Junior, Luiz Guilherme; de Mello Costa, Thalita Cristina; Simoes, Belinda P.; Stracieri, Ana Beatriz] Univ Sao Paulo, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [da Silva, Paula Moreira; Mauad, Marcos; Machado, Clarisse M.] Amaral Carvalho Fdn, HSCT Program, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Inst Trop Med, Sao Paulo, SP, Brazil.
EM clarimm@usp.br
RI JUNIOR, LUIZ GUILHERME DARRIGO/AAH-1776-2019; Darrigo Junior,
   Luiz/A-2686-2019; Simoes, Belinda P/M-7469-2016
OI JUNIOR, LUIZ GUILHERME DARRIGO/0000-0001-6007-8908; Darrigo Junior,
   Luiz/0000-0001-6007-8908; 
CR Azevedo LS, 2007, TRANSPLANTATION, V84, P792, DOI 10.1097/01.tp.0000280547.91617.25
   Bandyopadhyay S, 2006, TROP MED INT HEALTH, V11, P1238, DOI 10.1111/j.1365-3156.2006.01678.x
   Centers for Disease Control and Prevention, EP DENG CDC
   Chacko B, 2004, TRANSPLANTATION, V77, P634, DOI 10.1097/01.TP.0000114608.44000.D7
   Costa SD, 2015, AM J TROP MED HYG, V93, P394, DOI 10.4269/ajtmh.15-0038
   Duran A, 2013, INVEST CLIN, V54, P299
   Maia SHF, 2015, REV SOC BRAS MED TRO, V48, P783, DOI 10.1590/0037-8682-0205-2015
   Fujimoto Denys Eiti, 2014, Rev. Bras. Hematol. Hemoter., V36, P115, DOI 10.5581/1516-8484.20140027
   Garcia JHP, 2006, TRANSPLANTATION, V82, P850, DOI 10.1097/01.tp.0000235151.60237.fe
   Guilarde AO, 2008, J INFECT DIS, V197, P817, DOI 10.1086/528805
   Kalayanarooj Siripen, 2011, Trop Med Health, V39, P83, DOI 10.2149/tmh.2011-S10
   Khan NA, 2008, ACTA TROP, V105, P39, DOI 10.1016/j.actatropica.2007.09.005
   Lee IK, 2008, AM J TROP MED HYG, V79, P149, DOI 10.4269/ajtmh.2008.79.149
   Lee Min-Sheng, 2006, Journal of Microbiology Immunology and Infection, V39, P121
   Levi JE, 2015, TRANSFUSION, V55, P961, DOI 10.1111/trf.12944
   Low JGH, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001191
   Machado CM, 2009, REV INST MED TROP SP, V51, P309, DOI 10.1590/S0036-46652009000600002
   Nasim A, 2013, TRANSPL INFECT DIS, V15, P516, DOI 10.1111/tid.12114
   Ng CFS, 2007, J CLIN VIROL, V40, P202, DOI 10.1016/j.jcv.2007.08.017
   Park SB, 2008, TRANSPL P, V40, P2431, DOI 10.1016/j.transproceed.2008.07.037
   Petersen LR, 2012, TRANSFUSION, V52, P1647, DOI 10.1111/j.1537-2995.2011.03529.x
   Neto RDP, 2013, REV SOC BRAS MED TRO, V46, P765, DOI 10.1590/0037-8682-1716-2013
   Prasad N, 2012, TRANSPL INFECT DIS, V14, P163, DOI 10.1111/j.1399-3062.2011.00699.x
   Punzel M, 2014, EMERG INFECT DIS, V20, P1366, DOI 10.3201/eid2008.140508
   Rajat Jhamb, 2010, Journal of Communicable Diseases, V42, P255
   Ramos-De La Medina A, 2011, GASTROENT HEPAT-BARC, V34, P243, DOI 10.1016/j.gastrohep.2011.01.012
   Renaud CJ, 2007, NEPHROLOGY, V12, P305, DOI 10.1111/j.1440-1797.2007.00785.x
   Rigau-Perez Jose G., 2001, American Journal of Tropical Medicine and Hygiene, V64, P67
   Ross TM, 2010, CLIN LAB MED, V30, P149, DOI 10.1016/j.cll.2009.10.007
   Sabino EC, 2016, J INFECT DIS, V213, P694, DOI 10.1093/infdis/jiv326
   Saigal S, 2013, LIVER TRANSPLANT, V19, P1413, DOI 10.1002/lt.23755
   Sharma SK, 2011, MEDITERR J HEMATOL I, V3, DOI 10.4084/MJHID.2011.039
   Tan FLS, 2005, NEPHROL DIAL TRANSPL, V20, P447, DOI 10.1093/ndt/gfh601
   Tomashek KM, 2016, INFECT DIS RELATED T
   Visuthranukul J, 2009, INFECT DIS REP, V1, DOI 10.4081/idr.2009.e3
   Wang SM, 2010, AM J TROP MED HYG, V83, P690, DOI 10.4269/ajtmh.2010.10-0117
   WHO, 2016, DENG SEV DENG
   Wiwanitkit V, 2010, EXPERT REV ANTI-INFE, V8, P841, DOI [10.1586/eri.10.53, 10.1586/ERI.10.53]
NR 38
TC 8
Z9 8
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD AUG
PY 2017
VL 19
IS 4
AR e12721
DI 10.1111/tid.12721
PG 5
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA FD0HG
UT WOS:000407219800021
PM 28475281
DA 2020-12-15
ER

PT J
AU Machado, CM
   Pereira, BBD
   Felix, AC
   Oliveira, MC
   Darrigo, LG
   de Souza, MP
   Paton, EJD
   Neves, F
   Colturato, VR
   Simoes, BP
AF Machado, Clarisse Martins
   de Souza Pereira, Barbara Brito
   Felix, Alvina Clara
   Oliveira, Maria Carolina
   Darrigo, Luiz Guilherme, Jr.
   de Souza, Mair Pedro
   de Alencar Paton, Eduardo Jose
   Neves, Fabia
   Colturato, Vergilio Rensi
   Simoes, Belinda Pinto
TI Zika and chikungunya virus infections in hematopoietic stem cell
   transplant recipients and oncohematological patients
SO BLOOD ADVANCES
LA English
DT Article
ID TIME RT-PCR; DENGUE; TRANSMISSION; MICRONESIA; BRAZIL
AB Aedes mosquitoes are well adapted in domestic environments and widespread in tropical regions. Since 2015, Brazil has been experiencing a triple epidemic of dengue (DENV), chikungunya (CHKV), and Zika (ZIKV) viruses. The last 2 viruses are likely following the path of DENV, which has been endemic in most parts of the country since the 1980s. Given this triple epidemic, we proposed a prospective and collaborative study to assess the prevalence, morbidity, andmortality of DENV, CHKV, and ZIKV infections in hematopoietic stem cell transplant (HSCT) recipients and oncohematological patients. A case definition strategy (fever and rash) was used to prompt diagnostic investigation of DENV, ZIKV, and CHKV, which was accomplished by real-time polymerase chain reaction with plasma and urine samples. Clinical follow-up was performed 7 and 30 days after symptom onset. We report here the first cases of ZIKV and CHKV infections diagnosed in this ongoing study. From February to May 2016, 9 of the 26 patients (34.6%) fulfilling case definition criteria were diagnosed with DENV (3 cases), ZIKV (4 cases), or CHKV (2 cases) infections. Prolonged viremia and viruria were observed in dengue and Zika fever cases, respectively. Thrombocytopenia was the most frequent complication. Delayed engraftment was noted in 1 patient who acquired ZIKV 25 days before HSCT. All patients survived without sequelae. With the geographic expansion of arboviruses, donor and recipient screening may become mandatory. Patients living in areas where these viruses are not endemic are also at risk, since these viruses can be transmitted by blood as well as organ or tissue transplantation
C1 [Machado, Clarisse Martins; de Souza Pereira, Barbara Brito; Felix, Alvina Clara] Univ Sao Paulo, Inst Trop Med, Virol Lab, Av Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
   [Machado, Clarisse Martins; de Souza, Mair Pedro; Colturato, Vergilio Rensi] Amaral Carvalho Fdn, HSCT Program, Sao Paulo, Brazil.
   [Oliveira, Maria Carolina; Darrigo, Luiz Guilherme, Jr.; Simoes, Belinda Pinto] Univ Sao Paulo, Fac Med Ribeirao Preto, Sao Paulo, Brazil.
   [de Alencar Paton, Eduardo Jose] Hosp Cancer Barretos, HSCT Program, Sao Paulo, Brazil.
   [Neves, Fabia] Santa Casa Misericordia Itabuna, Salvador, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Inst Trop Med, Virol Lab, Av Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM clarimm@usp.br
RI Rodrigues, Maria Carolina Oliveira/A-2302-2012; Darrigo Junior,
   Luiz/A-2686-2019; JUNIOR, LUIZ GUILHERME DARRIGO/AAH-1776-2019; Simoes,
   Belinda P/M-7469-2016; CTC USP, CEPID 13 18/J-8951-2014
OI Rodrigues, Maria Carolina Oliveira/0000-0003-0691-2222; Darrigo Junior,
   Luiz/0000-0001-6007-8908; JUNIOR, LUIZ GUILHERME
   DARRIGO/0000-0001-6007-8908; CTC USP, CEPID 13 18/0000-0002-7123-9524
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2015/06947-5]; Virology Laboratory of Institute of
   Tropical Medicine, University of Sao Paulo
FX This study was supported in part by the Sao Paulo Research Foundation
   (research grant 2015/06947-5) (C.M.M.) and by the Virology Laboratory of
   Institute of Tropical Medicine, University of Sao Paulo.
CR Agencia Nacional de Vigilancia Sanitaria (ANVISA), CRIT TECN GER RISC S
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Brazil. Associaca o Brasileira de Transplantes. Registro Brasileiro de Transplantes, DIM TRANSPL BRAS CAD
   Cecilia D, 2015, ARCH VIROL, V160, P323, DOI 10.1007/s00705-014-2217-x
   Couderc T, 2012, J INFECT DIS, V206, P851, DOI 10.1093/infdis/jis296
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Faye O, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-311
   Garcia JHP, 2006, TRANSPLANTATION, V82, P850, DOI 10.1097/01.tp.0000235151.60237.fe
   Gasperina DD, 2015, TRANSPL INFECT DIS, V17, P876, DOI 10.1111/tid.12453
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Hepner Adriana, 2016, J Glob Oncol, V2, P250, DOI 10.1200/JGO.2016.003533
   Huhtamo E, 2010, J CLIN VIROL, V47, P49, DOI 10.1016/j.jcv.2009.11.001
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Levi JE, 2015, TRANSFUSION, V55, P961, DOI 10.1111/trf.12944
   Machado CM, 2009, REV INST MED TROP SP, V51, P309, DOI 10.1590/S0036-46652009000600002
   Musso D, 2014, EUROSURVEILLANCE, P19
   Nogueira ML, 2011, AM J TRANSPLANT, V17, P791
   Punzel M, 2014, EMERG INFECT DIS, V20, P1366, DOI 10.3201/eid2008.140508
   Renaud CJ, 2007, NEPHROLOGY, V12, P305, DOI 10.1111/j.1440-1797.2007.00785.x
   Rigau-Perez Jose G., 2001, American Journal of Tropical Medicine and Hygiene, V64, P67
   Sabino EC, 2016, J INFECT DIS, V213, P694, DOI 10.1093/infdis/jiv326
   SCHATZMAYR H G, 1986, Memorias do Instituto Oswaldo Cruz, V81, P245, DOI 10.1590/S0074-02761986000200019
   Sharma SK, 2011, MEDITERR J HEMATOL I, V3, DOI 10.4084/MJHID.2011.039
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 24
TC 6
Z9 6
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 2473-9529
EI 2473-9537
J9 BLOOD ADV
JI Blood Adv.
PD APR 11
PY 2017
VL 1
IS 10
BP 624
EP 627
DI 10.1182/bloodadvances.2016003285
PG 4
WC Hematology
SC Hematology
GA ES2PX
UT WOS:000399371500006
PM 29296705
OA Green Published
DA 2020-12-15
ER

PT J
AU Campos, SV
   Samano, MN
   Pego-Fernandes, PM
   Teixeira, RO
   Carraro, RM
   Afonso, JE
   Costa, AN
   Machado, CM
   Souza, AC
   Pereira, BB
   Fernandes, LM
   Abdalla, L
AF Campos, S. V.
   Samano, M. N.
   Pego-Fernandes, P. M.
   Teixeira, R. O.
   Carraro, R. M.
   Afonso-Junior, J. E.
   Costa, A. N.
   Machado, C. M.
   Souza, A. C.
   Pereira, B. B.
   Fernandes, L. M.
   Abdalla, L.
TI Clinical Assessment of Cytomegalovirus Specific Cell Mediated Immunity
   in a Prospective Cohort of Lung Transplant Recipients
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 37th Annual Meeting and Scientific Sessions of the
   International-Society-for-Heart-and-Lung-Transplantation (ISHLT)
CY APR 05-08, 2017
CL San Diego, CA
SP Int Soc Heart & Lung Transplantat
C1 [Campos, S. V.; Teixeira, R. O.; Carraro, R. M.; Afonso-Junior, J. E.; Costa, A. N.] Sao Paulo Med Sch, Inst Heart, Pneumol, Sao Paulo, Brazil.
   [Samano, M. N.; Pego-Fernandes, P. M.; Fernandes, L. M.; Abdalla, L.] Sao Paulo Med Sch, Inst Heart, Thorac Surg, Sao Paulo, Brazil.
   [Machado, C. M.; Souza, A. C.; Pereira, B. B.] Sao Paulo Med Sch, Inst Trop Med, Virol Lab LIM HCFMUSP 52, Sao Paulo, Brazil.
RI Nathan, Andre/E-2595-2016; Samano, Marcos/B-8982-2012
OI Nathan, Andre/0000-0002-8025-6940; Samano, Marcos/0000-0002-0602-0569
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1053-2498
EI 1557-3117
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2017
VL 36
IS 4
SU S
MA 987
BP S321
EP S321
PG 1
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA ER5KF
UT WOS:000398839801114
DA 2020-12-15
ER

PT J
AU Bezerra, TD
   de Moraes-Vasconcelos, D
   Pontillo, A
   Duarte, AJD
   Machado, CM
   Voas, LSV
AF Bezerra, Thiago de Almeida
   de Moraes-Vasconcelos, Dewton
   Pontillo, Alessandra
   da Silva Duarte, Alberto Jose
   Machado, Clarisse Martins
   Vilas Voas, Lucy Santos
TI EVALUATION OF ANTIVIRAL IMMUNITY IN NASAL WASH OF PATIENTS WITH COMMON
   VARIABLE IMMUNODEFICIENCY ALONG WITH VIRAL RHINOSINUSITIS.
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT CIS Annual Meeting on Immune Deficiency and Dysregulation North American
CY MAR 23-26, 2017
CL Seattle, WA
SP Clin Immunol Soc
C1 [Bezerra, Thiago de Almeida; de Moraes-Vasconcelos, Dewton] Univ Sao Paulo, Sch Med, Dermatol Manifestat Primary Immunodeficiencies AD, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD FEB
PY 2017
VL 37
IS 2
MA 5218
BP 218
EP 218
PG 1
WC Immunology
SC Immunology
GA EO8FO
UT WOS:000396924700066
DA 2020-12-15
ER

PT J
AU da Silva, PM
   da Silva, EM
   Simioni, AJ
   de Souza, MP
   Colturato, VAR
   Machado, CM
AF da Silva, Paula Moreira
   da Silva, Elen Monteiro
   Simioni, Anderson Joao
   de Souza, Mair Pedro
   Rensi Colturato, Vergilio Antonio
   Machado, Clarisse Martins
TI Difficulties in the revaccination program of hematopoietic stem cell
   transplantation recipients
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Hematopoietic stem cell transplantation; Immunization; Difficulties in
   revaccination
ID PNEUMOCOCCAL CONJUGATE VACCINE; MEASLES; RECOMMENDATIONS;
   POLYSACCHARIDE; REIMMUNIZATION; GUIDELINES; IMMUNITY; CHILDREN; SAFETY;
   ADULTS
AB Hematopoietic stem cell transplant (HSCT) recipients should be routinely revaccinated after transplantation. We evaluated the difficulties met in the revaccination program and how a prospective and tailored follow-up could help to overcome these obstacles. HSCT recipients (n=122) were prospectively followed up and categorized into Group 1 (n=72), recipients who had already started the revaccination program, and Group 2 (n=50), recipients starting their vaccines. Whenever a difficulty was reported, interventions and subsequent evaluations were performed. Reported problems were related to patient compliance, HSCT center and/or vaccination center. Problems related to patient compliance were less frequent than those related to HSCT center modifications of previous recommendations, or to errors made by the vaccination center. The main gap found was vaccination delays (81.9%). Advisory intervention was needed in 64% and 46% of Group 1 and Group 2, respectively (p=0.05), and was partially successful in around 70% of the cases. Total resolution was achieved in more than 35% in both groups. Improvements are needed in the Brazilian vaccination program for HSCT recipients to assure a complete and updated revaccination schedule. HSCT centers should assign nurses and transplant infectious disease specialist physicians to organize the revaccination schedule and to monitor the program development.
C1 [da Silva, Paula Moreira; da Silva, Elen Monteiro; Simioni, Anderson Joao; de Souza, Mair Pedro; Rensi Colturato, Vergilio Antonio; Machado, Clarisse Martins] Serv Transplante Medula Ossea, Fundacao Amaral Carvalho, Travessa Coronel Ricardo Auler 457, BR-17210200 Jau, SP, Brazil.
   [Machado, Clarisse Martins] Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Virol, LIM52, Sao Paulo, SP, Brazil.
RP da Silva, PM (corresponding author), Serv Transplante Medula Ossea, Fundacao Amaral Carvalho, Travessa Coronel Ricardo Auler 457, BR-17210200 Jau, SP, Brazil.
EM pauladc@gmail.com
OI Simione, Anderson/0000-0002-6939-906X
CR [Anonymous], 2016, VAC PNEUM 10 VAL CON
   Ariza-Heredia EJ, 2014, TRANSPL INFECT DIS, V16, P878, DOI 10.1111/tid.12312
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude. Departamento de Vigilancia das Doencas Transmissiveis, 2014, MAN CTR REF IM ESP
   Cordonnier C, 2015, CLIN INFECT DIS, V61, P313, DOI 10.1093/cid/civ287
   Cordonnier C, 2009, CLIN INFECT DIS, V48, P1392, DOI 10.1086/598324
   de Roux A, 2008, CLIN INFECT DIS, V46, P1015, DOI 10.1086/529142
   Hilgendorf Inken, 2011, Vaccine, V29, P2825, DOI 10.1016/j.vaccine.2011.02.018
   Hudspeth MP, 2010, PEDIATR BLOOD CANCER, V54, P970, DOI 10.1002/pbc.22444
   Johnston B Lynn, 2002, Can J Infect Dis, V13, P353
   Klok RM, 2013, CLIN THER, V35, P119, DOI 10.1016/j.clinthera.2012.12.006
   Lee DG, 2013, INFECT CHEMOTHER, V45, P272, DOI 10.3947/ic.2013.45.3.272
   Lerchenfeldt SM, 2013, TRANSPL INFECT DIS, V15, P634, DOI 10.1111/tid.12110
   Ljungman P, 2005, BONE MARROW TRANSPL, V35, P737, DOI 10.1038/sj.bmt.1704870
   LJUNGMAN P, 1994, BLOOD, V84, P657
   Ljungman P, 2004, BONE MARROW TRANSPL, V34, P589, DOI 10.1038/sj.bmt.1704634
   Ljungman P, 2009, BONE MARROW TRANSPL, V44, P521, DOI 10.1038/bmt.2009.263
   Ljungman P, 2010, BIOL BLOOD MARROW TR, V16, P1608, DOI 10.1016/j.bbmt.2010.08.009
   Machado CM, 2005, EXPERT REV VACCINES, V4, P219, DOI 10.1586/14760584.4.2.219
   Machado CM, 2004, BRAZ J MED BIOL RES, V37, P151, DOI 10.1590/S0100-879X2004000100021
   Machado CM, 2002, BLOOD, V99, P83, DOI 10.1182/blood.V99.1.83
   Molina AC, 2007, ACTA SCI-HEALTH SCI, V29, P99, DOI 10.4025/actascihealthsci.1077
   Nelson JC, 2009, AM J PUBLIC HEALTH, V99, pS389, DOI 10.2105/AJPH.2008.151332
   Patel SR, 2007, CLIN INFECT DIS, V44, P625, DOI 10.1086/511641
   Prager J, 1992, Kinderarztl Prax, V60, P195
   Rubin LG, 2014, CLIN INFECT DIS, V58, pE44, DOI 10.1093/cid/cit684
   Santos AC, 2009, BONE MARROW TRANS S1, V43, pS63
   Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019
NR 27
TC 0
Z9 0
U1 0
U2 4
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2017
VL 59
AR e69
DI 10.1590/S1678-9946201759069
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FM1DE
UT WOS:000414712400003
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Bezerra, E
   da Silva, RL
   Schmidt, J
   Santos, M
   Nascimento, M
   Simoes, A
   Xavier, E
   Almeida, M
   Mariano, LC
   Fernandes, P
   Marques, L
   Costa, S
   Seber, A
   Macedo, MC
   Machado, C
AF Bezerra, Evandro
   da Silva, Roberto Luiz
   Schmidt Filho, Jayr
   Santos, Marina
   Nascimento, Marina
   Simoes, Aline
   Xavier, Erick
   Almeida, Manuella
   Mariano, Livia Caroline
   Fernandes, Pedro
   Marques, Larissa
   Costa, Sylvia
   Seber, Adriana
   Macedo, Maria Cristina
   Machado, Clarisse
TI Viral Reactivation after T-Cell Replete Haploidentical Transplantation
   Using Myeloablative Conditioning and Post-Transplant Cyclophosphamide
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT BMT Tandem Meetings
CY FEB 18-22, 2016
CL Honolulu, HI
SP Ctr Int Blood & Marrow Transplant Res, Amer Soc Blood & Marrow Transplantat
C1 [Bezerra, Evandro; da Silva, Roberto Luiz; Schmidt Filho, Jayr; Nascimento, Marina; Xavier, Erick; Mariano, Livia Caroline; Costa, Sylvia; Seber, Adriana; Macedo, Maria Cristina] Univ Sao Paulo, Sch Med, Internal Med, Sao Paulo, Brazil.
   [da Silva, Roberto Luiz; Santos, Marina; Simoes, Aline; Almeida, Manuella; Fernandes, Pedro; Marques, Larissa; Macedo, Maria Cristina] Inst Brasileiro Controle Canc, Hematol, Sao Paulo, Brazil.
   [Machado, Clarisse] Univ Sao Paulo, Sch Med, Trop Med, Sao Paulo, Brazil.
RI Seber, Adriana/AAG-7978-2020
OI Seber, Adriana/0000-0003-4578-9423
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD MAR
PY 2016
VL 22
IS 3
SU 1
MA 552
BP S366
EP S367
DI 10.1016/j.bbmt.2015.11.875
PG 2
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA DE8TT
UT WOS:000370910300553
OA Other Gold
DA 2020-12-15
ER

PT J
AU Sumita, LM
   Rodrigues, JP
   Ferreira, NE
   Felix, AC
   Souza, NCS
   Machado, CM
   de Andrade, HF
AF Sumita, Laura Masami
   Rodrigues, Jaqueline Polizeli
   Ferreira, Noely Evangelista
   Felix, Alvina Clara
   Santiago Souza, Nathalia Caroline
   Machado, Clarisse Martins
   de Andrade Junior, Heitor Franco
TI DETECTION OF HUMAN ANTI-ZIKA VIRUS IgG BY ELISA USING AN ANTIGEN FROM in
   vitro INFECTED VERO CELLS: PRELIMINARY RESULTS
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Zika virus; Dengue virus; Congenital infection; IgG; Serology; Avidity
ID TOXOPLASMA-GONDII INFECTION; TRANSMISSION; PREGNANCY; DIAGNOSIS
AB Zika virus (ZKV) infection is a huge public health problem in Brazil because of the increased incidence of microcephaly in neonates from infected mothers. Detection of specific IgG antibodies in maternal serum samples constitutes an important approach for diagnosing ZKV infection and evaluating its relationship with neonatal microcephaly. However, as there is no serological test produced in Brazil to detect IgM and IgG antibodies against ZKV, we sought to examine specific IgG in serum samples from patients or suspected mothers to detect previous infection and to test for specificity with regard to flaviviral infections occurring in the same area. Brazilian Zika virus native antigens were obtained from infected Vero cell layers or free virions in the culture medium and then used in ELISA. We tested sera from eight ZKV RNA-diagnosed infected patients (ZKVR), seven neonates with microcephaly and their mothers after delivery (MM), 140 dengue virus IgM-positive (DM) and IgG (DG)-positive patients, and 100 yellow fever (YF)-vaccinated patients. According to the ELISA, ZKVR samples were mostly positive (7/8), and all the MM serum samples were positive for ZKV IgG (7/7). In contrast, cross-reactions for dengue or yellow fever-vaccinated patients were observed, including DM (48/95), DG (10/45) or YF (3/100) serum samples; however, these cross-reactions exhibited low antigen avidity so that 6 M urea largely removed this cross-reactivity, with only a few cross-reacting samples remaining (8/140). ELISA based on extracted virions was much more specific, with all ZKVR (8/8) and MM sera being positive for ZKV IgG (7/7) and only borderline cross-reactivity found for DM (6/95), DG (3/45) or YF (4/100)-vaccinated serum samples. This technique (ELISA) can identify specific IgG in ZKV-infected patients and may be helpful in diagnosing congenital infetions after maternal RNA virus clearance or in epidemiological studies.
C1 [Sumita, Laura Masami; Ferreira, Noely Evangelista; Felix, Alvina Clara; Santiago Souza, Nathalia Caroline; Machado, Clarisse Martins] Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Virol, Sao Paulo, SP, Brazil.
   [Rodrigues, Jaqueline Polizeli; de Andrade Junior, Heitor Franco] Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Protozool, Ave Dr Eneas de Carvalho Aguiar 470 Cerqueira, BR-05403000 Sao Paulo, SP, Brazil.
RP Rodrigues, JP (corresponding author), Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Protozool, Ave Dr Eneas de Carvalho Aguiar 470 Cerqueira, BR-05403000 Sao Paulo, SP, Brazil.
EM jaquepolizeli@gmail.com
RI de Andrade Junior, Heitor Franco/AAP-4689-2020; de Andrade Junior,
   Heitor Franco/F-7082-2012
OI de Andrade Junior, Heitor Franco/0000-0003-4697-4647; de Andrade Junior,
   Heitor Franco/0000-0003-4697-4647; Polizeli Rodrigues,
   Jaqueline/0000-0002-6254-8800
CR Andrade JQ, 2006, J CLIN VIROL, V35, P285, DOI 10.1016/j.jcv.2005.09.007
   Beck C, 2013, INT J ENV RES PUB HE, V10, P6049, DOI 10.3390/ijerph10116049
   Burt TD, 2013, AM J REPROD IMMUNOL, V69, P346, DOI 10.1111/aji.12083
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cordeiro MT, 2016, LANCET, V387, P1811, DOI 10.1016/S0140-6736(16)30253-7
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502
   deSouza VAUF, 1997, J MED VIROL, V52, P275
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Gerber S, 2003, CHILD NERV SYST, V19, P429, DOI 10.1007/s00381-003-0766-5
   Gyurech D, 2016, SWISS MED WKLY, V146, DOI 10.4414/smw.2016.14296
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Neu N, 2015, CLIN PERINATOL, V42, P77, DOI 10.1016/j.clp.2014.11.001
   Pomares C, 2016, J CLIN MICR IN PRESS
   Prince HE, 2014, CLIN VACCINE IMMUNOL, V21, P1377, DOI 10.1128/CVI.00487-14
   Racicot K, 2014, AM J REPROD IMMUNOL, V72, P107, DOI 10.1111/aji.12289
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Sensini A, 2006, CLIN MICROBIOL INFEC, V12, P504, DOI 10.1111/j.1469-0691.2006.01444.x
   Souza Vanda A. U. F., 1994, Revista do Instituto de Medicina Tropical de Sao Paulo, V36, P373, DOI 10.1590/S0036-46651994000400011
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Villard O, 2016, DIAGN MICR INFEC DIS, V84, P22, DOI 10.1016/j.diagmicrobio.2015.09.009
NR 24
TC 4
Z9 7
U1 0
U2 2
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2016
VL 58
AR 89
DI 10.1590/S1678-9946201658089
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EN8HH
UT WOS:000396241000004
PM 27982355
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU de Araujo, AL
   Silva, LCR
   Fernandes, JR
   Matias, MDT
   Boas, LS
   Machado, CM
   Garcez-Leme, LE
   Benard, G
AF de Araujo, Adriana Ladeira
   Rodrigues Silva, Leia Cristina
   Fernandes, Juliana Ruiz
   Toledo Matias, Manuella de Sousa
   Boas, Lucy Santos
   Machado, Clarisse Martins
   Garcez-Leme, Luiz Eugenio
   Benard, Gil
TI Elderly men with moderate and intense training lifestyle present
   sustained higher antibody responses to influenza vaccine
SO AGE
LA English
DT Article
DE Vaccine; Influenza; Antibody response; Exercise; Lifestyle
ID SEDENTARY OLDER-ADULTS; PSYCHOSOCIAL FACTORS; PHYSICAL-ACTIVITY;
   IMMUNE-SYSTEM; EXERCISE; INTERVENTION; PROTECTION; IMPROVES; STATE
AB We aimed to verify whether different levels of training performed regularly and voluntarily for many years could have an impact on one of the main issues of immunosenescence: the poor response to vaccines. We recruited 61 healthy elderly men (65-85 years old), 23 with a moderate training (MT) lifestyle (for 17.0 +/- 3.2 years), 22 with an intense training (IT) lifestyle (for 25.9 +/- 3.4 years), and 16 without a training lifestyle (NT). Fitness was evaluated through the IPAQ and VO2max consumption. The participants were evaluated regarding cognitive aspects, nutritional status, depression, and quality of life. Antibody titers were determined by hemagglutination inhibition assay prior to influenza vaccination and at 6 weeks and 6 months post-vaccination. Strains used were B, H3N2, and H1N1. Our groups were matched for most characteristics, except for those directly influenced by their lifestyles, such as BMI, VO(2)max, and MET. In general, MT and IT elderly men showed significantly higher antibody titers to the three vaccine strains post-vaccination than NT elderly men. There were also higher titers against B and H1N1 strains in the trained groups before vaccination. Additionally, there were higher proportions of seroprotected (titers >= 1:40) individuals in the pooled trained groups both at 6 weeks (B and H3N2, p<0.05) and 6 months (H1N1, p<0.05; B, p=0.07). There were no significant differences between the MT and IT groups. Either a moderate or an intense training is associated with stronger and longstanding antibody responses to the influenza vaccine, resulting in higher percentages of seroprotected individuals.
C1 [de Araujo, Adriana Ladeira; Rodrigues Silva, Leia Cristina; Fernandes, Juliana Ruiz; Benard, Gil] Clin Hosp, Div Dermatol, Lab Dermatol & Immunodeficiencies, BR-05403903 Sao Paulo, SP, Brazil.
   [Toledo Matias, Manuella de Sousa; Garcez-Leme, Luiz Eugenio] Univ Sao Paulo, Sch Med, Dept Orthoped & Traumatol, Sao Paulo, SP, Brazil.
   [Boas, Lucy Santos; Machado, Clarisse Martins] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Benard, Gil] Univ Sao Paulo, Inst Trop Med, Med Mycol Lab, Sao Paulo, Brazil.
RP Benard, G (corresponding author), Clin Hosp, Div Dermatol, Lab Dermatol & Immunodeficiencies, R Dr Eneas de Carvalho Aguiar,470 Cerqueira Cesar, BR-05403903 Sao Paulo, SP, Brazil.
EM mahong@usp.br
RI Garcez Leme, Luiz/C-6759-2009; Fernandes, Juliana Ruiz/T-9944-2017
OI Garcez Leme, Luiz/0000-0002-9738-5466; Fernandes, Juliana
   Ruiz/0000-0003-2127-8493; Ladeira de Araujo, Adriana/0000-0002-2261-8309
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2011/08817-0, 2011/18268-4];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCAPES
   [14952/13-0]; Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (#2011/08817-0 [GB] and #2011/18268-4 [LCRS]), Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (# 14952/13-0 [ALA]), and
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (LEGL and
   GB). We thank Terezinha M. Paiva of the Respiratory Diseases Center,
   Adolf Lutz Institute, Sao Paulo, for providing the influenza antigens,
   Magali Ruivo from the Cotia's county program "Saber Viver" for helping
   with recruitment of the participants, Paulo RS Silva for the
   ergospirometry testing, and Isac de Castro for statistics advice.
CR Agarwal S, 2010, ANN ALLERG ASTHMA IM, V104, P183, DOI 10.1016/j.anai.2009.11.009
   Alam I, 2013, AGE, V35, P1521, DOI 10.1007/s11357-012-9455-1
   Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014
   Ciconelli RM, 1999, REV BRAS REUMATOL, V39, P147
   de Araujo AL, 2013, IMMUNOTHERAPY-UK, V5, P879, DOI [10.2217/IMT.13.77, 10.2217/imt.13.77]
   GOODEVE A, 1983, J HYG-CAMBRIDGE, V90, P107, DOI 10.1017/S0022172400063907
   Grant RW, 2008, BRAIN BEHAV IMMUN, V22, P923, DOI 10.1016/j.bbi.2008.01.006
   HECK H, 1985, INT J SPORTS MED, V6, P117, DOI 10.1055/s-2008-1025824
   Kendal A, 1982, CONCEPTS PROCEDURES
   Keylock KT, 2007, J APPL PHYSIOL, V102, P1090, DOI 10.1152/japplphysiol.00790.2006
   Kohut ML, 2004, VACCINE, V22, P2298, DOI 10.1016/j.vaccine.2003.11.023
   Kohut ML, 2005, BRAIN BEHAV IMMUN, V19, P357, DOI 10.1016/j.bbi.2004.12.002
   Kohut ML, 2002, J GERONTOL A-BIOL, V57, pM557, DOI 10.1093/gerona/57.9.M557
   Larbi A, 2008, PHYSIOLOGY, V23, P64, DOI 10.1152/physiol.00040.2007
   McElhaney JE, 2006, J IMMUNOL, V176, P6333, DOI 10.4049/jimmunol.176.10.6333
   Milani RV, 2004, CIRCULATION, V110, pE27, DOI 10.1161/01.CIR.0000136811.45524.2F
   Pascoe AR, 2014, BRAIN BEHAV IMMUN, V39, P33, DOI 10.1016/j.bbi.2013.10.003
   Rohrbach LA, 2006, EVAL HEALTH PROF, V29, P302, DOI 10.1177/0163278706290408
   Santos-Silva PR, 2007, CLINICS, V62, P391, DOI 10.1590/S1807-59322007000400004
   Schuler PB, 2003, J SPORT MED PHYS FIT, V43, P404
   Senchina DS, 2007, CLIN INTERV AGING, V2, P3, DOI 10.2147/ciia.2007.2.1.3
   Sistema de vigilancia epidemiologica da gripe SIVEP-GRIPE, 2012, VIG SENT CIRC CIR
   Smith TP, 2004, J APPL PHYSIOL, V97, P491, DOI 10.1152/japplphysiol.01404.2003
   Vellas B, 1999, NUTRITION, V15, P116, DOI 10.1016/S0899-9007(98)00171-3
   Webster RG, 2002, WHOCDSCSRNCS20025, P37
   Weiskopf D, 2009, TRANSPL INT, V22, P1041, DOI 10.1111/j.1432-2277.2009.00927.x
   Woods JA, 2009, J AM GERIATR SOC, V57, P2183, DOI 10.1111/j.1532-5415.2009.02563.x
   Yang Y, 2007, AM J CHINESE MED, V35, P597, DOI 10.1142/S0192415X07005090
   YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4
NR 29
TC 20
Z9 20
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0161-9152
EI 1574-4647
J9 AGE
JI Age
PD DEC
PY 2015
VL 37
IS 6
AR 105
DI 10.1007/s11357-015-9843-4
PG 8
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA CZ9ET
UT WOS:000367401300001
PM 26480853
OA Green Published
DA 2020-12-15
ER

PT J
AU Ambati, A
   Boas, LSV
   Ljungman, P
   Testa, L
   de Oliveira, JF
   Aoun, M
   Colturato, V
   Maeurer, M
   Machado, CM
AF Ambati, A.
   Boas, L. S. V.
   Ljungman, P.
   Testa, L.
   de Oliveira, J. F.
   Aoun, M.
   Colturato, V.
   Maeurer, M.
   Machado, C. M.
TI Evaluation of pretransplant influenza vaccination in hematopoietic SCT:
   a randomized prospective study
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
ID BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; LONG-TERM
   IMMUNITY; IMMUNOCOMPROMISED HOST; DONOR IMMUNIZATION; ANTIBODY-RESPONSE;
   ADOPTIVE TRANSFER; ALLOGENEIC BMT; RECIPIENTS; VACCINES
AB Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n = 38), donor pretransplant vaccination (n = 44) or recipient pretransplant vaccination (n = 40). Specific IgG was assessed by both hemagglutinin inhibition (HI) and, in 57 patients, by an indirect influenza-specific ELISA at specified times after HSCT. Vaccinated donors had seroprotective HI titers for Ags H1 and H3 (P<0.001) compared with the other groups at the time of donation. The titers against H1 (P = 0.028) and H3 (P<0.001) were highest in the pretransplant recipient vaccination group until day 180 after transplantation. A significant difference was found in the specific Ig levels against pandemic H1N1 at 6 months after SCT (P = 0.02). The mean IgG levels against pandemic H1N1 and generic H1N1 and H3N2 were highest in the pretransplant recipient vaccination group. We conclude that pretransplant recipient vaccination improved the influenza-specific seroprotection rates.
C1 [Ambati, A.; Ljungman, P.] Karolinska Inst, Dept Med Huddinge, Div Hematol, Stockholm, Sweden.
   [Ambati, A.; Maeurer, M.] Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat CAST, Stockholm, Sweden.
   [Boas, L. S. V.; Machado, C. M.] Univ Sao Paulo, Inst Trop Med, Virol Lab LIM HCFMUSP 52, BR-05403000 Sao Paulo, Brazil.
   [Ljungman, P.] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.
   [Testa, L.; Colturato, V.; Machado, C. M.] Amaral Carvalho Fdn, Hematopoiet Stem Cell Transplant Program, Jahu, Brazil.
   [de Oliveira, J. F.] Univ Fed Minas Gerais, Clin Hosp Sch Med, Belo Horizonte, MG, Brazil.
   [Aoun, M.; Maeurer, M.] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol TIM, Stockholm, Sweden.
RP Machado, CM (corresponding author), Univ Sao Paulo, Inst Trop Med, Virol Lab LIM HCFMUSP 52, Ave Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
RI Ambati, Aditya/K-4095-2019; Ambati, Adityasai/D-9024-2015; Ljungman,
   Per/M-4946-2019; Ambati, Aditya/AAU-1333-2020
OI Ambati, Aditya/0000-0001-8462-3552; Ambati,
   Adityasai/0000-0001-8462-3552; Maeurer, Markus/0000-0002-8436-8077;
   Ljungman, Per/0000-0002-8281-3245
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP 2008/00282-8];
   Vetenskapradet (Swedish research council); Karolinska Instituet and
   Karolinska University Hospital
FX We thank all the patient participants. This work was supported by
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP
   2008/00282-8), Vetenskapradet (Swedish research council), Karolinska
   Instituet and Karolinska University Hospital.
CR Cordonnier C, 2009, CLIN INFECT DIS, V48, P1392, DOI 10.1086/598324
   de Lavallade H, 2011, HAEMATOL-HEMATOL J, V96, P307, DOI 10.3324/haematol.2010.032664
   Dhedin N, 2014, VACCINE, V32, P585, DOI 10.1016/j.vaccine.2013.11.073
   ENGELHARD D, 1993, BONE MARROW TRANSPL, V11, P1
   Engelhard D, 2011, VACCINE, V29, P1777, DOI 10.1016/j.vaccine.2010.12.113
   Garcia-Canas V, 2006, J CHROMATOGR A, V1123, P225, DOI 10.1016/j.chroma.2006.04.003
   Garcia-Canas V, 2010, BIOLOGICALS, V38, P294, DOI 10.1016/j.biologicals.2009.12.005
   Guerin-El Khourouj V, 2012, HUM IMMUNOL, V73, P884, DOI 10.1016/j.humimm.2012.07.039
   Ilan Y, 2000, BONE MARROW TRANSPL, V26, P633, DOI 10.1038/sj.bmt.1702571
   ILAN Y, 1993, HEPATOLOGY, V18, P246, DOI 10.1016/0270-9139(93)90003-6
   Kunisaki KM, 2009, LANCET INFECT DIS, V9, P493, DOI 10.1016/S1473-3099(09)70175-6
   LJUNGMAN P, 1994, BLOOD, V84, P657
   Ljungman P, 2004, BONE MARROW TRANSPL, V34, P1067, DOI 10.1038/sj.bmt.1704678
   Ljungman P, 2009, BONE MARROW TRANSPL, V44, P521, DOI 10.1038/bmt.2009.263
   Ljungman P, 2011, HAEMATOL-HEMATOL J, V96, P1231, DOI 10.3324/haematol.2011.041913
   LUM LG, 1986, BLOOD, V67, P582
   Machado CM, 2004, BONE MARROW TRANSPL, V34, P111, DOI 10.1038/sj.bmt.1704534
   Machado CM, 2005, BONE MARROW TRANSPL, V36, P897, DOI 10.1038/sj.bmt.1705159
   Molrine DC, 1996, BLOOD, V87, P3012, DOI 10.1182/blood.V87.7.3012.bloodjournal8773012
   Molrine DC, 2003, BLOOD, V101, P831, DOI 10.1182/blood-2002-03-0832
   Nichols WG, 2004, CLIN INFECT DIS, V39, P1300, DOI 10.1086/425004
   Parkkali T, 1997, BONE MARROW TRANSPL, V20, P663, DOI 10.1038/sj.bmt.1700959
   Parkkali T, 1997, BONE MARROW TRANSPL, V19, P933, DOI 10.1038/sj.bmt.1700768
   RENFREY S, 1994, VACCINE, V12, P747, DOI 10.1016/0264-410X(94)90227-5
   Ring A, 2002, SUPPORT CARE CANCER, V10, P462, DOI 10.1007/s00520-001-0337-9
   Rubin LG, 2014, CLIN INFECT DIS, V58, P309, DOI 10.1093/cid/cit816
   Salles MJC, 2012, TRANSPL INFECT DIS, V14, P564, DOI 10.1111/j.1399-3062.2012.00769.x
   SAXON A, 1986, J CLIN INVEST, V78, P959, DOI 10.1172/JCI112686
   Storek J, 2003, BLOOD, V101, P3319, DOI 10.1182/blood-2002-05-1376
   Terajima M, 2008, J VIROL, V82, P9283, DOI 10.1128/JVI.01047-08
   Vance E, 1998, BONE MARROW TRANSPL, V22, P735, DOI 10.1038/sj.bmt.1701424
   WAHREN B, 1984, J INFECT DIS, V150, P358, DOI 10.1093/infdis/150.3.358
   WIMPERIS JZ, 1986, LANCET, V1, P339
   Yalcin SS, 2010, ANN HEMATOL, V89, P913, DOI 10.1007/s00277-009-0897-1
NR 34
TC 12
Z9 13
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUN
PY 2015
VL 50
IS 6
BP 858
EP 864
DI 10.1038/bmt.2015.47
PG 7
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA CJ6HO
UT WOS:000355594900018
PM 25798680
OA Bronze
DA 2020-12-15
ER

PT J
AU David-Neto, E
   Triboni, AHK
   Paula, FJ
   Boas, LSV
   Machado, CM
   Agena, F
   Latif, AZA
   Alencar, CS
   Pierrotti, LC
   Nahas, WC
   Caiaffa, HH
   Pannuti, CS
AF David-Neto, Elias
   Triboni, Ana H. K.
   Paula, Flavio J.
   Vilas Boas, Lucy S.
   Machado, Clarisse M.
   Agena, Fabiana
   Latif, Acram Z. A.
   Alencar, Cecilia S.
   Pierrotti, Ligia C.
   Nahas, William C.
   Caiaffa-Filho, Helio H.
   Pannuti, Claudio S.
TI A Double-Blinded, Prospective Study to Define Antigenemia and
   Quantitative Real-Time Polymerase Chain Reaction Cutoffs to Start
   Preemptive Therapy in Low-Risk, Seropositive, Renal Transplanted
   Recipients
SO TRANSPLANTATION
LA English
DT Article
DE Cytomegalovirus; CMV; Renal transplantation; Preemptive therapy; Pp65
   antigenemia; qPCR
ID SOLID-ORGAN TRANSPLANTATION; CYTOMEGALOVIRUS-INFECTION; ORAL
   GANCICLOVIR; ALLOGRAFT RECIPIENTS; DISEASE; PROPHYLAXIS; REPLICATION;
   MANAGEMENT; REJECTION
AB Background. Cytomegalovirus (CMV) disease occurs in 16% to 20% of low-risk, CMV-positive renal transplant recipients. The cutoffs for quantitative real-time polymerase chain reaction (qPCR) or phosphoprotein (pp65) antigenemia (pp65emia) for starting preemptive therapy have not been well established.
   Methods. We measured qPCR and pp65emia weekly from day 7 to day 120 after transplantation, in anti-CMV immunoglobulin GYpositive donor and recipient pairs. Patients and physicians were blinded to the test results. Suspicion of CMV disease led to the order of new tests. In asymptomatic viremic patients, the highest pp65emia and qPCR values were used, whereas we considered the last value before diagnosis in those with CMV disease.
   Results. We collected a total of 1,481 blood samples from 102 adult patients. Seventeen patients developed CMV disease, 54 presented at least one episode of viremia that cleared spontaneously, and 31 never presented viremia. Five patients developed CMV disease after the end of the study period. The median (95% confidence interval) pp65emia and qPCR values were higher before CMV disease than during asymptomatic viremia (6 [9-82] vs. 3 [1-14] cells/10(6) cells; P<0.001 and 3,080 [1,263-15,605] vs. 258 [258-1,679] copies/mL; P=0.008, respectively). The receiver operating characteristic curve showed that pp65emia 4 cells/10(6) cells or greater showed a sensitivity and specificity to predict CMV disease of 69% and 81%, respectively (area, 0.769; P=0.001), with a positive predictive value of 37% and a negative predictive value of 93%. For qPCR 2,000 copies/mL or higher, the positive predictive value and negative predictive value were 57% and 91%, respectively (receiver operating characteristic area, 0.782; P=0.000).
   Conclusion. With these cutoffs, both methods are appropriate for detecting CMV disease.
C1 [David-Neto, Elias; Triboni, Ana H. K.; Paula, Flavio J.; Agena, Fabiana; Nahas, William C.] Univ Sao Paulo, Sch Med, Hosp Clin, Renal Transplant Serv,Div Urol, Sao Paulo, Brazil.
   [Vilas Boas, Lucy S.; Machado, Clarisse M.; Pannuti, Claudio S.] Univ Sao Paulo, Trop Med Inst Sao Paulo, Sao Paulo, Brazil.
   [Latif, Acram Z. A.; Alencar, Cecilia S.; Caiaffa-Filho, Helio H.] Univ Sao Paulo, Sch Med, Lab Med Invest 03, Sao Paulo, Brazil.
   [Pierrotti, Ligia C.] Univ Sao Paulo, Sch Med, Hosp Clin, Div Infect Dis, Sao Paulo, Brazil.
RP David-Neto, E (corresponding author), Av Eneas de Carvalho Aguiar 255 S-7036, BR-05403900 Sao Paulo, Brazil.
EM elias.david.neto@attglobal.net
RI Caiaffa-Filho, Helio H/H-6982-2012; Agena, Fabiana/C-5819-2015;
   Pierrotti, Ligia Camera/U-9225-2017; Agena, Fabiana/F-5807-2012; Neto,
   Elias David/O-3866-2018; Pierrotti, Ligia/C-5804-2015
OI Caiaffa-Filho, Helio H/0000-0001-6048-4527; Agena,
   Fabiana/0000-0002-4526-4857; Pierrotti, Ligia
   Camera/0000-0002-0216-3028; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo
   State Research Foundation)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2011/00446-3]
FX This study was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP, Sao Paulo State Research Foundation; grant
   2011/00446-3).
CR Abate D, 2010, J INFECT DIS, V202, P585, DOI 10.1086/654931
   Atabani SF, 2012, AM J TRANSPLANT, V12, P2457, DOI 10.1111/j.1600-6143.2012.04087.x
   Camargo LFA, 2001, TRANSPLANTATION, V71, P412, DOI 10.1097/00007890-200102150-00013
   Emery VC, 2012, J CLIN VIROL, V54, P125, DOI 10.1016/j.jcv.2012.02.020
   Geddes CC, 2003, NEPHROL DIAL TRANSPL, V18, P1891, DOI 10.1093/ndt/gfg283
   Halfon P, J MED VIROL, V83, P490
   Humar A, 2006, AM J TRANSPLANT, V6, P262, DOI 10.1111/j.1600-6143.2005.01207.x
   Humar A, 1999, TRANSPLANTATION, V68, P1305, DOI 10.1097/00007890-199911150-00015
   Jordan SC, 2002, AM J TRANSPLANT, V2, P671, DOI 10.1034/j.1600-6143.2002.20714.x
   Khoury JA, 2006, AM J TRANSPLANT, V6, P2134, DOI 10.1111/j.1600-6143.2006.01413.x
   Kliem V, 2008, AM J TRANSPLANT, V8, P975, DOI 10.1111/j.1600-6143.2007.02133.x
   Koetz AC, 2001, TRANSPLANTATION, V72, P1325, DOI 10.1097/00007890-200110150-00025
   Kotton CN, 2010, TRANSPLANTATION, V89, P779, DOI 10.1097/TP.0b013e3181cee42f
   Lautenschlager I, 2013, J CLIN VIROL, V57, P50, DOI 10.1016/j.jcv.2013.01.013
   Lilleri D, 2007, BLOOD, V110, P2757, DOI 10.1182/blood-2007-03-080820
   Martin-Gandul C, 2013, J CLIN VIROL, V56, P13, DOI 10.1016/j.jcv.2012.09.017
   Opelz G, 2004, AM J TRANSPLANT, V4, P928, DOI 10.1111/j.1600-6143.2004.00451.x
   Pannuti CS, 1996, AM J OPHTHALMOL, V122, P847, DOI 10.1016/S0002-9394(14)70381-2
   PORTELA D, 1995, J INFECT DIS, V171, P1014, DOI 10.1093/infdis/171.4.1014
   Razonable RR, 2003, J INFECT DIS, V187, P1801, DOI 10.1086/375194
   Sagedal S, 2003, NEPHROL DIAL TRANSPL, V18, P1899, DOI 10.1093/ndt/gfg302
   Sagedal S, 2000, TRANSPLANTATION, V70, P1166, DOI 10.1097/00007890-200010270-00007
NR 22
TC 12
Z9 17
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD NOV 27
PY 2014
VL 98
IS 10
BP 1077
EP 1081
DI 10.1097/TP.0000000000000189
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA AU0HK
UT WOS:000345304000011
PM 24839894
DA 2020-12-15
ER

PT J
AU Machado, CM
AF Machado, C. M.
TI Chagas Disease in Transplantation: Time to Enter an Era of Better
   Diagnosis and Better Outcomes
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Editorial Material
ID RECOMMENDATIONS; ORGAN
C1 [Machado, C. M.] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Machado, C. M.] Amaral Carvalho Fdn, HSCT Program, Jahu, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
EM clarimm@usp.br
CR Chin-Hong PV, 2011, AM J TRANSPLANT, V11, P672, DOI 10.1111/j.1600-6143.2011.03444.x
   Cura CI, 2013, AM J TRANSPLANT, V13, P3253, DOI 10.1111/ajt.12487
   Machado CM, 2012, INFECT DIS CLIN N AM, V26, P225, DOI 10.1016/j.idc.2012.02.008
   Pinazo MJ, 2011, TRANSPLANT REV-ORLAN, V25, P91, DOI 10.1016/j.trre.2010.12.002
   Schmunis GA, 2010, ACTA TROP, V115, P14, DOI 10.1016/j.actatropica.2009.11.003
   Schofield CJ, 2006, TRENDS PARASITOL, V22, P583, DOI 10.1016/j.pt.2006.09.011
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD DEC
PY 2013
VL 13
IS 12
BP 3065
EP 3066
DI 10.1111/ajt.12484
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 255JN
UT WOS:000327235300007
PM 24266965
OA Bronze
DA 2020-12-15
ER

PT J
AU Luiz, CR
   Machado, CM
   Canto, CLM
   Christ, SCC
   Pestana, JOM
   Kotton, CN
   Camargo, LFA
AF Luiz, Claudia R.
   Machado, Clarisse M.
   Canto, Cynthia L. M.
   Christ, Silvia C. C.
   Pestana, Jose O. M.
   Kotton, Camille N.
   Camargo, Luis F. A.
TI Monitoring for HHV-6 Infection After Renal Transplantation: Evaluation
   of Risk Factors for Sustained Viral Replication
SO TRANSPLANTATION
LA English
DT Article
DE Human herpesvirus 6 (HHV-6); Renal transplantation; PCR; Active viral
   infection; Sustained viral replication
ID HUMAN-HERPESVIRUS 6; STEM-CELL TRANSPLANTATION; HUMAN-HERPESVIRUS-6 DNA;
   LIVER-TRANSPLANTATION; RECIPIENTS; PCR; ENCEPHALITIS; BLOOD;
   PATHOGENESIS; DISEASE
AB Background. Human herpesvirus-6 (HHV-6) is known to reactivate after renal transplantation and has been associated with several clinical manifestations. Risk factors for sustained viral replication, however, remain unclear.
   Methods. Thirty consecutive kidney transplant patients were prospectively followed for HHV-6 replication between February 2007 and February 2008. Plasma samples for DNA detection were collected from the donor and the recipient before transplantation and from the recipient weekly for the first 2 months after transplantation and then every 2 weeks for 2 additional months. HHV-6 active infection was defined as detection of viral DNA in plasma, by polymerase chain reaction, in at least two consecutive samples over an interval of at least 1 week.
   Results. Active viral infection was detected in 25% of the recipients before transplantation and 27% (8 of 30) of the patients after transplantation. The mean time to onset of viral replication was 28.1 days after transplantation and 7 of 8 (87.5%) were asymptomatic. Risk factors associated with active HHV-6 infection were receiving an organ from a living donor (P=0.028), recipients with IgM antibodies detected before transplantation (P=0.005), and pretransplantation recipient HHV-6 viral load more than 10,000 copies/mL plasma (P=0.034).
   Conclusions. Active HHV-6 infection occurs early after renal transplantation and is mostly asymptomatic. Donor or recipient infection may occur at the time of transplantation and are related to higher rates of posttransplantation infections.
C1 [Luiz, Claudia R.; Camargo, Luis F. A.] Univ Fed Sao Paulo UNIFESP, Dept Infect Dis, BR-05685090 Sao Paulo, Brazil.
   [Machado, Clarisse M.; Canto, Cynthia L. M.] Univ Sao Paulo, Inst Med Trop Sao Paulo, Virol Lab, Sao Paulo, Brazil.
   [Christ, Silvia C. C.] Univ Fed Sao Paulo, Dept Infect Dis, Sao Paulo, Brazil.
   [Pestana, Jose O. M.] Univ Fed Sao Paulo UNIFESP, Dept Med, Div Nephrol, BR-05685090 Sao Paulo, Brazil.
   [Kotton, Camille N.] Massachusetts Gen Hosp, Div Infect Dis, Transplant Infect Dis & Compromised Host Serv, Boston, MA 02114 USA.
RP Camargo, LFA (corresponding author), Univ Fed Sao Paulo UNIFESP, Dept Infect Dis, Rua Barao Santa Eulalia 170 Ap 21, BR-05685090 Sao Paulo, Brazil.
EM Luis_camargo@einstein.br
OI Kotton, Camille/0000-0001-7320-2234
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX This work was supported by a grant from FAPESP.
CR Appleton AL, 1995, BONE MARROW TRANSPL, V16, P777
   Bollen AE, 2001, J NEUROL, V248, P619, DOI 10.1007/s004150170142
   Boutolleau D, 2003, J INFECT DIS, V187, P179, DOI 10.1086/367677
   Caiola D, 2012, J MED VIROL, V84, P450, DOI 10.1002/jmv.23206
   Caserta MT, 2010, J CLIN VIROL, V48, P55, DOI 10.1016/j.jcv.2010.02.007
   CONE RW, 1993, J CLIN MICROBIOL, V31, P1262, DOI 10.1128/JCM.31.5.1262-1267.1993
   Csoma E, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-403
   de Pagter PJA, 2008, BIOL BLOOD MARROW TR, V14, P831, DOI 10.1016/j.bbmt.2008.04.016
   Flamand L, 2008, J CLIN MICROBIOL, V46, P2700, DOI 10.1128/JCM.00370-08
   Hentrich M, 2005, BRIT J HAEMATOL, V128, P66, DOI 10.1111/j.1365-2141.2004.05254.x
   Herbein G, 1996, CLIN INFECT DIS, V22, P171, DOI 10.1093/clinids/22.1.171
   Ihira M, 2002, MICROBIOL IMMUNOL, V46, P701, DOI 10.1111/j.1348-0421.2002.tb02754.x
   Lautenschlager I, 1998, CLIN INFECT DIS, V26, P702, DOI 10.1086/514592
   Lee SO, 2011, NEPHROL DIAL TRANSPL, V26, P2391, DOI 10.1093/ndt/gfr259
   Ljungman P, 2000, BRIT J HAEMATOL, V111, P774, DOI 10.1046/j.1365-2141.2000.02422.x
   Locatelli G, 2000, J CLIN MICROBIOL, V38, P4042, DOI 10.1128/JCM.38.11.4042-4048.2000
   do Canto CLM, 2008, REV INST MED TROP SP, V50, P61, DOI 10.1590/S0036-46652008000100014
   Nash PJ, 2004, AM J TRANSPLANT, V4, P1200, DOI 10.1111/j.1600-6143.2004.00459.x
   OKUNO T, 1990, TRANSPLANTATION, V49, P519, DOI 10.1097/00007890-199003000-00009
   Paterson DL, 1999, LIVER TRANSPLANT SUR, V5, P454, DOI 10.1002/lt.500050504
   Rogers J, 2000, TRANSPLANTATION, V69, P2566, DOI 10.1097/00007890-200006270-00016
   Rossi C, 2001, TRANSPLANTATION, V71, P288, DOI 10.1097/00007890-200101270-00021
   Singh N, 1997, TRANSPLANTATION, V64, P674, DOI 10.1097/00007890-199709150-00002
   Singh N, 2000, TRANSPLANTATION, V69, P2474, DOI 10.1097/00007890-200006270-00002
   Volin L, 2004, BRIT J HAEMATOL, V126, P690, DOI 10.1111/j.1365-2141.2004.05101.x
   Ward KN, 2006, J CLIN MICROBIOL, V44, P1571, DOI 10.1128/JCM.44.4.1571-1574.2006
   Yoshikawa T, 2003, J MED VIROL, V70, P267, DOI 10.1002/jmv.10388
   Yoshikawa T, 2002, J INFECT DIS, V185, P847, DOI 10.1086/339411
   Yoshikawa T, 2000, J MED VIROL, V62, P52, DOI 10.1002/1096-9071(200009)62:1&lt;52::AID-JMV9&gt;3.0.CO;2-5
   YOSHIKAWA T, 1992, TRANSPLANTATION, V54, P879, DOI 10.1097/00007890-199211000-00022
   Zerr DM, 2005, NEW ENGL J MED, V352, P768, DOI 10.1056/NEJMoa042207
NR 31
TC 4
Z9 4
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD MAR 27
PY 2013
VL 95
IS 6
BP 842
EP 846
DI 10.1097/TP.0b013e3182807ab7
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 109CO
UT WOS:000316343000017
PM 23354300
DA 2020-12-15
ER

PT J
AU Salles, MJC
   Sens, YAS
   Malafronte, P
   Souza, JF
   Boas, LSV
   Machado, CM
AF Salles, M. J. C.
   Sens, Y. A. S.
   Malafronte, P.
   Souza, J. F.
   Vilas Boas, L. S.
   Machado, C. M.
TI Antibody response to the non-adjuvanted and adjuvanted influenza A
   H1N1/09 monovalent vaccines in renal transplant recipients
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE influenza A H1N1; renal transplantation; adjuvanted and non-adjuvanted
   vaccine; antibody response
ID KIDNEY-TRANSPLANT; PANDEMIC H1N1; IMMUNE-RESPONSE; VACCINATION; VIRUS;
   IMMUNOGENICITY; IMMUNIZATION; THERAPY; SAFETY; ADULTS
AB Background The 2009 pandemic influenza A (H1N1) virus spread rapidly throughout Brazil. Non-adjuvanted and the adjuvanted influenza A H1N1/09 monovalent vaccine were recommended as a single dose to persons at risk including renal transplant recipients (RTR). We analyzed the safety and the immune response of 2 influenza A H1N1/09 monovalent vaccines in RTR, and identified factors influencing the immune response. Methods A total of 78 RTR received a single dose of either influenza A H1N1 2009 monovalent AS03-adjuvanted vaccine or a non-adjuvanted vaccine, and 58 healthy controls received a single dose of non-adjuvanted vaccine. Antibody responses to influenza A H1N1 were measured by hemagglutination inhibition assay and were compared between groups on the day of vaccination and 2130 days thereafter, using geometric mean titer (GMT), and seroprotection (SP) and seroconversion (SC) rates. Results Among RTR, after adjuvanted and non-adjuvanted H1N1 vaccination, the SP rate increased from 16.7% to 61.7% (P < 0.001) and to 50% (P < 0.001), and SC rates were 61.7% and 50%, respectively. For healthy controls, SP rate increased from 25.8% to 89.7% (P < 0.001), and SC rate was 87.9% after vaccination. Pre-vaccination GMT for the adjuvanted and non-adjuvanted RTR vaccine groups and healthy controls was 9.7 (95% confidence interval [CI] 7.313.1), 8.9 (95% CI 5.414.7), and 12.5 (95% CI8.718.2), and significantly increased to 49.8 (95% CI 31.379.4, P < 0.001), 43.2 (95% CI 16.3114.4, P < 0.001), and 323.8 (95% CI 213.9490.2, P < 0.001), respectively. Deceased-donor type transplant significantly reduced SP (odds ratio [OR] = 4.62, 95% CI 1.3615.69, P = 0.014) and SC (OR = 6.29, 95% CI 1.8920.98, P = 0.003) rates, and younger age positively affected SP (OR = 0.11; 95% CI 0.030.04, P = 0.001). Adverse events were mild, and renal function showed no change post vaccination. Conclusion RTR vaccinated with either an adjuvanted or non-adjuvanted monovalent influenza vaccine presented poor response compared with healthy controls. Post-vaccination adverse events were mild, and no rejection episode or renal dysfunction was observed.
C1 [Salles, M. J. C.] Santa Casa Sao Paulo Sch Med, Infect Dis Clin, Dept Internal Med, Sao Paulo, Brazil.
   [Vilas Boas, L. S.; Machado, C. M.] Univ Sao Paulo IMTSP USP, Virol Lab, Inst Trop Med, Sao Paulo, Brazil.
RP Salles, MJC (corresponding author), Rua Visconde Ouro Preto 77,Ap 193, BR-01303060 Sao Paulo, Brazil.
EM mcsalles@osite.com.br
RI Salles, Mauro/R-9256-2019; Salles, Mauro/K-4760-2012
OI Salles, Mauro/0000-0002-5443-6024; Salles, Mauro/0000-0002-5443-6024
CR [Anonymous], 2009, Wkly Epidemiol Rec, V84, P301
   Bautista E, 2010, NEW ENGL J MED, V362, P2039
   Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449
   Beyer WEP, 2004, VIRUS RES, V103, P125, DOI 10.1016/j.virusres.2004.02.024
   Bickel M, 2011, CLIN INFECT DIS, V52, P122, DOI 10.1093/cid/ciq003
   Birdwell KA, 2009, AM J KIDNEY DIS, V54, P112, DOI 10.1053/j.ajkd.2008.09.023
   Brakemeier S, 2012, NEPHROL DIAL TRANSPL, V27, P423, DOI 10.1093/ndt/gfr278
   Broeders NE, 2011, CLIN J AM SOC NEPHRO, V6, P2573, DOI 10.2215/CJN.04670511
   Clark TW, 2009, NEW ENGL J MED, V361, P2424, DOI 10.1056/NEJMoa0907650
   Cordero E, 2011, AM J TRANSPLANT, V11, P2205, DOI 10.1111/j.1600-6143.2011.03692.x
   Danziger-Isakov L, 2010, TRANSPLANTATION, V89, P838, DOI 10.1097/TP.0b013e3181ca56f8
   Danzinger-Isakov L, 2009, AM J TRANSPLANT, V9, pS258, DOI 10.1111/j.1600-6143.2009.02917.x
   Dikow R, 2011, AM J KIDNEY DIS, V57, P716, DOI 10.1053/j.ajkd.2010.11.031
   *EUR COMM PROPR ME, 2004, CPMPVEG471703 EUR CO
   *EUR COMM PROPR ME, 2007, EMEACHMPVWP263499200
   Felldin M, 2012, TRANSPL INT, V25, P166, DOI 10.1111/j.1432-2277.2011.01391.x
   Greenberg ME, 2009, NEW ENGL J MED, V361, P2405, DOI 10.1056/NEJMoa0907413
   Gueller S, 2011, BIOL BLOOD MARROW TR, V17, P1546, DOI 10.1016/j.bbmt.2011.02.004
   Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453
   Harris K, 2009, VACCINE, V27, P2335, DOI 10.1016/j.vaccine.2009.02.026
   Ison MG, 2010, CURR OPIN INFECT DIS, V23, P365, DOI 10.1097/QCO.0b013e32833bc1c3
   Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0
   Katerinis I, 2011, AM J TRANSPLANT, V11, P1727, DOI 10.1111/j.1600-6143.2011.03604.x
   Kendal A, 1982, CONCEPTS PROCEDURES
   Kumar D, 2010, AM J TRANSPLANT, V10, P18, DOI 10.1111/j.1600-6143.2009.02960.x
   Kumar D, 2010, LANCET INFECT DIS, V10, P521, DOI 10.1016/S1473-3099(10)70133-X
   Kunisaki KM, 2009, LANCET INFECT DIS, V9, P493, DOI 10.1016/S1473-3099(09)70175-6
   Launay O, 2011, J INFECT DIS, V204, P124, DOI 10.1093/infdis/jir211
   Liang XF, 2010, LANCET, V375, P56, DOI 10.1016/S0140-6736(09)62003-1
   Lister P, 2009, LANCET, V374, P605, DOI 10.1016/S0140-6736(09)61512-9
   Manuel O, 2011, CLIN INFECT DIS, V52, P248, DOI 10.1093/cid/ciq104
   Meyer S, 2011, TRANSPLANTATION, V91, P1031, DOI 10.1097/TP.0b013e3182115be0
   Plennevaux E, 2010, LANCET, V375, P41, DOI 10.1016/S0140-6736(09)62026-2
   Roman F, 2010, VACCINE, V28, P1740, DOI 10.1016/j.vaccine.2009.12.014
   Salles MJC, 2010, CLIN TRANSPLANT, V24, pE17, DOI 10.1111/j.1399-0012.2009.01095.x
   Sanchez-Fructuoso AI, 2000, TRANSPLANTATION, V69, P436, DOI 10.1097/00007890-200002150-00023
   Scharpe J, 2008, AM J TRANSPLANT, V8, P332, DOI 10.1111/j.1600-6143.2007.02066.x
   Vajo Z, 2010, LANCET, V375, P49, DOI 10.1016/S0140-6736(09)62039-0
   Vilchez R A, 2002, Transpl Infect Dis, V4, P177, DOI 10.1034/j.1399-3062.2002.t01-4-02001.x
   WHO, 2009, WHO MAN AN INFL DIAG
   Zhu FC, 2009, NEW ENGL J MED, V361, P2414, DOI 10.1056/NEJMoa0908535
NR 41
TC 11
Z9 11
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD DEC
PY 2012
VL 14
IS 6
BP 564
EP 574
DI 10.1111/j.1399-3062.2012.00769.x
PG 11
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA 051TA
UT WOS:000312149100012
PM 22882692
DA 2020-12-15
ER

PT J
AU Gattas, VL
   Mondini, G
   Machado, CM
   Luna, E
AF Gattas, V. L.
   Mondini, G.
   Machado, C. M.
   Luna, E.
TI Community incidence of pandemic influenza (A/H1N1, 2009) in Sao Paulo,
   Brazil, 2009
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Gattas, V. L.; Mondini, G.] Inst Butantan, Sao Paulo, Brazil.
   [Machado, C. M.; Luna, E.] Univ Sao Paulo, BR-09500900 Sao Paulo, Brazil.
RI Gattas, Vera Lucia/B-7956-2018; Luna, Expedito J A/B-7948-2012; MONDINI,
   GABRIELLA/B-7958-2018
OI Gattas, Vera Lucia/0000-0001-5032-4570; Luna, Expedito J
   A/0000-0002-1145-9672; 
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JUN
PY 2012
VL 16
SU 1
BP E258
EP E258
DI 10.1016/j.ijid.2012.05.898
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA 999YX
UT WOS:000308353101220
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Machado, CM
   Levi, JE
AF Machado, Clarisse Martins
   Levi, Jose Eduardo
TI Transplant-Associated and Blood Transfusion-Associated Tropical and
   Parasitic Infections
SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Transplantation; Blood transfusion; Tropical diseases; Parasites;
   Transmission; Donors
ID HEPATITIS-C VIRUS; MYCOBACTERIUM-TUBERCULOSIS INFECTION;
   HUMAN-IMMUNODEFICIENCY-VIRUS; OF-THE-LITERATURE; CHAGAS-DISEASE;
   SOLID-ORGAN; LIVER-TRANSPLANTATION; UNITED-STATES; TRANSMISSION;
   RECIPIENTS
AB Blood transfusion and transplantation may represent efficient mechanisms of spreading infectious agents to naive populations. In the developed countries, as a consequence of globalization, several factors such as international commerce, tourism, and immigration have acted as important features for the emergence or reemergence of infectious diseases previously referred to as tropical. This article reviews the relevant bacterial, protozoan and viral infections that are more frequently associated with blood transfusion and/or solid organ or marrow transplantation and may affect susceptible populations worldwide.
C1 [Machado, Clarisse Martins; Levi, Jose Eduardo] Univ Sao Paulo, Virol Lab, Inst Trop Med, BR-05403000 Sao Paulo, Brazil.
   [Machado, Clarisse Martins] Amaral Carvalho Fdn, Hematopoiet Stem Cell Transplantat Program, BR-17210080 Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Virol Lab, Inst Trop Med, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
CR Aguado JM, 1997, TRANSPLANTATION, V63, P1278, DOI 10.1097/00007890-199705150-00015
   Al-Anazi Khalid A, 2009, Cases J, V2, P91, DOI 10.1186/1757-1626-2-91
   Alter HJ, 2008, BLOOD, V112, P2617, DOI 10.1182/blood-2008-07-077370
   Antinori S, 2008, LANCET INFECT DIS, V8, P191, DOI 10.1016/S1473-3099(08)70043-4
   Aregawi M, 2011, WORLD MALARIA REPORT
   Bacal F, 2010, CLIN TRANSPLANT, V24, pE29, DOI 10.1111/j.1399-0012.2009.01202.x
   Basset D, 2005, MICROBES INFECT, V7, P1370, DOI 10.1016/j.micinf.2005.06.002
   Batista MV, 2011, TROP MED INT HEALTH, V16, P1134, DOI 10.1111/j.1365-3156.2011.02816.x
   Bern C, 2007, JAMA-J AM MED ASSOC, V298, P2171, DOI 10.1001/jama.298.18.2171
   Bocchi EA, 2001, ANN THORAC SURG, V71, P1833, DOI 10.1016/S0003-4975(01)02587-5
   Bronnert J, 2007, J TRAVEL MED, V14, P177, DOI 10.1111/j.1708-8305.2006.00095.x
   Candotti D, 2009, J HEPATOL, V51, P798, DOI 10.1016/j.jhep.2009.05.020
   Centers for Disease Control and Prevention (CDC), 2008, MMWR Morb Mortal Wkly Rep, V57, P333
   Chiche L, 2003, TRANSPLANTATION, V75, P166, DOI 10.1097/00007890-200301150-00031
   Chin-Hong PV, 2011, AM J TRANSPLANT, V11, P672, DOI 10.1111/j.1600-6143.2011.03444.x
   Chocair P R, 1981, Rev Inst Med Trop Sao Paulo, V23, P280
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Cohn DL, 2000, AM J RESP CRIT CARE, V161, pS221
   Cruz I, 2002, LANCET, V359, P1124, DOI 10.1016/S0140-6736(02)08160-6
   D'Albuquerque LAC, 2007, AM J TRANSPLANT, V7, P680, DOI 10.1111/j.1600-6143.2007.01663.x
   De Serres G, 2008, CLIN INFECT DIS, V46, P1329, DOI 10.1086/586745
   Dey A, 2006, Indian J Med Microbiol, V24, P165
   Dias JP, 2008, REV SOC BRAS MED TRO, V41, P296, DOI 10.1590/S0037-86822008000300014
   Fischer L, 1999, CLIN TRANSPLANT, V13, P491, DOI 10.1034/j.1399-0012.1999.130609.x
   Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7
   Freitas J., 1952, REV PAULIST MED, V40, P36
   Gerlich WH, 2007, J MED VIROL, V79, pS32, DOI 10.1002/jmv.20963
   Humar A, 2010, AM J TRANSPLANT, V10, P889, DOI 10.1111/j.1600-6143.2009.02992.x
   Ison MG, 2011, AM J TRANSPLANT, V11, P1218, DOI 10.1111/j.1600-6143.2011.03597.x
   Koseoglu F, 2001, TRANSPLANT P, V33, P1782, DOI 10.1016/S0041-1345(00)02678-6
   Kotton CN, 2007, CLIN INFECT DIS, V44, P857, DOI 10.1086/511859
   Levi JE, 2011, ISBT SCI SER, V6, P116
   Linnen JM, 2008, TRANSFUSION, V48, P1355, DOI 10.1111/j.1537-2995.2008.01772.x
   Machado CM, 2009, REV INST MED TROP SP, V51, P309, DOI 10.1590/S0036-46652009000600002
   Machado CM, 2010, TRANSPLANT INFECT, P90
   Manning Susan E., 2008, Morbidity and Mortality Weekly Report, V57, P1
   Martin-Davila P, 2008, CLIN MICROBIOL REV, V21, P60, DOI 10.1128/CMR.00021-07
   Mascola L., 2006, Morbidity and Mortality Weekly Report, V55, P798
   Menichetti F, 2006, LIVER TRANSPLANT, V12, P674, DOI 10.1002/lt.20730
   Morris MI, 2010, INFECT DIS CLIN N AM, V24, P497, DOI 10.1016/j.idc.2010.02.002
   Munoz P, 2005, CLIN INFECT DIS, V40, P581, DOI 10.1086/427692
   Negro F, 2011, LIVER INT, V31, P1, DOI 10.1111/j.1478-3231.2011.02537.x
   Owusu-Ofori AK, 2010, CLIN INFECT DIS, V51, P1192, DOI 10.1086/656806
   Pinazo MJ, 2011, TRANSPLANT REV-ORLAN, V25, P91, DOI 10.1016/j.trre.2010.12.002
   Pruss A, 2010, TRANSPL INFECT DIS, V12, P375, DOI 10.1111/j.1399-3062.2010.00505.x
   QUARTO M, 1989, NEW ENGL J MED, V320, P1754
   Reesink HW, 2010, VOX SANG, V98, P468, DOI 10.1111/j.1423-0410.2009.01301.x
   Rigau-Perez Jose G., 2001, American Journal of Tropical Medicine and Hygiene, V64, P67
   Rose DN, 2000, ARCH INTERN MED, V160, P1513, DOI 10.1001/archinte.160.10.1513
   Roth WK, 2012, VOX SANG, V102, P82, DOI 10.1111/j.1423-0410.2011.01506.x
   Rupprecht CE, 2002, LANCET INFECT DIS, V2, P327, DOI 10.1016/S1473-3099(02)00287-6
   Scarlata F, 2008, T ROY SOC TROP MED H, V102, P394, DOI 10.1016/j.trstmh.2008.01.011
   Schmunis GA, 2005, CLIN MICROBIOL REV, V18, P12, DOI 10.1128/CMR.18.1.12-29.2005
   Schofield CJ, 2006, TRENDS PARASITOL, V22, P583, DOI 10.1016/j.pt.2006.09.011
   Singh N, 1998, CLIN INFECT DIS, V27, P1266, DOI 10.1086/514993
   Stramer S. L., 2007, Morbidity and Mortality Weekly Report, V56, P141
   Stramer SL, 2011, NEW ENGL J MED, V364, P236, DOI 10.1056/NEJMoa1007644
   Subramanian A, 2009, AM J TRANSPLANT, V9, pS57, DOI 10.1111/j.1600-6143.2009.02894.x
   Tan FLS, 2005, NEPHROL DIAL TRANSPL, V20, P447, DOI 10.1093/ndt/gfh601
   Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019
   Vermeulen M, 2009, TRANSFUSION, V49, P1115, DOI 10.1111/j.1537-2995.2009.02110.x
   Wendel S, 2010, ACTA TROP, V115, P28, DOI 10.1016/j.actatropica.2009.12.006
   WHO Expert Committee on the Control of Leishmaniases, 2010, WHO TECHN SER
   Wiwanitkit V, 2010, J INFECT DEV COUNTR, V4, P51, DOI 10.3855/jidc.145
   World Health Organization, 2011, GLOB TUB CONTR
   Zayas CF, 2002, JAMA-J AM MED ASSOC, V287, P1795
   Zou SM, 2012, TRANSFUS MED REV, V26, P119, DOI 10.1016/j.tmrv.2011.07.007
   Zou SM, 2004, NEW ENGL J MED, V351, P751, DOI 10.1056/NEJMoa032510
NR 68
TC 5
Z9 5
U1 0
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0891-5520
EI 1557-9824
J9 INFECT DIS CLIN N AM
JI Infect. Dis. Clin. North Am.
PD JUN
PY 2012
VL 26
IS 2
BP 225
EP +
DI 10.1016/j.idc.2012.02.008
PG 18
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 966QS
UT WOS:000305853100004
PM 22632636
OA Green Published
DA 2020-12-15
ER

PT J
AU Machado, DM
   Fink, MC
   Pannuti, CS
   Succi, RCD
   Machado, AA
   do Carmo, FB
   Gouvea, ADB
   Urbano, PR
   Beltrao, SV
   dos Santos, ICL
   Machado, CM
AF Machado, Daisy Maria
   Fink, Maria Cristina
   Pannuti, Claudio Sergio
   de Menezes Succi, Regina Celia
   Machado, Alessandra Aparecida
   do Carmo, Fabiana Bononi
   Barbosa Gouvea, Aida de Fatima
   Urbano, Paulo Roberto
   Beltrao, Suenia Vasconcelos
   Lopes dos Santos, Isabel Cristina
   Machado, Clarisse Martins
TI Human polyomaviruses JC and BK in the urine of Brazilian children and
   adolescents vertically infected by HIV
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE HIV-1; child; adolescent; JC virus; BK virus; urine
ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; POLYMERASE-CHAIN-REACTION;
   AIDS PATIENTS; VIRUS-DNA; EPIDEMIOLOGY; POPULATION; PROMOTER; PATIENT;
   SAMPLES; TAT
AB The aim of this study was to characterize the urinary excretion of the BK (BKV) and JC (JCV) human polyomaviruses in a cohort of human immunodeficiency virus (HIV)-infected children and adolescents. One hundred and fifty-six patients were enrolled: Group I included 116 HIV-infected children and adolescents [median age = 11.4 years (y); range 1-22 y]; Group II included 40 non-HIV-infected healthy controls (median age = 11.37 y; range 7-16 y). Single urine samples from both groups were screened for the presence of JCV and BKV DNA by polymerase chain reaction at enrolment. The overall rate of JCV and BKV urinary excretion was found to be 24.4% and 40.4%, respectively (n = 156). Group I had urinary excretion of JCV and BKV in 27.6% and 54.3% of subjects, respectively. In contrast, Group II showed positive results for JCV in 17.5% of subjects and for BKV in 12.5% of subjects (p Pearson JCV = 0.20; p Pearson BKV < 0.0001). In Group I, there was no association between JCV/BKV shedding and age, gender or CD4 values. Patients with an HIV viral load < 50 copies/mL had a lower excretion of BKV (p < 0.001) and a trend of lower JCV excretion (p = 0.07). One patient in Group I (1/116, 0.9%) showed clinical and radiological features consistent with progressive multifocal leukoencephalopathy, suggesting that children with HIV/polyomavirus coinfection should be kept under surveillance.
C1 [Machado, Daisy Maria; Fink, Maria Cristina; Pannuti, Claudio Sergio; Machado, Alessandra Aparecida; Urbano, Paulo Roberto; Machado, Clarisse Martins] Univ Sao Paulo, Inst Med Trop Sao Paulo, Virol Lab, BR-05403000 Sao Paulo, Brazil.
   [Machado, Daisy Maria; de Menezes Succi, Regina Celia; do Carmo, Fabiana Bononi; Barbosa Gouvea, Aida de Fatima; Beltrao, Suenia Vasconcelos; Lopes dos Santos, Isabel Cristina] Univ Fed Sao Paulo, Disciplina Infectol Pediat, Dept Pediat, Sao Paulo, Brazil.
RP Machado, DM (corresponding author), Univ Sao Paulo, Inst Med Trop Sao Paulo, Virol Lab, Av Dr Eneas Carvalho de Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM dm.machado@uol.com.br
RI Fink, Maria Cristina/M-8718-2015; Urbano, Paulo R/M-1182-2013; Pannuti,
   Claudio/B-7649-2012
OI Urbano, Paulo R/0000-0001-6240-5933; Machado, Daisy/0000-0003-1993-6442;
   Urbano, Paulo/0000-0001-7621-1208
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [07/06687-7]
FX FAPESP (07/06687-7)
CR Agostini HT, 1997, P NATL ACAD SCI USA, V94, P14542, DOI 10.1073/pnas.94.26.14542
   Antinori A, 2001, J NEUROVIROL, V7, P323, DOI 10.1080/13550280152537184
   ARTHUR RR, 1989, J CLIN MICROBIOL, V27, P1174, DOI 10.1128/JCM.27.6.1174-1179.1989
   Behzad-Behbahani A, 2004, J CLIN VIROL, V29, P224, DOI 10.1016/S1386-6532(03)00155-0
   Bratt G, 1999, AIDS, V13, P1071, DOI 10.1097/00002030-199906180-00010
   Caldwell MB, 1994, MMWR RECOMM REP, V43, P1
   CHOWDHURY M, 1993, ONCOGENE, V8, P887
   CHOWDHURY M, 1992, J VIROL, V66, P7355, DOI 10.1128/JVI.66.12.7355-7361.1992
   Degener AM, 1997, MICROBIOLOGICA, V20, P115
   Drake AK, 2007, EUR J NEUROL, V14, P418, DOI 10.1111/j.1468-1331.2007.01686.x
   Fink MCDS, 2006, J INFECTION, V52, P30, DOI 10.1016/j.jinf.2005.02.015
   Lafon ME, 1998, J INFECT DIS, V177, P1502, DOI 10.1086/515305
   LI J, 1993, J MED VIROL, V41, P11, DOI 10.1002/jmv.1890410104
   MAJOR EO, 1995, CURR OPIN NEUROL, V8, P184
   MARKOWITZ RB, 1993, J INFECT DIS, V167, P13, DOI 10.1093/infdis/167.1.13
   Matos A, 2010, J MED VIROL, V82, P494, DOI 10.1002/jmv.21710
   Schaffer K, 2006, J NEUROVIROL, V12, P39, DOI 10.1080/13550280600614965
   SUNDSFJORD A, 1994, J INFECT DIS, V169, P485, DOI 10.1093/infdis/169.3.485
   Vidal Jose E, 2007, AIDS Res Ther, V4, P13, DOI 10.1186/1742-6405-4-13
   Weinberg GA, 2010, PEDIATR INFECT DIS J, V29, P257, DOI 10.1097/INF.0b013e3181d01c6d
NR 20
TC 12
Z9 12
U1 0
U2 4
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD DEC
PY 2011
VL 106
IS 8
BP 931
EP 935
DI 10.1590/S0074-02762011000800006
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 875XP
UT WOS:000299068800006
PM 22241113
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Kanashiro, TM
   Boas, LSV
   Thomaz, AM
   Tozetto-Mendoza, TR
   Setsuko, M
   Machado, CM
AF Kanashiro, Tatiana Mitiko
   Vilas Boas, Lucy Santos
   Thomaz, Ana Maria
   Tozetto-Mendoza, Tania Regina
   Setsuko, Monica
   Machado, Clarisse Martins
TI IDENTIFICATION OF RESPIRATORY VIRUS IN INFANTS WITH CONGENITAL HEART
   DISEASE BY COMPARISON OF DIFFERENT METHODS
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Respiratory viruses; Congenital heart disease; Direct immunofluorescence
   assay; Multiplex PCR; PCR
ID PRIMING OLIGONUCLEOTIDE SYSTEM; POLYMERASE-CHAIN-REACTION; PCR ASSAY;
   IMMUNOFLUORESCENCE TECHNIQUES; SYNCYTIAL VIRUS; MULTIPLEX PCR; VIRAL
   CULTURE; INFECTIONS; PATHOGENS; YOUNG
AB Respiratory virus infections are the main cause of infant hospitalization and are potentially severe in children with congenital heart disease (CHD). Rapid and sensitive diagnosis is very important to early introduction of antiviral treatment and implementation of precautions to control transmission, reducing the risk of nosocomial infections. In the present study we compare different techniques in the diagnosis of respiratory viruses in CHD infants. Thirty-nine samples of nasopharyngeal aspirate were obtained from CHD infants with symptoms of respiratory infection. The Multiplex PCR (Seeplex (R) RV 12 ACE Detection) driven to the detection of 12 respiratory viruses was compared with the direct immunofluorescence assay (DFA) and PCR, both targeting seven respiratory viruses. The positivity found by DFA, Multiplex and PCR was 33.3%, 51.3% and 48.7%, respectively. Kappa index comparing DFA and Multiplex, DFA and PCR and PCR and Multiplex PCR was 0.542, 0.483 and 0.539, respectively. The concordance between techniques was considered moderate. Both Multiplex PCR (p = 0.001) and PCR (p = 0.002) detected significantly more respiratory virus than DFA. As the performance of the tests may vary, the combination of two or more techniques may increase diagnostic sensitivity favoring the diagnosis of co-infections, early introduction of antiviral therapy and implementation of appropriate measures.
C1 [Kanashiro, Tatiana Mitiko; Vilas Boas, Lucy Santos; Tozetto-Mendoza, Tania Regina; Machado, Clarisse Martins] Univ Sao Paulo, Virol Lab, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil.
   [Thomaz, Ana Maria; Setsuko, Monica] Univ Sao Paulo, INCOR Unidade Terapia Intens, Inst Coracao, Hosp Clin,Fac Med, BR-05403900 Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Virol Lab, Inst Med Trop Sao Paulo, Ave Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
RI Tozetto-Mendoza, Tania Regina/B-9572-2015
FU AbbottAbbott Laboratories
FX The study was partially supported by Abbott. Kit Seeplex was kindly
   provided by Bioeasy Diagnostica.
CR Allard A, 2001, J CLIN MICROBIOL, V39, P498, DOI 10.1128/JCM.39.2.498-505.2001
   Bharaj P, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-89
   Chun JY, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm051
   Drews SJ, 2008, ANN CLIN LAB SCI, V38, P376
   Falsey AR, 2003, J INFECT DIS, V187, P785, DOI 10.1086/367901
   Harrison TJ, 1998, J CLIN PATHOL, V51, P491, DOI 10.1136/jcp.51.7.491
   Kim SR, 2009, J VIROL METHODS, V156, P111, DOI 10.1016/j.jviromet.2008.11.007
   Klapper PE, 1998, CLIN CHEM, V44, P1737
   Liolios L, 2001, J CLIN MICROBIOL, V39, P2779, DOI 10.1128/JCM.39.8.2779-2783.2001
   Mahony JB, 2008, CLIN MICROBIOL REV, V21, P716, DOI 10.1128/CMR.00037-07
   Marshall DJ, 2007, J CLIN MICROBIOL, V45, P3875, DOI 10.1128/JCM.00838-07
   Medrano C, 2007, CARDIOL YOUNG, V17, P360, DOI 10.1017/S104795110700042X
   Medrano Lopez C, 2007, An Pediatr (Barc), V67, P329
   Lopez CM, 2009, AN PEDIATR, V71, P38, DOI 10.1016/j.anpedi.2008.11.007
   Reis AD, 2008, REV INST MED TROP SP, V50, P37, DOI 10.1590/S0036-46652008000100008
   Roh KH, 2008, ANN CLIN LAB SCI, V38, P41
   SOUZA AV, UNPUB COMMUNICATION
   SULLENDER WM, 1993, J CLIN MICROBIOL, V31, P1224, DOI 10.1128/JCM.31.5.1224-1231.1993
   van Coppenraet LESB, 2010, J VIROL METHODS, V169, P188, DOI 10.1016/j.jviromet.2010.07.032
   van Elden LJR, 2001, J CLIN MICROBIOL, V39, P196, DOI 10.1128/JCM.39.1.196-200.2001
   World Health Organization, 2008, GLOB BURD DIS 2004 U
   Yoo SJ, 2007, KOREAN J LAB MED, V27, P420, DOI 10.3343/kjlm.2007.27.6.420
NR 22
TC 6
Z9 7
U1 0
U2 2
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD SEP-OCT
PY 2011
VL 53
IS 5
BP 241
EP 246
DI 10.1590/S0036-46652011000500001
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 835GY
UT WOS:000296025600001
PM 22012448
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Machado, AA
   Machado, CM
   Boas, LSV
   Lopes, MC
   Gouvea, ADB
   Succi, RCD
   Mendoza, TRT
   Kanashiro, TM
   Machado, DM
AF Machado, Alessandra Aparecida
   Machado, Clarisse Martins
   Vilas Boas, Lucy Santos
   Lopes, Mariana Corniani
   Barbosa Gouvea, Aida de Fatima
   de Menezes Succi, Regina Celia
   Tozetto Mendoza, Tania Regina
   Kanashiro, Tatiana Mitiko
   Machado, Daisy Maria
TI Short Communication: Immunogenicity of an Inactivated Influenza Vaccine
   and Postvaccination Influenza Surveillance in HIV-Infected and
   Noninfected Children and Adolescents
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID ANTIBODY-RESPONSE; INDIVIDUALS; IMMUNIZATION; TETANUS; SAFETY; CELLS
AB Individuals infected with HIV are at higher risk for severe cases of seasonal influenza infection and should receive annual doses of vaccine. Our objectives were to evaluate the immunogenicity of an influenza vaccine in 37 HIV-infected patients (HIV group) compared to 29 uninfected individuals (control group) and to carry out a clinical and virological surveillance of influenza during a 6-month follow-up. Both groups received the vaccine recommended for the southern hemisphere in 2008. Antibody responses to antigens H1N1, H3N2, and B were measured in blood samples at vaccination (T0) and after 1 month (T1). Influenza surveillance was performed by weekly telephone calls for a follow-up period of 6 months. Nasal washes were taken from subjects with respiratory symptoms. The direct immunofluorescence assay in house polymerase chain reaction (PCR) and real-time PCR were used for the detection of different respiratory viruses. The median age of the participants was 13.3 years (sd = 2.2) and 12.1 years (sd = 1.3) for the HIV group and control group, respectively. One month after vaccination (T1), both groups showed significant increases in the antibody geometric mean titers (GMTs) for all antigens. However, healthy controls showed higher values for antigens A/H1N1 and A/H3N2 (p = 0.002 and 0.001, respectively). There was a higher increase in the percentage of HIV-uninfected subjects with protective A/H1N1 antibodies (96.6%) compared to HIV-infected vaccinees (67.6%) at T1 (p = 0.004). Rhinovirus (27.7%) and coronavirus (22.5%) were the most prevalent agents identified in HIV-infected individuals. In the control group, the viruses most frequently found were rhinovirus (24.2%) and adenovirus (21.2%). The seroprotection rate for the H1N1 antigen was higher in the control group, which also showed a greater increase in GMTs for H1N1 and H3N2 antigens after immunization. Viral agents were identified in 39/60 (65%) episodes of respiratory infections from the HIV-infected group and in 17/32 episodes (53.1%) from the control group (p = 0.273).
C1 [Machado, Alessandra Aparecida; Machado, Clarisse Martins; Vilas Boas, Lucy Santos; Lopes, Mariana Corniani; Tozetto Mendoza, Tania Regina; Kanashiro, Tatiana Mitiko; Machado, Daisy Maria] Univ Sao Paulo, Virol Lab, Inst Trop Med, Sao Paulo, Brazil.
   [Barbosa Gouvea, Aida de Fatima; de Menezes Succi, Regina Celia; Machado, Daisy Maria] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
RP Machado, DM (corresponding author), Rua Pedro de Toledo 924, BR-04039002 Sao Paulo, Brazil.
EM dm.machado@uol.com.br
RI Tozetto-Mendoza, Tania Regina/B-9572-2015
OI Machado, Daisy/0000-0003-1993-6442
CR Amendola A, 2002, VACCINE, V20, P3720, DOI 10.1016/S0264-410X(02)00357-2
   Amendola A, 2010, VACCINE, V28, P2700, DOI 10.1016/j.vaccine.2010.01.021
   Atashili J, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-138
   Berkelhamer S, 2001, CLIN INFECT DIS, V32, P1090, DOI 10.1086/319591
   [Anonymous], 2001, MMWR CDC Surveill Summ, V50, P1
   *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P12
   Carvalho Aroldo P. de, 2003, J. Pediatr. (Rio J.), V79, P29, DOI 10.1590/S0021-75572003000100007
   Gouvea AFTB, 2005, CLIN INFECT DIS, V41, P544, DOI 10.1086/432055
   Hirst GK, 1941, SCIENCE, V94, P22, DOI 10.1126/science.94.2427.22
   Jackson CR, 1997, PEDIATR INFECT DIS J, V16, P200, DOI 10.1097/00006454-199702000-00007
   KROON FP, 1994, AIDS, V8, P469, DOI 10.1097/00002030-199404000-00008
   Kroon FP, 2000, VACCINE, V18, P3040, DOI 10.1016/S0264-410X(00)00079-7
   Lange CG, 2003, AIDS, V17, P2015, DOI 10.1097/00002030-200309260-00002
   Lima M, 2004, PEDIATR INFECT DIS J, V23, P604, DOI 10.1097/01.inf.0000128780.79145.5c
   Pessoa SD, 2010, VACCINE, V28, P1606, DOI 10.1016/j.vaccine.2009.11.045
   Rosenblatt HM, 2005, J ALLERGY CLIN IMMUN, V116, P698, DOI 10.1016/j.jaci.2005.05.016
   Rucker RP, 2004, ANN ALLERG ASTHMA IM, V93, P272, DOI 10.1016/S1081-1206(10)61500-1
   Salk JE, 1944, J IMMUNOL, V49, P87
   Vigano A, 2008, JAIDS-J ACQ IMM DEF, V48, P289, DOI 10.1097/QAI.0b013e3181632cda
   Zaccarelli CA, 2007, CYTOM PART B-CLIN CY, V72B, P14, DOI 10.1002/cyto.b.20152
   Zanetti AR, 2002, VACCINE, V20, pB29, DOI 10.1016/S0264-410X(02)00511-X
NR 21
TC 2
Z9 3
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD SEP
PY 2011
VL 27
IS 9
BP 999
EP 1003
DI 10.1089/aid.2010.0306
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 810XQ
UT WOS:000294163700010
PM 21284525
DA 2020-12-15
ER

PT J
AU Inoue, J
   Machado, CM
   Lima, GFMD
   Nascimento, MDC
   Colturato, VR
   Di Santi, SM
AF Inoue, Juliana
   Machado, Clarisse Martins
   Maciel de Castro Lima, Giselle Fernandes
   Costa Nascimento, Maria de Jesus
   Colturato, Vergilio Rensi
   Di Santi, Silvia Maria
TI THE MONITORING OF HEMATOPOIETIC STEM CELL TRANSPLANT DONORS AND
   RECIPIENTS FROM ENDEMIC AREAS FOR MALARIA
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Hematopoietic stem cell transplantation; Malaria; Molecular diagnostic;
   Microscopy
ID TRANSFUSION-TRANSMITTED MALARIA; BONE-MARROW-TRANSPLANTATION;
   PLASMODIUM-FALCIPARUM; HIGH PREVALENCE; VIVAX; TRANSMISSION; GUIDELINES;
   INFECTION; BRAZIL
AB Malaria is an unusual complication after hematopoietic stem cell transplantation in non-endemic countries. However, transplant candidates, recipients and donors living in endemic regions frequently report previous episodes of malaria. This fact could represent an important risk for immunosuppressed recipients that could develop severe malaria cases. We report a case of hematopoietic stem cell transplant (HSCT) in which the donor had a history of previous malaria, and close monitoring was performed before and after procedure by parasitological and molecular tests. The donor presented Plasmodium vivax in thick blood smears one month after transplant and was treated according to Brazilian Health Ministry guidelines. The polymerase chain reaction (PCR) was able to detect malaria infection in the donor one week earlier than thick blood film. Even without positive results, the recipient was pre-emptively treated with chloroquine in order to prevent the disease. We highlight the importance of monitoring recipients and donors in transplant procedures with the aim of reducing the risk of malaria transmission.
C1 [Di Santi, Silvia Maria] Univ Sao Paulo, Inst Med Trop Sao Paulo, Secretaria Saude Estado S Paulo, Nucleo Estudos Malaria,Malaria Res Ctr, BR-05403000 Sao Paulo, Brazil.
   [Machado, Clarisse Martins; Colturato, Vergilio Rensi] Amaral Carvalho Fdn, Hematopoiet Stem Cell Transplant Program, Jau, SP, Brazil.
RP Di Santi, SM (corresponding author), Univ Sao Paulo, Inst Med Trop Sao Paulo, Secretaria Saude Estado S Paulo, Nucleo Estudos Malaria,Malaria Res Ctr, Av Dr Eneas de Carvalho Aguiar 470,Sala 107, BR-05403000 Sao Paulo, Brazil.
EM santi@usp.br
RI Inoue, Juliana/J-3314-2014; Di Santi, Silvia/D-8973-2012; Lima,
   Giselle/M-8335-2014
OI Di Santi, Silvia/0000-0001-8049-2014; 
FU Health Secretariat of Sao Paulo State and Tropical Medicine Institute of
   Sao Paulo; Amaral Carvalho Foundation
FX This work was supported by: 1) Health Secretariat of Sao Paulo State and
   Tropical Medicine Institute of Sao Paulo, as part of a technical
   cooperation agreement; 2) Amaral Carvalho Foundation.
CR Alves FP, 2002, AM J TROP MED HYG, V66, P641, DOI 10.4269/ajtmh.2002.66.641
   Belizario V. Y., 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P552
   BOULOS M, 1991, REV I MED TROP, V33, P143, DOI 10.1590/S0036-46651991000200009
   Chiche L, 2003, TRANSPLANTATION, V75, P166, DOI 10.1097/00007890-200301150-00031
   DEANDRADE ALSS, 1995, CLIN INFECT DIS, V20, P475, DOI 10.1093/clinids/20.2.475
   GUPTA S, 1994, PARASITE IMMUNOL, V16, P361, DOI 10.1111/j.1365-3024.1994.tb00361.x
   HOLZER BR, 1985, TRANSPLANTATION, V39, P315, DOI 10.1097/00007890-198503000-00023
   Kirchgatter K, 2005, BMJ-BRIT MED J, V331, p576b
   Kitchen A, 2005, VOX SANG, V88, P200, DOI 10.1111/j.1423-0410.2005.00610.x
   Kitchen AD, 2006, VOX SANG, V90, P77, DOI 10.1111/j.1423-0410.2006.00733.x
   Krotoski W A, 1989, Prog Clin Parasitol, V1, P1
   Lefere F, 1996, BONE MARROW TRANSPL, V18, P473
   Machado CM, 2009, REV INST MED TROP SP, V51, P309, DOI 10.1590/S0036-46652009000600002
   Mungai M, 2001, NEW ENGL J MED, V344, P1973, DOI 10.1056/NEJM200106283442603
   O'Donnell J, 1998, BONE MARROW TRANSPL, V21, P313, DOI 10.1038/sj.bmt.1701073
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019
   Tran VB, 1997, BONE MARROW TRANSPL, V19, P1259, DOI 10.1038/sj.bmt.1700822
   White NJ, 2008, CLIN INFECT DIS, V46, P172, DOI 10.1086/524889
NR 19
TC 6
Z9 6
U1 0
U2 3
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD SEP-OCT
PY 2010
VL 52
IS 5
BP 281
EP 284
DI 10.1590/S0036-46652010000500012
PG 4
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 675SS
UT WOS:000283854300011
PM 21049235
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Machado, CM
   Martins, TC
   Colturato, I
   Leite, MS
   Simione, AJ
   de Souza, MP
   Mauad, MA
   Colturato, VR
AF Machado, Clarisse Martins
   Martins, Talita Chaves
   Colturato, Iago
   Leite, Marilia Souza
   Simione, Anderson Joao
   de Souza, Mair Pedro
   Mauad, Marcos Augusto
   Colturato, Vergilio Rensi
TI EPIDEMIOLOGY OF NEGLECTED TROPICAL DISEASES IN TRANSPLANT RECIPIENTS.
   REVIEW OF THE LITERATURE AND EXPERIENCE OF A BRAZILIAN HSCT CENTER
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Review
DE Neglected tropical diseases; Transplantation; Developing countries;
   HSCT; Epidemiology
ID MYCOBACTERIUM-TUBERCULOSIS INFECTION; STEM-CELL TRANSPLANTATION; DENGUE
   SHOCK SYNDROME; CHAGAS-DISEASE; ORGAN-TRANSPLANTATION; YELLOW-FEVER;
   RISK-FACTORS; LIVER-TRANSPLANTATION; MEASLES VACCINATION; LATIN-AMERICA
AB The rising success rate of solid organ (SOT) and haematopoietic stern cell transplantation (HSCT)and modern immunosuppression make transplants the first therapeutic Option for many diseases affecting a considerable number of people worldwide. Consequently, developing countries have also grown their transplant programs and have started to face the impact of neglected tropical diseases (NTDs) in transplant recipients. We reviewed the literature data on the epidemiology of NTDs with greatest disease burden. which have affected transplant recipients in developing countries or may represent,I threat to transplant recipients living in other regions. Tuberculosis, Leprosy, Chagas disease, Malaria, Leishmaniasis, Dengue. Yellow fever and Measles are the topics included in this review. In addition, we retrospectively revised the experience concerning the management of NTDs at the HSCT program of Amaral Carvalho Foundation, a public transplant program of the state of Sao Paulo, Brazil.
C1 [Machado, Clarisse Martins; Martins, Talita Chaves; Leite, Marilia Souza; Simione, Anderson Joao; de Souza, Mair Pedro; Mauad, Marcos Augusto; Colturato, Vergilio Rensi] Fundacao Hosp Amaral Carvalho, HSCT Program, Jau, SP, Brazil.
   [Machado, Clarisse Martins; Colturato, Iago] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.bi
RI Grossi, Paolo Antonio/A-6158-2013
OI Grossi, Paolo Antonio/0000-0003-2883-5061; Souza,
   Mair/0000-0002-7411-9296; Simione, Anderson/0000-0002-6939-906X
CR Abel L, 1998, J INFECT DIS, V177, P133, DOI 10.1086/513830
   AGAMANOLIS DP, 1979, ARCH NEUROL-CHICAGO, V36, P686, DOI 10.1001/archneur.1979.00500470056011
   Aguado JM, 1997, TRANSPLANTATION, V63, P1278, DOI 10.1097/00007890-199705150-00015
   Altclas JD, 2008, JAMA-J AM MED ASSOC, V299, P1134, DOI 10.1001/jama.299.10.1134-a
   Antinori S, 2005, CLIN MICROBIOL INFEC, V11, P343, DOI 10.1111/j.1469-0691.2004.01046.x
   Antinori S, 2008, LANCET INFECT DIS, V8, P191, DOI 10.1016/S1473-3099(08)70043-4
   AREGAWI M, 2008, WORLD MALARIA REPORT
   Azevedo LS, 2007, TRANSPLANTATION, V84, P792, DOI 10.1097/01.tp.0000280547.91617.25
   Barrett ADT, 2007, ANNU REV ENTOMOL, V52, P209, DOI 10.1146/annurev.ento.52.110405.091454
   BEATTY ME, 2008, DENGUE FEVER CDC HLT
   Bern C, 2008, CURR OPIN INFECT DIS, V21, P476, DOI 10.1097/QCO.0b013e32830ef5b6
   Bern C, 2007, JAMA-J AM MED ASSOC, V298, P2171, DOI 10.1001/jama.298.18.2171
   Bocchi EA, 2001, ANN THORAC SURG, V71, P1833, DOI 10.1016/S0003-4975(01)02587-5
   Boggild AK, 2004, CAN MED ASSOC J, V170, P71
   Britton WJ, 2004, LANCET, V363, P1209, DOI 10.1016/S0140-6736(04)15952-7
   Budak-Alpdogan T, 2000, BIOL BLOOD MARROW TR, V6, P370, DOI 10.1016/S1083-8791(00)70013-9
   Campos SV, 2008, J HEART LUNG TRANSPL, V27, P597, DOI 10.1016/j.healun.2008.02.017
   CANTAROVICH F, 1992, TRANSPL P, V24, P1902
   Cetron Martin S, 2002, MMWR Recomm Rep, V51, P1
   Chacko B, 2004, TRANSPLANTATION, V77, P634, DOI 10.1097/01.TP.0000114608.44000.D7
   Chiche L, 2003, TRANSPLANTATION, V75, P166, DOI 10.1097/00007890-200301150-00031
   Chocair P R, 1981, Rev Inst Med Trop Sao Paulo, V23, P280
   CIFRAS INE, 2008, B INFORM I NACL ESTA
   Clark BM, 2008, AM J TROP MED HYG, V78, P962, DOI 10.4269/ajtmh.2008.78.962
   Cordonnier C, 2004, CLIN INFECT DIS, V38, P1229, DOI 10.1086/383307
   Cruz I, 2002, LANCET, V359, P1124, DOI 10.1016/S0140-6736(02)08160-6
   *CTR VIG SAUD MIN, 2008, BOL EP CVS
   D'Albuquerque LAC, 2007, AM J TRANSPLANT, V7, P680, DOI 10.1111/j.1600-6143.2007.01663.x
   Date A, 1998, LEPROSY REV, V69, P40
   *DEP EP, 2008, SIT EP DENG ISL PAS
   Deps PD, 2008, INDIAN J DERMATOL VE, V74, P338, DOI 10.4103/0378-6323.42897
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   Desjeux P, 2001, T ROY SOC TROP MED H, V95, P239, DOI 10.1016/S0035-9203(01)90223-8
   Dias JP, 2008, REV SOC BRAS MED TRO, V41, P296, DOI 10.1590/S0037-86822008000300014
   Duchini A, 2003, CLIN MICROBIOL REV, V16, P357, DOI 10.1128/CMR.16.3.357-364.2003
   Eurosurveillance Editorial team, 2008, EUROSURVEILLANCE, V13
   Figueiredo L T, 1990, Bull Pan Am Health Organ, V24, P217
   Fischer L, 1999, CLIN TRANSPLANT, V13, P491, DOI 10.1034/j.1399-0012.1999.130609.x
   Freedman DO, 2006, NEW ENGL J MED, V354, P119, DOI 10.1056/NEJMoa051331
   Garcia JHP, 2006, TRANSPLANTATION, V82, P850, DOI 10.1097/01.tp.0000235151.60237.fe
   Gasink LB, 2006, J HEART LUNG TRANSPL, V25, P854, DOI 10.1016/j.healun.2006.03.016
   Gay NJ, 2004, J INFECT DIS, V189, pS27, DOI 10.1086/381592
   Gibbons RV, 2002, BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563
   Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2
   Halkic N, 2004, CAN J ANAESTH, V51, P84, DOI 10.1007/BF03018554
   Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142
   Hotez PJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000300
   INOUE J, 2009, REV SOC BRAS MED S1, V42, P206
   *INT ORG MIGR, 2008, MIGR 21 CENT FACTS F
   John GT, 2001, KIDNEY INT, V60, P1148, DOI 10.1046/j.1523-1755.2001.0600031148.x
   JOKIPII L, 1992, SCAND J INFECT DIS, V24, P677, DOI 10.3109/00365549209054657
   JUNGMAN P, 2008, VACCINE, P1403
   Kalman S, 2002, PEDIATR TRANSPLANT, V6, P432, DOI 10.1034/j.1399-3046.2002.02028.x
   Kano H, 2002, TRANSPLANTATION, V74, P543, DOI 10.1097/00007890-200208270-00020
   Khan S, 2006, PEDIATR TRANSPLANT, V10, P78, DOI 10.1111/j.1399-3046.2005.00403.x
   KLAPPER PE, 1991, ARCH DIS CHILD, V66, P369, DOI 10.1136/adc.66.3.369-b
   Koseoglu F, 2001, TRANSPLANT P, V33, P1782, DOI 10.1016/S0041-1345(00)02678-6
   Launius Beatrice K, 2004, Crit Care Nurs Q, V27, P87
   le Fichoux Y, 1999, J CLIN MICROBIOL, V37, P1953, DOI 10.1128/JCM.37.6.1953-1957.1999
   Lee DG, 2006, INT J INFECT DIS, V10, P410, DOI 10.1016/j.ijid.2005.09.007
   Linnen JM, 2008, TRANSFUSION, V48, P1355, DOI 10.1111/j.1537-2995.2008.01772.x
   LJUNGMAN P, 1989, J INFECT DIS, V159, P610, DOI 10.1093/infdis/159.4.610
   Lockwood DNJ, 2005, B WORLD HEALTH ORGAN, V83, P230
   Luthy KE, 2006, J AM ACAD NURSE PRAC, V18, P494, DOI 10.1111/j.1745-7599.2006.00163.x
   Machado CM, 2005, BONE MARROW TRANSPL, V35, P787, DOI 10.1038/sj.bmt.1704878
   Machado CM, 2002, BLOOD, V99, P83, DOI 10.1182/blood.V99.1.83
   MALONE N, 2000, FOREIGN BORN POPULAT
   Martin-Davila P, 2008, CLIN MICROBIOL REV, V21, P60, DOI 10.1128/CMR.00021-07
   Mascola L., 2006, Morbidity and Mortality Weekly Report, V55, P798
   Medina-Pestana JO, 2006, ARTIF ORGANS, V30, P498, DOI 10.1111/j.1525-1594.2006.00250.x
   Menichetti F, 2006, LIVER TRANSPLANT, V12, P674, DOI 10.1002/lt.20730
   Menzies D, 2007, ANN INTERN MED, V146, P340, DOI 10.7326/0003-4819-146-5-200703060-00006
   Lessa Marcus Miranda, 2007, Rev. Bras. Otorrinolaringol., V73, P843, DOI 10.1016/S1808-8694(15)31181-2
   Modi K, 2003, AM J TRANSPLANT, V3, P1600, DOI 10.1046/j.1600-6135.2003.00284.x
   Mohammed H, 2008, TRANSFUSION, V48, P1348, DOI 10.1111/j.1537-2995.2008.01771.x
   Monath TP, 2002, CLIN INFECT DIS, V34, P1369, DOI 10.1086/340104
   Munoz P, 2005, CLIN INFECT DIS, V40, P581, DOI 10.1086/427692
   O'Donnell J, 1998, BONE MARROW TRANSPL, V21, P313, DOI 10.1038/sj.bmt.1701073
   Pai M, 2008, ANN INTERN MED, V149, P177, DOI 10.7326/0003-4819-149-3-200808050-00241
   Park SB, 2008, TRANSPL P, V40, P2431, DOI 10.1016/j.transproceed.2008.07.037
   Pieroni F, 2007, BONE MARROW TRANSPL, V40, P859, DOI 10.1038/sj.bmt.1705824
   RAND EB, 1993, J PEDIATR-US, V123, P87, DOI 10.1016/S0022-3476(05)81545-8
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   Renaud CJ, 2007, NEPHROLOGY, V12, P305, DOI 10.1111/j.1440-1797.2007.00785.x
   Riarte A, 1999, CLIN INFECT DIS, V29, P561, DOI 10.1086/598634
   Rigau-Perez Jose G., 2001, American Journal of Tropical Medicine and Hygiene, V64, P67
   Rima BK, 2006, J PATHOL, V208, P199, DOI 10.1002/path.1873
   Rizvi SA, 2003, KIDNEY INT S, V83, pS96, DOI DOI 10.1046/J.1523-1755.63.S83.20.X
   Rose DN, 2000, ARCH INTERN MED, V160, P1513, DOI 10.1001/archinte.160.10.1513
   Schmunis GA, 2005, CLIN MICROBIOL REV, V18, P12, DOI 10.1128/CMR.18.1.12-29.2005
   Schofield CJ, 2006, TRENDS PARASITOL, V22, P583, DOI 10.1016/j.pt.2006.09.011
   *SECR VIG SAUD PRO, 2006, MAN CTR REF IM ESP 2
   Singh N, 1998, CLIN INFECT DIS, V27, P1266, DOI 10.1086/514993
   Sousa AA, 2004, TRANSPL P, V36, P868, DOI 10.1016/j.transproceed.2004.03.113
   Stramer S. L., 2007, Morbidity and Mortality Weekly Report, V56, P141
   SUNDBERG R, 1991, TRANSPLANT P, V23, P3091
   Tan FLS, 2005, NEPHROL DIAL TRANSPL, V20, P447, DOI 10.1093/ndt/gfh601
   TARGETED T, 2000, AM J RESP CRIT CARE, V161, pS221
   Tavil B, 2007, PEDIATR TRANSPLANT, V11, P414, DOI 10.1111/j.1399-3046.2007.00679.x
   THAMBO S, 1989, REV MED CHILE, V117, P18
   Tomblyn M, 2009, BONE MARROW TRANSPL, V44, P453, DOI 10.1038/bmt.2009.254
   Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019
   Torralba JM, 2007, ADV MATER RES-SWITZ, V23, P1, DOI 10.4028/www.scientific.net/AMR.23.1
   Tran VB, 1997, BONE MARROW TRANSPL, V19, P1259, DOI 10.1038/sj.bmt.1700822
   Turnera A, 2006, AM J TRANSPLANT, V6, P1459, DOI 10.1111/j.1600-6143.2006.01330.x
   Vasconcelos P. F, 2003, REV SOC BRAS MED TRO, V36, P275, DOI DOI 10.1590/S0037-86822003000200012
   Warmington L, 2005, PEDIATR TRANSPLANT, V9, P311, DOI 10.1111/j.1399-3046.2005.00313.x
   *WHO, 2008, GLOB TUB CONTR SURV
   *WHO, 2007, MEASL
   *WHO, 2008, CONTR NEGL TROP DIS
   Wilder-Smith A, 2005, NEW ENGL J MED, V353, P924, DOI 10.1056/NEJMra041927
   Yoo JH, 2004, BONE MARROW TRANSPL, V34, P497, DOI 10.1038/sj.bmt.1704636
   Zayas CF, 2002, JAMA-J AM MED ASSOC, V287, P1795
   2008, MMWR, V57, P893
NR 114
TC 39
Z9 41
U1 0
U2 7
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD NOV-DEC
PY 2009
VL 51
IS 6
BP 309
EP 324
DI 10.1590/S0036-46652009000600002
PG 16
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 539ZM
UT WOS:000273299200002
PM 20209266
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Ljungman, P
   Cordonnier, C
   Einsele, H
   Englund, J
   Machado, CM
   Storek, J
   Small, T
AF Ljungman, P.
   Cordonnier, C.
   Einsele, H.
   Englund, J.
   Machado, C. M.
   Storek, J.
   Small, T.
TI Vaccination of hematopoietic cell transplant recipients
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE vaccines; immune recovery; hematopoietic cell transplantation
C1 [Ljungman, P.] Karolinska Univ Hosp, Stockholm, Sweden.
   [Cordonnier, C.] Hop Henri Mondor, F-94010 Creteil, France.
   [Einsele, H.] Univ Klin Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany.
   [Englund, J.] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA.
   [Englund, J.] Univ Washington, Reg Med Ctr, Seattle, WA 98195 USA.
   [Machado, C. M.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Storek, J.] Univ Calgary, Dept Med Oncol Microbiol & Infect Dis, Calgary, AB, Canada.
   [Small, T.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RP Ljungman, P (corresponding author), Karolinska Univ Hosp Huddinge M54, Dept Hematol, S-14186 Stockholm, Sweden.
EM Per.Ljungman@ki.se
RI Ljungman, Per/M-4946-2019
OI Saccardi, Riccardo/0000-0002-5763-5467
NR 0
TC 270
Z9 287
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD OCT
PY 2009
VL 44
IS 8
BP 521
EP 526
DI 10.1038/bmt.2009.263
PG 6
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 512KJ
UT WOS:000271247300010
PM 19861986
OA Bronze
DA 2020-12-15
ER

PT J
AU Machado, AF
   Sallum, MAM
   Boas, LSV
   Tateno, AF
   Machado, CM
AF Machado, Adriana F.
   Sallum, Maria Anice M.
   Boas, Lucy S. Vilas
   Tateno, Adriona F.
   Machado, Clarisse M.
TI Molecular Characterization of Strains of Respiratory Syncytial Virus
   Identified in a Hematopoietic Stem Cell Transplant Outpatient Unit Over
   2 Years: Community or Nosocomial Infection?
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Respiratory synctial virus; Hematopoietic stem cell transplantation;
   Molecular epidemiology; Nosocomial transmission; Outpatient care
ID CIRCULATION PATTERNS; GROUP-A; OUTBREAK; EPIDEMIOLOGY; GENOTYPES;
   EVOLUTION
AB Respiratory syncytial virus (RSV) is recognized as the leading cause of nosocomial respiratory infection among hematopoietic stem cell transplant (HSCT) recipients, causing considerable morbidity and mortality. RSV is easily transmitted by contact with contaminated surfaces, and in HSCT units, more than 50% of RSV infections have been characterized as of nosocomial origin. From April 2001 to October 2002, RSV was identified by direct immunofluorescent assay in 42 symptomatic HSCT recipients. Seven RSV strains from 2001 and 12 RSV strains from 2002 were sequenced. RNA extraction, cDNA synthesis, and seminested polymerase chain reaction (PCR) with primers complementary to RSV genes G and F were pet-formed. PCR products were analyzed by nucleotide sequencing of the C-terminal region of gene G for typing (in group A or B). Of the 7 strains analyzed in 2001, only 2 belonged to group B; the other 5 belonged to group A. Of these 7 strains, 3 were identical and were from recipients receiving outpatient care. In 2002, of the 12 strains analyzed, 3 belonged to group A and the other 9 belonged to group B. Of these 9 strains, 7 were genetically identical and were also from recipients receiving outpatient care. Therefore, multiple strains of RSV cocirculated in the hematopoietic stem cell transplant units (ward and outpatient units) between 2001 and 2002. Nosocomial transmission was more likely to occur at the HSCT outpatient unit than in the HSCT ward. Infection control practices should also be implemented in the outpatient setting.
C1 [Machado, Adriana F.; Boas, Lucy S. Vilas; Tateno, Adriona F.; Machado, Clarisse M.] Univ Sao Paulo, Inst Trop Med, Virol Lab LIM52 HCFMUSP, Sao Paulo, Brazil.
   [Machado, Adriana F.; Boas, Lucy S. Vilas; Tateno, Adriona F.; Machado, Clarisse M.] Univ Sao Paulo, Fac Med Sci, Sao Paulo, Brazil.
   [Sallum, Maria Anice M.] Univ Sao Paulo, Fac Publ Hlth, Sao Paulo, Brazil.
   [Boas, Lucy S. Vilas] Univ Sao Paulo, Fac Med Sci, BMT Program, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Av Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
RI Sallum, Maria Anice Mureb/B-8537-2012
OI Sallum, Maria Anice Mureb/0000-0002-7051-2891
FU FapespFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2001/11087-2, 2002 08465-8]; CAPESCAPES; Brazilian Ministry of
   Education
FX This study was supported by Fapesp Grant 2001/11087-2 and 2002 08465-8.
   Adriana Freire Machado received a grant from CAPES, Brazilian Ministry
   of Education. The authors thank Dr Frederico L. Dulley and the
   clinicians and nurses assisting the HSCT recipients for excellent health
   care.
CR CANE PA, 1995, J VIROL, V69, P2918, DOI 10.1128/JVI.69.5.2918-2925.1995
   Cane PA, 2001, REV MED VIROL, V11, P103, DOI 10.1002/rmv.305
   Dykewicz CA, 2001, BIOL BLOOD MARROW TR, V7, p19S, DOI 10.1053/bbmt.2001.v7.pm11777100
   Englund JA, 1996, J CLIN MICROBIOL, V34, P1649, DOI 10.1128/JCM.34.7.1649-1653.1996
   ENGLUND JA, 1991, J CLIN MICROBIOL, V29, P115, DOI 10.1128/JCM.29.1.115-119.1991
   Garcia R, 1997, INFECT CONT HOSP EP, V18, P412, DOI 10.1086/647640
   Hall CB, 2000, CLIN INFECT DIS, V31, P590, DOI 10.1086/313960
   HARRINGTON RD, 1992, J INFECT DIS, V165, P987, DOI 10.1093/infdis/165.6.987
   Jalal H, 2007, J CLIN MICROBIOL, V45, P1690, DOI 10.1128/JCM.01912-06
   MACHADO CM, 2004, INT J INFECT DIS S, V8, pS1
   Martino R, 2005, BIOL BLOOD MARROW TR, V11, P781, DOI 10.1016/j.bbmt.2005.07.007
   Mazzulli T, 1999, J INFECT DIS, V180, P1686, DOI 10.1086/315085
   Melero JA, 1997, J GEN VIROL, V78, P2411, DOI 10.1099/0022-1317-78-10-2411
   Nichols WG, 2004, BIOL BLOOD MARROW TR, V10, P58, DOI 10.1016/j.bbmt.2003.09.010
   Peret TCT, 1998, J GEN VIROL, V79, P2221, DOI 10.1099/0022-1317-79-9-2221
   Peret TCT, 2000, J INFECT DIS, V181, P1891, DOI 10.1086/315508
   Raad Issam, 1997, American Journal of Medicine, V102, P48, DOI 10.1016/S0002-9343(97)00011-9
   Raboni SM, 2003, TRANSPLANTATION, V76, P142, DOI 10.1097/01.TP.0000072012.26176.58
   Tablan Ofelia C, 2004, MMWR Recomm Rep, V53, P1
   Taylor GS, 2001, J CLIN MICROBIOL, V39, P801, DOI 10.1128/JCM.39.2.801-803.2001
   Venter M, 2002, J MED VIROL, V68, P452, DOI 10.1002/jmv.10225
   Whimbey E, 1996, CLIN INFECT DIS, V22, P778, DOI 10.1093/clinids/22.5.778
   Whimbey Estella, 1997, American Journal of Medicine, V102, P10, DOI 10.1016/S0002-9343(97)80004-6
   Zheng HQ, 1996, J CLIN MICROBIOL, V34, P334, DOI 10.1128/JCM.34.2.334-337.1996
NR 24
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD DEC
PY 2008
VL 14
IS 12
BP 1348
EP 1355
DI 10.1016/j.bbmt.2008.09.012
PG 8
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 384OR
UT WOS:000261754600004
PM 19041056
OA Other Gold
DA 2020-12-15
ER

PT J
AU Mendes, AVA
   Kallas, EG
   Benard, G
   Pannuti, CS
   Menezes, R
   Dulley, FL
   Evans, TG
   Salomao, R
   Machado, CM
AF Almeida Mendes, Ana Verena
   Kallas, Esper Georges
   Benard, Gil
   Pannuti, Claudio Sergio
   Menezes, Renee
   Dulley, Frederico Luiz
   Evans, Thomas George
   Salomao, Reinaldo
   Machado, Clarisse Martins
TI IMPACT OF CYTOMEGALOVIRUS AND GRAFTS VERSUS HOST DISEASE ON THE DYNAMICS
   OF CD57+CD28-CD8+T CELLS AFTER BONE MARROW TRANSPLANT
SO CLINICS
LA English
DT Article
DE Cytomegalovirus; Graft versus host disease; Bone marrow transplant;
   CD57+lymphocytes; immuno-constitution
ID IFN-GAMMA PRODUCTION; LYMPHOCYTE SUBSET RECONSTITUTION; CYTOTOXIC
   T-LYMPHOCYTES; ALLOGRAFT RECIPIENTS; HEALTHY-INDIVIDUALS;
   FLOW-CYTOMETRY; ALLOGENEIC BMT; EXPANSION; CD57(+); INFECTION
AB OBJECTIVES: The present study aimed to evaluate the dynamics of CD28 and CD57 expression in CD8+ T lymphocytes during cytomegalovirus viremia in bone marrow transplant recipients.
   METHODS: In a prospective study, blood samples were obtained once weekly once from 33 healthy volunteers and weekly from 33 patients. To evaluate the expression of CD57 and CD28 on CD8+ T lymphocytes, flow cytometry analysis was performed on blood samples for four months after bone marrow transplant, together with cytomegalovirus antigenemia assays.
   RESULTS: Compared to cytomegalovirus-seronegative healthy subjects, seropositive healthy subjects demonstrated a higher percentage of CD57+ and a lower percentage of CD28+ cells (p < 0.05). A linear regression model demonstrated a continuous decrease in CD28+ expression and a continuous increase in CD57+ expression after bone marrow transplant. The occurrence of cytomegalovirus antigenemia was associated with a steep drop in the percentage of CD28+ cells (5.94%, p < 0.01) and an increase in CD57+ lymphocytes (5.60%, p < 0.01). This cytomegalovirus-dependent effect was for the most part concentrated in the allogeneic bone marrow transplant patients. The development of acute graft versus host disease, which occurred at an earlier time than antigenemia (day 26 vs. day 56 post-bone marrow transplant), also had an impact on the CD57+ subset, triggering an increase of 4.9% in CD57+ lymphocytes (p < 0.05).
   CONCLUSION: We found continuous relative changes in the CD28+ and CD57+ subsets during the first 120 days post-bone marrow transplant, as part of immune system reconstitution and maturation. A clear correlation was observed between the expansion of the CD57+CD28-CD8+ T lymphocyte subpopulation and the occurrence of graft versus host disease and cytomegalovirus viremia.
C1 [Almeida Mendes, Ana Verena] Univ Sao Paulo, Fac Med, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Lab Imunol, Escola Med, Sao Paulo, Brazil.
RP Mendes, AVA (corresponding author), Univ Sao Paulo, Fac Med, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
EM avamendes@gmail.com
RI Dulley, Frederico Luiz/H-7063-2013; Salomao, Reinaldo/C-6419-2013;
   Pannuti, Claudio/B-7649-2012; Kallas, Esper G/C-9539-2012
OI Salomao, Reinaldo/0000-0003-1149-4598; Kallas, Esper/0000-0003-2026-6925
FU University of Sao Paulo
FX We thank Marta Anesia Viana, Milena Brunialti, Helena Tomiyama, and Lucy
   Vilas Boas for their continuous support during the laboratory work, as
   well as the nursing staff of the Bone Marrow Transplant Program of The
   Hematology and Hemotherapy Discipline of the University of Sao Paulo for
   helping identify patients and collect specimens during this project.
CR Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Arai K, 1998, CLIN EXP IMMUNOL, V111, P345
   Aubert G, 2001, J INFECT DIS, V184, P955, DOI 10.1086/323354
   Bandres E, 2000, CLIN IMMUNOL, V96, P230, DOI 10.1006/clim.2000.4894
   Bilgrami S, 1999, BONE MARROW TRANSPL, V24, P69, DOI 10.1038/sj.bmt.1701827
   Boeckh M, 1996, BLOOD, V88, P4063, DOI 10.1182/blood.V88.10.4063.bloodjournal88104063
   Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103
   Bronke C, 2005, IMMUNOL LETT, V97, P215, DOI 10.1016/j.imlet.2004.11.004
   DANGEAC AD, 1994, EUR J IMMUNOL, V24, P1503, DOI 10.1002/eji.1830240707
   De Rosa SC, 2001, NAT MED, V7, P245, DOI 10.1038/84701
   DOLSTRA H, 1995, BRIT J HAEMATOL, V90, P300, DOI 10.1111/j.1365-2141.1995.tb05150.x
   Dolstra H, 1996, BONE MARROW TRANSPL, V18, P339
   Evans TG, 1999, AIDS, V13, P1139, DOI 10.1097/00002030-199906180-00019
   Frassanito MA, 1998, BRIT J HAEMATOL, V100, P469
   GARIN L, 1995, CLIN IMMUNOL IMMUNOP, V77, P139, DOI 10.1006/clin.1995.1137
   Gillespie GMA, 2000, J VIROL, V74, P8140, DOI 10.1128/JVI.74.17.8140-8150.2000
   GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303
   GOROCHOV G, 1994, BLOOD, V83, P587
   Hazzan M, 1997, TRANSPLANTATION, V63, P693, DOI 10.1097/00007890-199703150-00014
   Hooper M, 1999, J RHEUMATOL, V26, P1452
   Horiuchi T, 2001, BONE MARROW TRANSPL, V27, P731, DOI 10.1038/sj.bmt.1702859
   HUNTER AE, 1995, J ANTIMICROB CHEMOTH, V36, P119, DOI 10.1093/jac/36.suppl_B.119
   Kern F, 1999, EUR J IMMUNOL, V29, P2908, DOI 10.1002/(SICI)1521-4141(199909)29:09<2908::AID-IMMU2908>3.0.CO;2-8
   Khan N, 2002, J INFECT DIS, V185, P1025, DOI 10.1086/339963
   Khan N, 2002, J IMMUNOL, V169, P1984, DOI 10.4049/jimmunol.169.4.1984
   Koike Y, 2002, CLIN EXP IMMUNOL, V130, P162, DOI 10.1046/j.1365-2249.2002.01958.x
   LABALETTE M, 1994, CLIN EXP IMMUNOL, V95, P465
   Lee S, 1997, BONE MARROW TRANSPL, V20, P883, DOI 10.1038/sj.bmt.1700986
   LEGENDRE CM, 1985, J IMMUNOL, V135, P1061
   Lieberman J, 1999, AIDS, V13, P891, DOI 10.1097/00002030-199905280-00004
   Ljungman P, 2002, CLIN INFECT DIS, V34, P1094, DOI 10.1086/339329
   Looney RJ, 1999, CLIN IMMUNOL, V90, P213, DOI 10.1006/clim.1998.4638
   Machado CM, 2000, BONE MARROW TRANSPL, V26, P413, DOI 10.1038/sj.bmt.1702526
   Mendes AVA, 2002, ACTA HAEMATOL-BASEL, V107, P187, DOI 10.1159/000058313
   Merino J, 1998, CLIN EXP IMMUNOL, V112, P48
   MORLEY JK, 1995, J IMMUNOL, V154, P6182
   Moss P, 2004, HUM IMMUNOL, V65, P456, DOI 10.1016/j.humimm.2004.02.014
   Ozdemir E, 2002, BLOOD, V100, P3690, DOI 10.1182/blood-2002-05-1387
   Pannuti CS, 1996, AM J OPHTHALMOL, V122, P847, DOI 10.1016/S0002-9394(14)70381-2
   Rowbottom AW, 2000, BRIT J HAEMATOL, V110, P315, DOI 10.1046/j.1365-2141.2000.02107.x
   SULLIVAN KM, 1989, J ALLERGY CLIN IMMUN, V84, P632, DOI 10.1016/0091-6749(89)90202-9
   Sze DMY, 2001, BLOOD, V98, P2817, DOI 10.1182/blood.V98.9.2817
   THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706
   VANDERBIJ W, 1988, J MED VIROL, V25, P179, DOI 10.1002/jmv.1890250208
   WANG EC, 1995, SCAND J INFECT DIS S, V99, pS69
   WANG ECY, 1995, J IMMUNOL, V155, P5046
   Weekes MP, 1999, IMMUNOLOGY, V98, P443, DOI 10.1046/j.1365-2567.1999.00901.x
   YABE H, 1990, BONE MARROW TRANSPL, V5, P295
   Yu XZ, 2000, J IMMUNOL, V164, P4564, DOI 10.4049/jimmunol.164.9.4564
NR 49
TC 7
Z9 9
U1 0
U2 2
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PD OCT
PY 2008
VL 63
IS 5
BP 667
EP 676
DI 10.1590/S1807-59322008000500016
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 361ZQ
UT WOS:000260168400015
PM 18925328
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Oliveira, RR
   Machado, AF
   Tateno, AF
   Boas, LSV
   Pannuti, CS
   Machado, CM
AF Oliveira, R. R.
   Machado, A. F.
   Tateno, A. F.
   Boas, L. S. Vilas
   Pannuti, C. S.
   Machado, C. M.
TI Frequency of human metapneumovirus infection in hematopoietic SCT
   recipients during 3 consecutive years
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE human metapneumovirus; HSCT; respiratory symptoms; molecular typing;
   real-time PCR
ID RESPIRATORY-TRACT INFECTIONS; CELL TRANSPLANT RECIPIENTS; STEM-CELL;
   VIRUS-INFECTIONS; PEDIATRIC-PATIENTS; SYNCYTIAL VIRUS; YOUNG-CHILDREN;
   DISEASE; BRAZIL
AB Respiratory viruses can cause significant morbidity in immunocompromised hosts. Human metapneumovirus (hMPV) has been increasingly associated with lower respiratory tract infection in hematopoietic SCT (HSCT) recipients, with mortality rates up to 50%. No data on the occurrence of hMPV infection in HSCT recipients have been reported in the southern hemisphere. We conducted a retrospective study including 228 nasal wash samples from 153 HSCT recipients with respiratory symptoms during 2001, 2002 and 2003. hMPV was detected by real-time PCR with primers complementary to the nucleocapsid region of hMPV genome. Eleven of the 153 patients (7.2%) acquired hMPV infection during the study period (6.4% in 2001, 4.7% in 2002 and 11.1% in 2003). Among the 11 HSCT recipients with hMPV infection, 1 died 8 days after the diagnosis, but the role of hMPV in the patient's death could not be established. In 2001 and 2003, hMPV group A prevailed over group B. In 2002, both groups were detected equally. hMPV infections were diagnosed in late winter and spring. The frequency of hMPV infection in HSCT recipients living in Brazil was similar to those observed in the northern hemisphere. Sensitive techniques to detect hMPV should be included in the diagnostic assessment of HSCT recipients with respiratory symptoms.
C1 [Oliveira, R. R.; Machado, A. F.; Tateno, A. F.; Boas, L. S. Vilas; Pannuti, C. S.; Machado, C. M.] Univ Sao Paulo, Virol Lab, Inst Trop Med, BR-05403000 Sao Paulo, Brazil.
   [Pannuti, C. S.] Univ Sao Paulo, Sch Med, Dept Molestias Infecciosas & Parasitarias, BR-05403000 Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Virol Lab, Inst Trop Med, Av Dr Eneas De C Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
RI Pannuti, Claudio/B-7649-2012
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [05/01455-5]
FX This study was supported by FAPESP Grant no. 05/01455-5. We thank Dr
   Frederico L Dulley and the clinicians assisting the HSCT recipients for
   excellent health care; Dr Tereza Peret (Center for Diseases Control,
   USA), Dr Edson Durigon (Instituto de Ciencias Biomedicas, USP, Brazil)
   and Dr Vivian Luchsinger (Programa de Virologia, University of Chile)
   for suggestions and technical support.
CR Agapov E, 2006, J INFECT DIS, V193, P396, DOI 10.1086/499310
   Biacchesi S, 2003, VIROLOGY, V315, P1, DOI 10.1016/S0042-6822(03)00528-2
   Cane PA, 2003, BONE MARROW TRANSPL, V31, P309, DOI 10.1038/sj.bmt.1703849
   Cuevas LE, 2003, EMERG INFECT DIS, V9, P1626, DOI 10.3201/eid0912.030522
   DOCARMO DM, 2007, J CLIN VIROL, V39, P59
   Englund JA, 2006, ANN INTERN MED, V144, P344, DOI 10.7326/0003-4819-144-5-200603070-00010
   Englund JA, 1996, J CLIN MICROBIOL, V34, P1649, DOI 10.1128/JCM.34.7.1649-1653.1996
   Gerna G, 2005, ARCH VIROL, V150, P2365, DOI 10.1007/s00705-005-0581-2
   Gerna G, 2006, J MED VIROL, V78, P408, DOI 10.1002/jmv.20555
   Kaida A, 2006, J CLIN VIROL, V35, P394, DOI 10.1016/j.jcv.2005.12.009
   Kim YJ, 2007, SEMIN RESP CRIT CARE, V28, P222, DOI 10.1055/s-2007-976494
   Kumar D, 2005, AM J TRANSPLANT, V5, P2031, DOI 10.1111/j.1600-6143.2005.00971.x
   Luchsinger VF, 2005, REV MED CHILE, V133, P1059, DOI 10.4067/S0034-98872005000900009
   MACHADO AF, 2007, BONE MARROW TRANS S1, V39, pS1
   Machado CM, 2003, BONE MARROW TRANSPL, V31, P695, DOI 10.1038/sj.bmt.1703900
   MACHADO CM, 2004, INT J INFECT DIS S, V8, pS1
   Martino R, 2005, BIOL BLOOD MARROW TR, V11, P781, DOI 10.1016/j.bbmt.2005.07.007
   Nichols WG, 2004, BIOL BLOOD MARROW TR, V10, P58, DOI 10.1016/j.bbmt.2003.09.010
   Peck AJ, 2007, BLOOD, V110, P1681, DOI 10.1182/blood-2006-12-060343
   Pelletier G, 2002, EMERG INFECT DIS, V8, P976, DOI 10.3201/eid0809.020238
   Thomazelli LM, 2007, J PEDIAT-BRAZIL, V83, P422, DOI 10.1590/S0021-75572007000600005
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   Viazov S, 2003, J CLIN MICROBIOL, V41, P3043, DOI 10.1128/JCM.41.7.3043-3045.2003
NR 23
TC 27
Z9 28
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD AUG
PY 2008
VL 42
IS 4
BP 265
EP 269
DI 10.1038/bmt.2008.153
PG 5
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 341LP
UT WOS:000258716300006
PM 18516078
OA Bronze
DA 2020-12-15
ER

PT J
AU Campos, S
   Machado, C
   VilasBoas, L
   Caramori, M
   Teixeira, R
   Afonso, J
   Carraro, R
   Pego-Fernandes, P
   Jatene, F
AF Campos, Silvia
   Machado, Clarisse
   VilasBoas, Lucy
   Caramori, Marlova
   Teixeira, Ricardo
   Afonso, Jose, Jr.
   Carraro, Rafael
   Pego-Fernandes, Paulo
   Jatene, Fabio
TI Respiratory virus infections in lung transplant recipients: A Brazilian
   study
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Campos, Silvia; Caramori, Marlova; Teixeira, Ricardo; Afonso, Jose, Jr.; Carraro, Rafael; Pego-Fernandes, Paulo; Jatene, Fabio] Sao Paulo Med Sch, Heart Inst InCor, Lung Transplant Grp, Sao Paulo, Brazil.
   [Machado, Clarisse; VilasBoas, Lucy] Sao Paulo Med Sch, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
RI Afonso, Jose E/M-2289-2013
OI Afonso, Jose E/0000-0001-8167-0986
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JUN
PY 2008
VL 12
SU 2
MA 18
BP S8
EP S9
DI 10.1016/S1201-9712(08)60020-X
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 326MB
UT WOS:000257662300018
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Salles, MJC
   Sensz, YAD
   Boas, LV
   Machado, CM
AF Costa Salles, Mauro Jose
   dos Santos Sensz, Yvoty Alves
   Boas, Lucy Villas
   Machado, Clarisse Martins
TI Respiratory viral infections in renal transplant recipients
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Costa Salles, Mauro Jose] Santa Casa Sao Paulo Sch Med, Dept Internal Med, Clin Infect Dis, Sao Paulo, Brazil.
   [Boas, Lucy Villas; Machado, Clarisse Martins] Univ Sao Paulo IMTSP, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
RI Salles, Mauro/K-4760-2012; Salles, Mauro/R-9256-2019
OI Salles, Mauro/0000-0002-5443-6024; Salles, Mauro/0000-0002-5443-6024
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JUN
PY 2008
VL 12
SU 2
MA 33
BP S15
EP S15
DI 10.1016/S1201-9712(08)60035-1
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA 326MB
UT WOS:000257662300033
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Reis, AD
   Fink, MCD
   Machado, CM
   Paz, JD
   Oliveira, RR
   Tateno, AF
   Machado, AF
   Cardoso, MR
   Pannuti, CS
AF Reis, Alexanda Dias
   Domingues Fink, Maria Cristina
   Machado, Clarisse Martins
   Paz, Jose de Paula, Jr.
   Oliveira, Renato Reis
   Tateno, Adriana Fumie
   Machado, Adriana Freire
   Cardoso, Maria Regina
   Pannuti, Claudio Sergio
CA Chiado & RDGV FAPESP Res Grp
TI Comparison of direct immunofluorescence, conventional cell culture and
   polymerase chain reaction techniques for detecting respiratory syncytial
   virus in nasopharyngeal aspirates from infants
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE respiratory syncytial virus; infants; diagnosis; cell culture;
   polymerase chain reactions; immunofluorescence
ID TRANSCRIPTASE PCR ASSAY; REAL-TIME PCR; CIRCULATION PATTERNS; TRACT
   INFECTIONS; VIRAL CULTURE; GROUP-A; DIAGNOSIS; CHILDREN; STRAINS
AB A total of 316 samples of nasopliaryngeal aspirate from infants up to two years of age with acute respiratory-tract illnesses were processed for detection of respiratory syncytial virus (RSV) using three different. techniques: viral isolation, direct immunofluorescence, and PCR. Of the samples, 36 (11.4%) were positive for RSV, considering the three techniques. PCR was the most sensitive technique, providing positive findings in 35/316 (11.1%) of the samples. followed by direct immunofluorescence (25/316, 7.9%) and viral isolation (20/315, 6.3%) (p < 0.001). A sample was positive by immunofluorescence and negative by PCR, and 11 (31.4%) were positive only by RT-PCR. We conclude that RT-PCR is more sensitive than IF and viral isolation to detect RSV in nasopharyngeal aspirate specimens in newborn and infants.
C1 [Reis, Alexanda Dias; Domingues Fink, Maria Cristina; Machado, Clarisse Martins; Paz, Jose de Paula, Jr.; Oliveira, Renato Reis; Tateno, Adriana Fumie; Machado, Adriana Freire; Pannuti, Claudio Sergio] Univ Sao Paulo, Virol Lab, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil.
   [Reis, Alexanda Dias; Domingues Fink, Maria Cristina; Machado, Clarisse Martins; Paz, Jose de Paula, Jr.; Oliveira, Renato Reis; Tateno, Adriana Fumie; Machado, Adriana Freire; Pannuti, Claudio Sergio] Univ Sao Paulo, Fac Med, Dept Molestias Infecc & Parasitarias LIMHC, BR-05403000 Sao Paulo, Brazil.
   [Cardoso, Maria Regina] Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, BR-01246904 Sao Paulo, Brazil.
RP Pannuti, CS (corresponding author), Univ Sao Paulo, Virol Lab, Inst Med Trop Sao Paulo, Av Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM cpannuti@usp.br
RI Fink, Maria Cristina/M-8718-2015; Pannuti, Claudio/B-7649-2012; Cardoso,
   Maria Regina A/J-7280-2012
CR AHLUWALIA G, 1987, J CLIN MICROBIOL, V25, P763, DOI 10.1128/JCM.25.5.763-767.1987
   Barenfanger J, 2000, J CLIN MICROBIOL, V38, P2824, DOI 10.1128/JCM.38.8.2824-2828.2000
   Boivin G, 2004, J CLIN MICROBIOL, V42, P45, DOI 10.1128/JCM.42.1.45-51.2004
   Calegari Tatiany, 2005, Braz J Infect Dis, V9, P156, DOI 10.1590/S1413-86702005000200006
   Chaiwatpongsakorn S, 2011, FIELDS VIROLOGY, V85, P3968
   Cintra OAL, 2001, J MED VIROL, V65, P408, DOI 10.1002/jmv.2049
   Diniz Edna Maria de Albuquerque, 2005, Rev. Inst. Med. trop. S. Paulo, V47, P37, DOI 10.1590/S0036-46652005000100007
   Englund JA, 1996, J CLIN MICROBIOL, V34, P1649, DOI 10.1128/JCM.34.7.1649-1653.1996
   Falsey AR, 2005, DRUG AGING, V22, P577, DOI 10.2165/00002512-200522070-00004
   KUMAR ML, 1987, J CLIN MICROBIOL, V25, P873, DOI 10.1128/JCM.25.5.873-875.1987
   Mentel R, 2003, J MED MICROBIOL, V52, P893, DOI 10.1099/jmm.0.05290-0
   OGRA PL, 2004, PAEDIAT RESP REV SA, V5, P119
   Peret TCT, 1998, J GEN VIROL, V79, P2221, DOI 10.1099/0022-1317-79-9-2221
   Peret TCT, 2000, J INFECT DIS, V181, P1891, DOI 10.1086/315508
   Perkins SM, 2005, J CLIN MICROBIOL, V43, P2356, DOI 10.1128/JCM.43.5.2356-2362.2005
   Pierangeli A, 2007, J MED VIROL, V79, P463, DOI 10.1002/jmv.20832
   Raboni SM, 2003, TRANSPLANTATION, V76, P142, DOI 10.1097/01.TP.0000072012.26176.58
   Riccetto Adriana Gut Lopes, 2006, Braz J Infect Dis, V10, P357, DOI 10.1590/S1413-86702006000500011
   Rovida F, 2005, J MED VIROL, V75, P336, DOI 10.1002/jmv.20276
   Straliotto SM, 2004, MEM I OSWALDO CRUZ, V99, P883, DOI 10.1590/S0074-02762004000800017
   van Elden LJR, 2002, CLIN INFECT DIS, V34, P177, DOI 10.1086/338238
   Weinberg GA, 2004, J INFECT DIS, V189, P706, DOI 10.1086/381456
   Whimbey E, 2000, CURR CLIN TOPICS INF, V20, P232
   Zheng HQ, 1996, J CLIN MICROBIOL, V34, P334, DOI 10.1128/JCM.34.2.334-337.1996
NR 24
TC 23
Z9 23
U1 0
U2 3
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD JAN-FEB
PY 2008
VL 50
IS 1
BP 37
EP 40
DI 10.1590/S0036-46652008000100008
PG 4
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 306UX
UT WOS:000256274400008
PM 18327485
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU do Canto, CLM
   Sumita, LM
   Machado, AF
   Tateno, A
   da Cunha, EV
   Machado, CM
AF Motta do Canto, Cynthia Liliane
   Sumita, Laura Massami
   Machado, Adriana Freire
   Tateno, Adriana
   da Cunha, Eveline Vieira
   Machado, Clarisse Martins
TI Optimization of the Sybr Green Real Time PCR for the detection of human
   herpes virus type 6 (HHV-6)
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE human herpes virus 6 (HHV-6); PCR; real-time PCR; Sybr Green
ID POLYMERASE-CHAIN-REACTION; BONE-MARROW-TRANSPLANTATION; HUMAN
   HERPESVIRUS-6; HUMAN-HERPESVIRUS-6 DNA; QUANTITATIVE PCR; INFECTION;
   PLASMA; REACTIVATION; LIGHTCYCLER
AB HHV-6 is the etiological agent of Exanthem subitum which is considered the sixth most frequent disease in infancy. In immuno-compromised hosts, reactivation of Intent HHV-6 infection may cause severe acute disease. We developed a Sybr Green Real Time PCR for HHV-6 and compared the results with nested conventional PCR. A 214 pb PCR derived fragment was cloned using pGEM-T easy from Promega system. Subsequently, serial dilutions were made in a pool of negative leucocytes from 10-(6) ng/mu L (equivalent to 2465.8 molecules/mu L) to 10-(9) (equivalent to 2.46 molecules/mu L). Dilutions of the plasmid were amplified by Sybr Green Real Time PCR, using primers HHV3 (5'TTG TGC GGG TCC GTT CCC ATC ATA 3)'and HHV4 (5'TCG GGA TAG AAA AAC CTA ATC CCT 3') and by conventional nested PCR using primers HHV1 (outer): 5'CAA, TGC TTT TCT AGC CGC CTC TTC 3'; HHV2 (outer): 5' ACA TCT ATA ATT TTA GAC GAT CCC 3'; HHV3 (inner) and HHV4 (inner) 3'. The detection threshold was determined by plasmid serial dilutions. Threshold for Sybr Green real time PCR was 24.6 molecules/mu L and for the nested PCR was 2.46 molecules/mu L. We chose the Real Time PCR for diagnosing and quantifying HHV-6 DNA from samples using the new Sybr Green chemistry due to its sensitivity and lower risk of contamination.
C1 [Motta do Canto, Cynthia Liliane; Sumita, Laura Massami; Machado, Adriana Freire; Tateno, Adriana; da Cunha, Eveline Vieira; Machado, Clarisse Martins] Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Virol LIM HC FMUSP 52, Sao Paulo, Brazil.
RP do Canto, CLM (corresponding author), Univ Sao Paulo, Inst Med Trop Sao Paulo, Av Dr Eneas Carvalho Aguiar 470-2 Andar, BR-05403000 Sao Paulo, Brazil.
EM ccanto@usp.br
CR Allen UD, 2001, BONE MARROW TRANSPL, V28, P473, DOI 10.1038/sj.bmt.1703153
   Alvarez-Lafuente R, 2002, ARCH NEUROL-CHICAGO, V59, P929, DOI 10.1001/archneur.59.6.929
   Aritaki K, 2001, BONE MARROW TRANSPL, V28, P975, DOI 10.1038/sj.bmt.1703266
   Braun DK, 1997, CLIN MICROBIOL REV, V10, P521, DOI 10.1128/CMR.10.3.521
   Clark DA, 2003, BRIT J HAEMATOL, V120, P384, DOI 10.1046/j.1365-2141.2003.04048.x
   Durtschi JD, 2007, ANAL BIOCHEM, V361, P55, DOI 10.1016/j.ab.2006.11.023
   Fernandez F, 2006, MICROBIOL RES, V161, P158, DOI 10.1016/j.micres.2005.07.007
   Fotheringham J, 2007, J INFECT DIS, V195, P450, DOI 10.1086/510757
   HUANG LM, 1992, J MED VIROL, V38, P7, DOI 10.1002/jmv.1890380103
   Kearns AM, 2001, J CLIN MICROBIOL, V39, P3020, DOI 10.1128/JCM.39.8.3020-3021.2001
   Locatelli G, 2000, J CLIN MICROBIOL, V38, P4042, DOI 10.1128/JCM.38.11.4042-4048.2000
   Morishima T, 1999, Nagoya J Med Sci, V62, P83
   Nitsche A, 2001, J INFECT DIS, V183, P130, DOI 10.1086/317651
   Ohyashiki JH, 2000, INT J MOL MED, V6, P427
   OHYASHIKI JH, 2001, RAPID CYCLE REAL TIM, P211
   Reddy S, 2005, BIOL BLOOD MARROW TR, V11, P530, DOI 10.1016/j.bbmt.2005.04.010
   SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520
   Tan BH, 2004, EXPERT REV MOL DIAGN, V4, P219, DOI 10.1586/14737159.4.2.219
   YAMANISHI K, 1988, LANCET, V1, P1065
   2003, SEQUENCE DETECTION S
NR 20
TC 3
Z9 3
U1 0
U2 3
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD JAN-FEB
PY 2008
VL 50
IS 1
BP 61
EP 63
DI 10.1590/S0036-46652008000100014
PG 3
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 306UX
UT WOS:000256274400014
PM 18327491
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Madeira, MIA
   Favarin, MC
   Palma, LC
   Barros, GMN
   Souza, CA
   Machado, CM
   Voltarelli, JC
   Stracieri, ABPL
   Simoes, BP
AF Madeira, Maria I. A.
   Favarin, Maria C.
   Palma, Leonardo C.
   Barros, George M. N.
   Souza, Cristina A.
   Machado, Clarisse M.
   Voltarelli, Julio C.
   Stracieri, Ana B. P. L.
   Simoes, Belinda P.
TI Zygomycosis: A severe fungal infection with challenging diagnostic
   difficulties: A case with cardiac involvement without cardiac symptoms
SO BLOOD
LA English
DT Meeting Abstract
CT 49th Annual Meeting of the American-Society-of-Hematology
CY DEC 08-11, 2007
CL Atlanta, GA
SP Amer Soc Hematol
C1 [Madeira, Maria I. A.; Favarin, Maria C.; Palma, Leonardo C.; Barros, George M. N.; Voltarelli, Julio C.; Stracieri, Ana B. P. L.; Simoes, Belinda P.] Med Sch Rebeirao, Ribeirao Preto, Brazil.
   [Souza, Cristina A.; Machado, Clarisse M.] Inst Trop Med, Sao Paulo, Brazil.
RI Simoes, Belinda P/M-7469-2016
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD NOV 16
PY 2007
VL 110
IS 11
MA 5019
BP 334B
EP 334B
DI 10.1182/blood.V110.11.5019.5019
PN 2
PG 1
WC Hematology
SC Hematology
GA 233OV
UT WOS:000251101102311
DA 2020-12-15
ER

PT J
AU da Silva, AR
   Park, M
   Boas, LSV
   Machado, CM
AF da Silva, Alexandre Rodrigues
   Park, Marcelo
   Boas, Lucy S. Vilas
   Machado, Clarisse Martins
TI Respiratory syncytial virus rhinosinusitis in intensive care unit
   patients
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE respiratory syncytial virus; RSV; rhinosinusitis; AIDS; ICU infection;
   viral infection
ID COMMUNITY-ACQUIRED SINUSITIS; MAXILLARY SINUSITIS; INFECTIONS; THERAPY
AB This study reported a case of rhinosinusitis for Respiratory Syncytial Virus in Intensive Care Unit patient. The settings were Intensive Care Unit at Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo, Brazil. One female HIV-infected patient with respiratory failure and circulatory shock due to splenic and renal abscesses, who developed rhinosinusitis caused by RSV and bacteria. Respiratory viruses can play a pathogenic role in airways infection allowing secondary bacterial overgrowth.
C1 [da Silva, Alexandre Rodrigues; Boas, Lucy S. Vilas; Machado, Clarisse Martins] Univ Sao Paulo, Sch Med, Inst Trop Med, Virol Lab LIM HCFMUSP 52, BR-05508 Sao Paulo, Brazil.
   [Park, Marcelo] Univ Sao Paulo, Sch Med, Dept Internal Med, Hosp Clin,Intens Care Unit, BR-05508 Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Av Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
CR EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502
   Gurney Theresa A, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P45, DOI 10.1097/00020840-200302000-00010
   Gwaltney JM, 1996, CLIN INFECT DIS, V23, P1209, DOI 10.1093/clinids/23.6.1209
   HALL CB, 1976, J PEDIATR-US, V89, P11, DOI 10.1016/S0022-3476(76)80918-3
   HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197
   Hayase Y, 2002, J GASTROENTEROL, V37, P101, DOI 10.1007/s005350200003
   Jiang ZL, 1999, INFECT IMMUN, V67, P187, DOI 10.1128/IAI.67.1.187-192.1999
   Laheij RJF, 2003, ALIMENT PHARM THER, V18, P847, DOI 10.1046/j.1365-2036.2003.01744.x
   Lindbaek M, 2004, DRUGS, V64, P805, DOI 10.2165/00003495-200464080-00002
   Osguthorpe JD, 1999, MED CLIN N AM, V83, P27, DOI 10.1016/S0025-7125(05)70085-7
   Osur SL, 2002, ANN ALLERG ASTHMA IM, V89, P553, DOI 10.1016/S1081-1206(10)62101-1
   Palm J, 2000, ACTA OTO-LARYNGOL, V120, P420, DOI 10.1080/000164800750000676
   Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791
   ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352
   SOCIEDAD E, 2003, REV ESP QUIMIOTERAP, V16, P239
NR 15
TC 2
Z9 2
U1 0
U2 0
PU CONTEXTO
PI SALVADOR
PA RUA ALFREDO MAGALHAES, 04-BARRA, SALVADOR, BAHIA 40140-140, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD FEB
PY 2007
VL 11
IS 1
BP 163
EP 165
DI 10.1590/S1413-86702007000100034
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 274JM
UT WOS:000253997600034
PM 17625748
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Machado, CM
AF Machado, C. M.
TI Idiopathic thrombocytopenic purpura after influenza vaccination in a
   bone marrow transplantation recipient - Reply to Ikegame et al.
SO BONE MARROW TRANSPLANTATION
LA English
DT Letter
ID BENEFIT
C1 Univ Sao Paulo, Virol Lab, Inst Trop Med, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Virol Lab, Inst Trop Med, Sao Paulo, Brazil.
EM clarimm@usp.br
FU Grants-in-Aid for Scientific ResearchMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)Japan Society for the
   Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [18591090] Funding Source: KAKEN
CR Bridges CB, 2000, JAMA-J AM MED ASSOC, V284, P1655, DOI 10.1001/jama.284.13.1655
   BRIDGES CB, 2004, MMWR-MORBID MORTAL W, V53, P1
   Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961
   GOVAERT TME, 1993, BMJ-BRIT MED J, V307, P988, DOI 10.1136/bmj.307.6910.988
   Ljungman P, 2005, BONE MARROW TRANSPL, V35, P737, DOI 10.1038/sj.bmt.1704870
   Machado CM, 2005, BONE MARROW TRANSPL, V36, P897, DOI 10.1038/sj.bmt.1705159
NR 6
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD AUG
PY 2006
VL 38
IS 4
BP 324
EP 325
DI 10.1038/sj.bmt.1705443
PG 3
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 071JV
UT WOS:000239598900015
OA Bronze
DA 2020-12-15
ER

PT J
AU Godoi, ER
   de Souza, VAUF
   Cakmak, S
   Machado, AF
   Boas, LSV
   Machado, CM
AF Godoi, E. R.
   de Souza, V. A. U. F.
   Cakmak, S.
   Machado, A. F.
   Boas, L. S. Vilas
   Machado, C. M.
TI Loss of hepatitis A virus antibodies after bone marrow transplantation
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE hepatitis A; seroprevalence; antibody loss; vaccination; epidemiology
ID CELL; RECIPIENTS; IMMUNITY; CHILDREN; MEASLES; BRAZIL; POLIO
AB Reimmunization guidelines have recommended the inactivated HAV vaccine for hematopoietic stem cell transplant ( HSCT) recipients living in or traveling to areas where hepatitis A is endemic. As a shift from high to medium hepatitis A endemicity has been observed in several countries in Latin America, we conducted a retrospective study to evaluate the prevalence of hepatitis A pre-bone marrow transplant ( BMT) and the loss of specific antibodies in consecutive stored serum samples from 77 BMT recipients followed up from 82 to 1530 days. The prevalence of HAV antibodies was 92.2% before BMT. As vaccine was not available in Brazil when the samples were taken, it was assumed that this prevalence reflects natural infection. Survival analysis showed that the probability of becoming seronegative was 4.5% ( +/- 2.6%), 7.9% ( +/- 3.4%), 10.1% ( +/- 4.0%), 23.4% ( +/- 9.6%) at 1, 2, 3 and 4 years after transplant, respectively. The loss of HAV antibodies was significantly associated with longer follow-up ( P = 0.0015), younger age ( P = 0.049) and acute graft-versus-host disease ( P = 0.035). As most reimmunization protocols start around day +365, in developing countries with similar HAV endemicity, BMT recipients should have serological screening before HAV vaccination and the inactivated vaccine should be advised to those seronegative.
C1 Univ Sao Paulo, Sao Paulo Inst Trop Med, Virol Lab, BR-05403000 Sao Paulo, Brazil.
   Hlth Canada, HECS Branch, Ottawa, ON, Canada.
RP Machado, CM (corresponding author), Univ Sao Paulo, Sao Paulo Inst Trop Med, Virol Lab, Av Dr Eneas C Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
OI Cakmak, Sabit/0000-0001-9921-2107
CR Debray D, 1997, HEPATOLOGY, V26, P1018, DOI 10.1002/hep.510260433
   Dignani MC, 2003, BONE MARROW TRANSPL, V31, P809, DOI 10.1038/sj.bmt.1704028
   GLODE MP, 1999, MMWR RECOMM REP, V48, P1
   GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951
   Hammarstrom V, 1998, BONE MARROW TRANSPL, V22, P67, DOI 10.1038/sj.bmt.1701289
   Ljungman P, 2005, BONE MARROW TRANSPL, V35, P737, DOI 10.1038/sj.bmt.1704870
   LJUNGMAN P, 1991, BONE MARROW TRANSPL, V7, P89
   Machado CM, 2002, BLOOD, V99, P83, DOI 10.1182/blood.V99.1.83
   Parkkali T, 1996, APMIS, V104, P383, DOI 10.1111/j.1699-0463.1996.tb00731.x
   Pauksen K, 1995, BONE MARROW TRANSPL, V16, P807
   Tanaka J, 2000, VACCINE, V18, pS57, DOI 10.1016/S0264-410X(99)00466-1
   Vitral CL, 1998, MEM I OSWALDO CRUZ, V93, P1, DOI 10.1590/S0074-02761998000100001
NR 12
TC 7
Z9 8
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUL
PY 2006
VL 38
IS 1
BP 37
EP 40
DI 10.1038/sj.bmt.1705391
PG 4
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 059CG
UT WOS:000238710300007
PM 16715111
OA Bronze
DA 2020-12-15
ER

PT J
AU Ferrari, V
   Cacere, CR
   Machado, CM
   Pannuti, CS
   Dulley, FL
   Barros, JCA
   Duarte, AJD
   Benard, G
AF Ferrari, Valeria
   Cacere, Camila Rodrigues
   Machado, Clarisse Martins
   Pannuti, Claudio Sergio
   Dulley, Frederico Luiz
   Barros, Jose Carlos Antonio
   da Silva Duarte, Alberto Jose
   Benard, Gil
TI Distinct patterns of regeneration of central memory, effector memory and
   effector TCD8+ cell subsets after different hematopoietic cell
   transplant types: Possible influence in the recovery of
   anti-cytomegalovirus immune response and risk for its reactivation
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE memory TCD8+cells; cytomegalovirus; bone marrow transplantation; immune
   reconstitution
ID BONE-MARROW-TRANSPLANTATION; T-CELLS; CYTOMEGALOVIRUS DISEASE; ACUTE
   GVHD; IFN-GAMMA; BLOOD; RECONSTITUTION; CD8(+); PROLIFERATION;
   EXPRESSION
AB TCD8+ cells may be divided into subsets with different phenotypes and functions: naive, central memory, effector memory and effector. Aiming to better understand the differences in early reconstitution of these TCD8+ cell subsets and their relationship with post-transplant anti-cytomegatovirus (CMV) immune responses recovery, we prospectively analyzed the transfer and expansion of these subsets in different transplant types. We found that graft cells from donor's peripheral blood, either allogeneic or autologous, were enriched for central memory, effector memory and effector phenotypes compared to allogeneic bone marrow grafts, as assessed by surface markers phenotyping and granzyme B expression. However, post-transplant, these subsets expanded in autologous recipients only, reaching numbers much greater than in allo-recipients at days +29 and +96. At the same time, autologous recipients presented less CMV reactivation and more vigorous CMV-induced interferon- and lymphopro-liferative responses. The marked loss of allo-transferred memory TCD8+ cells was probably due to the fact that they were more activated and more prone to apoptosis than auto-transferred TCD8+ cells as assessed by CD69 and active caspase 3 expression. Thus, transfer of peripheral blood stem cells in the allogeneic but not autologous setting is associated with poor expansion of memory TCD8+ cells, probably delaying antiviral immune reconstitution. These data may have important implications for the design of better strategies to immunoprotect this population against infectious challenges since different transplant types have different potentials for memory TCD8+ cells transfer and expansion. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Lab Dermatol & Immunodeficiencies, LIM 56, Sao Paulo, Brazil.
   Univ Sao Paulo, Virol Lab, Inst Trop Med, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Bone Marrow Transplant Program, Hematol & Hemotherapy Div, Sao Paulo, Brazil.
   Sant Casa Med Sch, Bone Marrow Transplant Unit, Sao Paulo, Brazil.
RP Benard, G (corresponding author), Univ Sao Paulo, Sch Med, Lab Dermatol & Immunodeficiencies, LIM 56, Av Dr Eneas Carvalho Aguiar 500 3rd Floor, Sao Paulo, Brazil.
EM mahong@usp.br
RI Dulley, Frederico Luiz/H-7063-2013; Benard, Gil/D-9414-2013; Pannuti,
   Claudio/B-7649-2012
CR Abrahamsen IW, 2005, HAEMATOLOGICA, V90, P86
   Benard G, 2001, CYTOKINE, V13, P248, DOI 10.1006/cyto.2000.0824
   Boeckh M, 2003, BLOOD, V101, P407, DOI 10.1182/blood-2002-03-0993
   Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615
   Cho BK, 1999, P NATL ACAD SCI USA, V96, P2976, DOI 10.1073/pnas.96.6.2976
   Dai ZH, 2000, J IMMUNOL, V165, P3031, DOI 10.4049/jimmunol.165.6.3031
   DEGAST GC, 1985, BLOOD, V66, P428
   DONNENBERG AD, 1995, RES IMMUNOL, V146, P11, DOI 10.1016/0923-2494(96)80236-7
   Fiorentini S, 2001, J IMMUNOL, V166, P900, DOI 10.4049/jimmunol.166.2.900
   FUKUDA H, 1994, BONE MARROW TRANSPL, V13, P181
   Gamadia LE, 2001, BLOOD, V98, P754, DOI 10.1182/blood.V98.3.754
   Gor D, 1998, BONE MARROW TRANSPL, V21, P597, DOI 10.1038/sj.bmt.1701139
   Hakki M, 2003, BLOOD, V102, P3060, DOI 10.1182/blood-2002-11-3472
   Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407
   Hebib NC, 1999, BLOOD, V94, P1803, DOI 10.1182/blood.V94.5.1803.417a28_1803_1813
   Hochberg EP, 2001, BLOOD, V98, P1116, DOI 10.1182/blood.V98.4.1116
   Holmberg LA, 1999, BLOOD, V94, P4029, DOI 10.1182/blood.V94.12.4029.424k21_4029_4035
   Jaksch M, 2003, BONE MARROW TRANSPL, V31, P183, DOI 10.1038/sj.bmt.1703807
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Machado CM, 2001, BONE MARROW TRANSPL, V28, P1053, DOI 10.1038/sj.bmt.1703282
   Mackall CL, 1997, IMMUNOL REV, V157, P61, DOI 10.1111/j.1600-065X.1997.tb00974.x
   Mackall CL, 1997, BLOOD, V89, P3700, DOI 10.1182/blood.V89.10.3700.3700_3700_3707
   MACKALL CL, 1993, BLOOD, V82, P2585
   Mackall CL, 2000, BLOOD, V96, P754
   Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065
   Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867
   Mendes AVA, 2002, ACTA HAEMATOL-BASEL, V107, P187, DOI 10.1159/000058313
   Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377
   Osarogiagbon RU, 2000, BIOL BLOOD MARROW TR, V6, P280, DOI 10.1016/S1083-8791(00)70010-3
   Ottinger HD, 1996, BLOOD, V88, P2775, DOI 10.1182/blood.V88.7.2775.bloodjournal8872775
   Ozdemir E, 2002, BLOOD, V100, P3690, DOI 10.1182/blood-2002-05-1387
   Peggs KS, 2003, BIOL BLOOD MARROW TR, V9, P198, DOI 10.1053/bbmt.2003.50010
   Powles R, 2000, LANCET, V355, P1231, DOI 10.1016/S0140-6736(00)02090-0
   ROBERTS MM, 1993, BONE MARROW TRANSPL, V12, P469
   Rutella S, 2001, EXP HEMATOL, V29, P1503, DOI 10.1016/S0301-472X(01)00747-0
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   SHULMAN HM, 1984, PATHOLOGY BONE MARRO, P40
   Storek J, 1997, AM J HEMATOL, V54, P131, DOI 10.1002/(SICI)1096-8652(199702)54:2<131::AID-AJH6>3.0.CO;2-Y
   Storek J, 2001, BLOOD, V97, P3380, DOI 10.1182/blood.V97.11.3380
   Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057
   TANCHOT C, 1999, BONE MARROW TRANSPL, V23, P451
   Tayebi H, 2001, BONE MARROW TRANSPL, V27, P167, DOI 10.1038/sj.bmt.1702753
   Trenschel R, 2000, BONE MARROW TRANSPL, V25, P665, DOI 10.1038/sj.bmt.1702216
   Wang ECY, 1995, SCAND J INFECT DIS, P69
   Zekri ARN, 2004, TRANSPL IMMUNOL, V13, P305, DOI 10.1016/j.trim.2004.10.001
NR 46
TC 11
Z9 12
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUN
PY 2006
VL 119
IS 3
BP 261
EP 271
DI 10.1016/j.clim.2005.12.001
PG 11
WC Immunology
SC Immunology
GA 047TR
UT WOS:000237902100005
PM 16426894
DA 2020-12-15
ER

PT J
AU Machado, CM
   Cardoso, MRA
   da Rocha, IF
   Boas, LSV
   Dulley, FL
   Pannuti, CS
AF Machado, CM
   Cardoso, MRA
   da Rocha, IF
   Boas, LSV
   Dulley, FL
   Pannuti, CS
TI The benefit of influenza vaccination after bone marrow transplantation
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE influenza; risk factors; vaccination; compliance
ID STEM-CELL TRANSPLANTATION; VIRUS-INFECTIONS
AB Infulenza vaccine is recommended yearly for recipients after the sixth month of BMT. Although a higher risk of complications of influenza is expected to occur in BMT patients, no study has addressed the clinical efficacy of influenza vaccination in this setting. Focusing on the clinical benefits of influenza vaccination, we evaluated the risk factors for influenza infection in a cohort of 177 BMT recipients followed up for 1 year. Influenza was diagnosed in 39 patients. Multivariate analyses showed that seasonal exposure and more aggressive conditioning regimens were independently associated with increased risk for influenza. Influenza vaccination and steroid use showed a protective role. Of the 43 patients who had received BMT longer than 6 months, 19 were vaccinated (compliance rate 44.2%) and vaccine efficacy was 80%. We conclude that in. uenza vaccination plays an important role in protecting BMT recipients against influenza and all efforts should be made to ensure good compliance with vaccination.
C1 Univ Sao Paulo, Virol Lab, Inst Med Trop, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, BMT Program, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Virol Lab, Inst Med Trop, Av Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
RI Pannuti, Claudio/B-7649-2012; Cardoso, Maria Regina A/J-7280-2012;
   Dulley, Frederico Luiz/H-7063-2013
CR American Medical Association, 2004, MMWR Recomm Rep, V53, P1
   Bowden Raleigh A., 1997, American Journal of Medicine, V102, P27, DOI 10.1016/S0002-9343(97)00007-7
   Bridges Carolyn B, 2003, MMWR Recomm Rep, V52, P1
   COUGH RB, 1997, AM J MED, V102, P2
   Doebbeling BN, 1997, PREV MED, V26, P68, DOI 10.1006/pmed.1996.9991
   DYKEWICZ CA, 2000, MMWR-MORBID MORTAL W, V49, P1
   ENGELHARD D, 2001, BONE MARROW TRANSPL, V28, P775
   GANDHI MK, 1993, BONE MARROW TRANSPL, V11, P1
   Ljungman P, 2001, BONE MARROW TRANSPL, V28, P479, DOI 10.1038/sj.bmt.1703139
   Machado CM, 2004, BONE MARROW TRANSPL, V34, P111, DOI 10.1038/sj.bmt.1704534
   Nichols WG, 2004, CLIN INFECT DIS, V39, P1300, DOI 10.1086/425004
   van Essen GA, 2003, VACCINE, V21, P1780, DOI 10.1016/S0264-410X(03)00072-0
   WHIMBEY E, 1994, BONE MARROW TRANSPL, V13, P437
NR 13
TC 79
Z9 80
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD NOV
PY 2005
VL 36
IS 10
BP 897
EP 900
DI 10.1038/sj.bmt.1705159
PG 4
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 980CL
UT WOS:000232991400010
PM 16170332
OA Bronze
DA 2020-12-15
ER

PT J
AU Machado, CM
AF Machado, CM
TI Influenza infections after hematopoietic stem cell transplantation
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
ID VACCINATION
C1 Univ Sao Paulo, Sao Paulo Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Sao Paulo Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
EM clarimm@usp.br
CR Doebbeling BN, 1997, PREV MED, V26, P68, DOI 10.1006/pmed.1996.9991
   Link M. W., 2004, Morbidity and Mortality Weekly Report, V53, P1147
   Machado CM, 2004, BONE MARROW TRANSPL, V34, P111, DOI 10.1038/sj.bmt.1704534
   MACHADO CM, 2003, 43 INT C ANT AG CHEM, P279
   *MIN SAUD FUND NAC, 2004, DES INFL EP ORG VIG
   Nichols WG, 2004, CLIN INFECT DIS, V39, P1300, DOI 10.1086/425004
   van Essen GA, 2003, VACCINE, V21, P1780, DOI 10.1016/S0264-410X(03)00072-0
NR 7
TC 9
Z9 10
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL 15
PY 2005
VL 41
IS 2
BP 273
EP 274
DI 10.1086/431304
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 936YF
UT WOS:000229890800029
PM 15983934
OA Bronze
DA 2020-12-15
ER

PT J
AU Pereira, CN
   Del Nero, G
   Lacaz, CS
   Machado, CM
AF Pereira, CN
   Del Nero, G
   Lacaz, CS
   Machado, CM
TI The contribution of galactomannan detection in the diagnosis of invasive
   aspergillosis in bone marrow transplant recipients
SO MYCOPATHOLOGIA
LA English
DT Article
DE antigen detection; Aspergillosis; galactomannan; HSCT; Platelia; serum
   storage
ID LATEX AGGLUTINATION-TEST; LINKED-IMMUNOSORBENT-ASSAY;
   ENZYME-IMMUNOASSAY; CIRCULATING GALACTOMANNAN; PULMONARY ASPERGILLOSIS;
   ANTIGEN; REPRODUCIBILITY; INFECTIONS; FUMIGATUS
AB Until recently, accurate microbiological diagnosis of invasive aspergillosis (IA) was seldom established in HSCT recipients. Blood samples are rarely positive for Aspergillus species, the reliability of the cultures depends of the specimen ( if taken from a normally sterile site or not) and biopsy samples require invasive procedures, rarely recommended in patients with severe thrombocytopenia. Implementing the international consensus de. ning the microbiological criteria for the diagnosis of Aspergillus infection, we retrospectively evaluated the role of serum galactomannan (GM) detection by EIA to diagnose IA among HSCT patients with proven invasive fungal infection (IFI) and the impact of serum storage in GM concentrations. The EIA assay allowed categorizing as "probable'' 5 of the 10 cases of "possible'' aspergillosis (50%). Considering a lower cut-off level for the reaction (1.0), 80% of the cases could be categorized as "probable'' aspergillosis. Positive or undetermined results were detected one to 4 months before the diagnosis of IA in eight of the 11 patients (72.7%) with proven IFI. Retesting the stored samples after a second storage for four years, we could observe lower reactivity in 20% of the samples. The detection of galactomannan by the EIA test represents a major advance in the diagnosis of IA in HSCT recipients at high risk of IA. A better understanding of the kinetics of the GM in different clinical situations is necessary to maximize the benefit of the test in Aspergillus surveillance.
C1 Univ Sao Paulo, Inst Trop Med, Mycol Lab, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Children Inst LIM 36, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, BMT Program, Discipline Hematol, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Trop Med, Virol Lab, BR-05508 Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
CR Ansorg R, 1997, MYCOSES, V40, P353, DOI 10.1111/j.1439-0507.1997.tb00249.x
   Ascioglu S, 2002, CLIN INFECT DIS, V34, P7, DOI 10.1086/323335
   Becker MJ, 2000, J CLIN MICROBIOL, V38, P1434, DOI 10.1128/JCM.38.4.1434-1438.2000
   Hamaki T, 2001, BONE MARROW TRANSPL, V28, P633, DOI 10.1038/sj.bmt.1703209
   Kami M, 2000, HAEMATOLOGICA, V85, P745
   Latge JP, 1999, CLIN MICROBIOL REV, V12, P310, DOI 10.1128/CMR.12.2.310
   Machetti M, 1998, BONE MARROW TRANSPL, V21, P917, DOI 10.1038/sj.bmt.1701206
   Maertens J, 2001, BLOOD, V97, P1604, DOI 10.1182/blood.V97.6.1604
   Maertens J, 1999, J CLIN MICROBIOL, V37, P3223, DOI 10.1128/JCM.37.10.3223-3228.1999
   MAERTENS J, 2002, TRANSPL INFECT DIS, V4, P1
   MCLAUGHLIN L, 2004, LANCET INFECT DIS, V4, P349
   PEREIRA CN, 2001, THESIS U SAO PAULO
   Reiss E, 2000, MED MYCOL, V38, P147, DOI 10.1080/mmy.38.s1.147.159
   Ribaud P, 1999, CLIN INFECT DIS, V28, P322, DOI 10.1086/515116
   Rubin R H, 2002, Transpl Infect Dis, V4, P1, DOI 10.1034/j.1399-3062.2002.2e001.x
   Sulahian A, 1996, EUR J CLIN MICROBIOL, V15, P139, DOI 10.1007/BF01591487
   Sulahian A, 2003, NEW ENGL J MED, V349, P2366, DOI 10.1056/NEJM200312113492424
   SULAHIAN A, 2001, CANCER, V9, P311
   Verweij PE, 1998, J CLIN MICROBIOL, V36, P1612, DOI 10.1128/JCM.36.6.1612-1616.1998
   Verweij PE, 2002, J CLIN MICROBIOL, V40, P2648, DOI 10.1128/JCM.40.7.2648-2650.2002
   VERWEIJ PE, 1995, J CLIN PATHOL, V48, P474, DOI 10.1136/jcp.48.5.474
   Wheat L J, 2003, Transpl Infect Dis, V5, P158
NR 22
TC 15
Z9 17
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-486X
EI 1573-0832
J9 MYCOPATHOLOGIA
JI Mycopathologia
PD JUN
PY 2005
VL 159
IS 4
BP 487
EP 493
DI 10.1007/s11046-005-4996-9
PG 7
WC Mycology
SC Mycology
GA 940JW
UT WOS:000230141800001
PM 15983733
DA 2020-12-15
ER

PT J
AU Machado, CM
   de Souza, VAUF
   Sumita, LM
   da Rocha, IF
   Dulley, FL
   Pannuti, CS
AF Machado, CM
   de Souza, VAUF
   Sumita, LM
   da Rocha, IF
   Dulley, FL
   Pannuti, CS
TI Early measles vaccination in bone marrow transplant recipients
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE measles vaccine; early vaccination; safety; long-term immunity
ID STEM-CELL TRANSPLANTATION; RUBELLA VACCINE; MUMPS; REIMMUNIZATION;
   IMMUNIZATION; IMMUNITY; SAFETY; BLOOD
AB Measles vaccination has been recommended after the second year following bone marrow transplant ( BMT) in patients not receiving immunosuppressive drugs. During a measles outbreak, we vaccinated all patients after the first year of transplant, and conducted a prospective trial to evaluate safety, effectiveness and sustained immunity after early vaccination. Patients received attenuated virus vaccine between 9 and 18 months after BMT. A total of 51 patients were evaluated and 27 of them ( 52.9%) were receiving immunosuppressive drugs. Only mild adverse reactions were noted. Nine patients ( 17.6%) were susceptible ( IgG <= 100 mIU/ ml) at vaccination, and all seroconverted. In those immune at vaccination, a four- fold increase in measles IgG titers was found in one of 34 patients ( 2.9%) with specific IgG >= 200mIU/ ml compared to 14 of 17 ( 82.3%) with IgG < 200 mIU/ ml ( P < 0.0001). Sustained immunity after 24 months was more likely to occur in patients with specific IgG levels <= 200 or >= 500 mIU/ mL ( 83.4 and 100%, respectively) in comparison to patients with 200 < IgG < 499 mIU/ ml at vaccination ( 50%; P = 0.017). We conclude that even though early measles vaccination is safe, few patients are susceptible on day + 365 and this strategy should be reserved for epidemic situations posing significant threat for the patients.
C1 Univ Sao Paulo, Sch Med, Inst Trop Med, IMTSP,Virol Lab,HCFMUSP,LIM 52, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Discipline Hematol, BMT Program, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Sch Med, Inst Trop Med, IMTSP,Virol Lab,HCFMUSP,LIM 52, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
RI Pannuti, Claudio/B-7649-2012; Dulley, Frederico Luiz/H-7063-2013
CR Angel J. B., 1996, Morbidity and Mortality Weekly Report, V45, P603
   DYKEWICZ CA, 2000, MMWR-MORBID MORTAL W, V49, P1
   Henning KJ, 1997, JAMA-J AM MED ASSOC, V277, P1148, DOI 10.1001/jama.277.14.1148
   King SM, 1996, BONE MARROW TRANSPL, V17, P633
   LJUNGMAN P, 1994, BLOOD, V84, P657
   Ljungman P, 2004, BONE MARROW TRANSPL, V34, P589, DOI 10.1038/sj.bmt.1704634
   LJUNGMAN P, 1989, J INFECT DIS, V159, P610, DOI 10.1093/infdis/159.4.610
   LJUNGMAN P, 1995, BONE MARROW TRANSPL, V15, P455
   Machado CM, 2002, BLOOD, V99, P83, DOI 10.1182/blood.V99.1.83
   Pauksen K, 1996, BONE MARROW TRANSPL, V18, P969
   Shaw PJ, 2002, BLOOD, V99, P3486, DOI 10.1182/blood-2002-01-0212
   Singhal S, 1999, BONE MARROW TRANSPL, V23, P637, DOI 10.1038/sj.bmt.1701640
   SOMANI J, 1995, AM J MED, V98, P389, DOI 10.1016/S0002-9343(99)80319-2
   Souza Vanda Akico Ueda Fick De, 1997, Journal of Medical Virology, V52, P275
NR 14
TC 28
Z9 30
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2005
VL 35
IS 8
BP 787
EP 791
DI 10.1038/sj.bmt.1704878
PG 5
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 913JD
UT WOS:000228146800008
PM 15750610
OA Bronze
DA 2020-12-15
ER

PT J
AU Machado, CM
AF Machado, CM
TI Reimmunization after hematopoietic stem cell transplantation
SO EXPERT REVIEW OF VACCINES
LA English
DT Review
DE allogeneic; autologous; BMT; conjugate; inactivate; live atrenuate;
   PBSCT; polysaccharide; toxoid; vaccination
ID INFLUENZAE TYPE-B; BONE-MARROW-TRANSPLANTATION; LONG-TERM IMMUNITY;
   PNEUMOCOCCAL POLYSACCHARIDE; CONJUGATE VACCINE; ALLOGENEIC BMT; DONOR
   IMMUNIZATION; ANTIBODY-RESPONSES; VARICELLA VACCINE; WORKING PARTY
AB Hematopoietic stem cell transplant recipients lose immune memory of exposure to infectious agents and vaccines accumulated through a lifetime, and therefore need to be revaccinated. Reimmunization protocols vary greatly among hematopoietic stem cell transplant centers. Diphtheria and tetanus toxoids, pertussis vaccine, Haemophilus influenza type B conjugate, 23-valent pneumococcal polysaccharide, inactivated influenza and polio vaccine and live attenuated measles-mumps-rubella vaccine are the currently recommended vaccines to be included in a vaccination program after hematopoietic stem cell transplant. Other variables, such as stem cell source, new adjuvants, T-cell depleted transplants, nonmyeloablative conditioning and donor Immunization have recently been introduced and a constant update of current recommendations are needed. Studies recently published, the use of other vaccines and the perspectives for different vaccination protocols are discussed in this review.
C1 Univ Sao Paulo, Virol Lab, Inst Trop Med, BNT Unit,Amaral Carvalho Fdn, Reg Jau, SP, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Virol Lab, Inst Trop Med, BNT Unit,Amaral Carvalho Fdn, Reg Jau, SP, Brazil.
EM clarimm@usp.br
CR Arvin AM, 2004, CLIN INFECT DIS, V39, P233, DOI 10.1086/421999
   Au WY, 2003, CLIN TRANSPLANT, V17, P121, DOI 10.1034/j.1399-0012.2003.00022.x
   AVANZINI MA, 1995, J CLIN IMMUNOL, V15, P137, DOI 10.1007/BF01543105
   Avigan D, 2001, BIOL BLOOD MARROW TR, V7, P171, DOI 10.1053/bbmt.2001.v7.pm11302551
   BARRA A, 1992, J INFECT DIS, V166, P1021, DOI 10.1093/infdis/166.5.1021
   Bozza S, 2003, BLOOD, V102, P3807, DOI 10.1182/blood-2003-03-0748
   Caselitz M, 1997, J HEPATOL, V27, P572, DOI 10.1016/S0168-8278(97)80363-7
   Dignani MC, 2003, BONE MARROW TRANSPL, V31, P809, DOI 10.1038/sj.bmt.1704028
   DYKEWICZ CA, 2000, MMWR-MORBID MORTAL W, V49, P1
   ENGELHARD D, 1991, BONE MARROW TRANSPL, V8, P295
   ENGELHARD D, 1993, BONE MARROW TRANSPL, V11, P1
   Gandhi MK, 2001, BONE MARROW TRANSPL, V28, P775, DOI 10.1038/sj.bmt.1703239
   GUINAN EC, 1994, TRANSPLANTATION, V57, P677, DOI 10.1097/00007890-199403150-00009
   Hammarstrom V, 1998, BONE MARROW TRANSPL, V22, P67, DOI 10.1038/sj.bmt.1701289
   HAMMARSTROM V, 1993, SUPPORT CARE CANCER, V1, P195, DOI 10.1007/BF00366446
   Harper Scott A., 2004, Morbidity and Mortality Weekly Report, V53, P1
   Hata A, 2002, NEW ENGL J MED, V347, P26, DOI 10.1056/NEJMoa013441
   Henning KJ, 1997, JAMA-J AM MED ASSOC, V277, P1148, DOI 10.1001/jama.277.14.1148
   Horwitz SM, 2004, BLOOD, V103, P777, DOI 10.1182/blood-2003-04-1257
   ILAN Y, 1993, HEPATOLOGY, V18, P246, DOI 10.1016/0270-9139(93)90003-6
   KAPLAN LJ, 1992, JAMA-J AM MED ASSOC, V267, P1237, DOI 10.1001/jama.267.9.1237
   Lausen BF, 2004, J IMMUNOL, V172, P3305, DOI 10.4049/jimmunol.172.5.3305
   LIVOLTI S, 1994, BONE MARROW TRANSPL, V14, P225
   LJUNGMAN P, 1994, BLOOD, V84, P657
   Ljungman P, 2004, BONE MARROW TRANSPL, V34, P1067, DOI 10.1038/sj.bmt.1704678
   Ljungman P, 2003, SUPPORT CARE CANCER, V11, P739, DOI 10.1007/s00520-003-0527-8
   LJUNGMAN P, 1989, J INFECT DIS, V159, P610, DOI 10.1093/infdis/159.4.610
   LJUNGMAN P, 1995, BONE MARROW TRANSPL, V15, P455
   Ljungman P, 1999, BONE MARROW TRANSPL, V23, P635, DOI 10.1038/sj.bmt.1701641
   LJUNGMAN P, 1991, BONE MARROW TRANSPL, V7, P89
   LJUNGMAN P, 1990, J INFECT DIS, V162, P496, DOI 10.1093/infdis/162.2.496
   Locasciulli A, 1999, TRANSPLANTATION, V68, P1486, DOI 10.1097/00007890-199911270-00010
   LORTAN JE, 1992, CLIN EXP IMMUNOL, V88, P512
   LUM LG, 1986, J CLIN IMMUNOL, V6, P389, DOI 10.1007/BF00915378
   LUM LG, 1987, BLOOD, V69, P369
   Machado CM, 2004, BRAZ J MED BIOL RES, V37, P151, DOI 10.1590/S0100-879X2004000100021
   Machado CM, 2002, BLOOD, V99, P83, DOI 10.1182/blood.V99.1.83
   MACHADO CM, 2003, 43 INT C ANT AG CHEM, P279
   MACHADO CM, 2005, IN PRESS BONE MARROW, V35
   Martinez C, 2000, LEUKEMIA LYMPHOMA, V37, P535, DOI 10.3109/10428190009058505
   Molrine DC, 1996, BLOOD, V87, P3012, DOI 10.1182/blood.V87.7.3012.bloodjournal8773012
   Molrine DC, 2003, PEDIATR TRANSPLANT, V7, P76, DOI 10.1034/j.1399-3046.7.s3.12.x
   Molrine DC, 2003, BLOOD, V101, P831, DOI 10.1182/blood-2002-03-0832
   Musher DM, 1997, J INVEST MED, V45, P57
   NAGLER A, 1995, BONE MARROW TRANSPL, V15, P475
   Nakano T, 1996, ACTA PAEDIATR JAPON, V38, P212
   Ozdogan O, 2003, J CLIN GASTROENTEROL, V36, P421, DOI 10.1097/00004836-200305000-00013
   Parkkali T, 1997, BONE MARROW TRANSPL, V20, P663, DOI 10.1038/sj.bmt.1700959
   Parkkali T, 1997, BONE MARROW TRANSPL, V19, P933, DOI 10.1038/sj.bmt.1700768
   Parkkali T, 2001, BONE MARROW TRANSPL, V27, P79, DOI 10.1038/sj.bmt.1702742
   Parkkali T, 1996, BONE MARROW TRANSPL, V18, P961
   Parkkali T, 2001, BONE MARROW TRANSPL, V27, P207, DOI 10.1038/sj.bmt.1702779
   Parkkali T, 1996, APMIS, V104, P383, DOI 10.1111/j.1699-0463.1996.tb00731.x
   PAUKSEN K, 1992, BONE MARROW TRANSPL, V9, P427
   Pauksen K, 2000, CLIN INFECT DIS, V30, P342, DOI 10.1086/313663
   Redman RL, 1997, J INFECT DIS, V176, P578, DOI 10.1086/514077
   Sauerbrei A, 1997, BONE MARROW TRANSPL, V20, P381, DOI 10.1038/sj.bmt.1700909
   Singhal S, 1999, BONE MARROW TRANSPL, V23, P637, DOI 10.1038/sj.bmt.1701640
   SMALL TN, 2004, BLOOD, V104, P2226
   SOMANI J, 1995, AM J MED, V98, P389, DOI 10.1016/S0002-9343(99)80319-2
   Spoulou V, 2004, BONE MARROW TRANSPL, V33, P1187, DOI 10.1038/sj.bmt.1704476
   Spoulou V, 2000, J INFECT DIS, V182, P965, DOI 10.1086/315798
   Stevens DA, 2004, CLIN INFECT DIS, V38, P1131, DOI 10.1086/382882
   Storek J, 2004, BONE MARROW TRANSPL, V33, P337, DOI 10.1038/sj.bmt.1704336
   Vance E, 1998, BONE MARROW TRANSPL, V22, P735, DOI 10.1038/sj.bmt.1701424
   Vernacchio L, 2000, J INFECT DIS, V181, P1162, DOI 10.1086/315307
   Wilson ME, 2001, INFECT DIS CLIN N AM, V15, P231, DOI 10.1016/S0891-5520(05)70277-4
   WINSTON DJ, 1983, ARCH INTERN MED, V143, P1735, DOI 10.1001/archinte.143.9.1735
NR 68
TC 14
Z9 15
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-0584
EI 1744-8395
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD APR
PY 2005
VL 4
IS 2
BP 219
EP 228
DI 10.1586/14760584.4.2.219
PG 10
WC Immunology
SC Immunology
GA 982YZ
UT WOS:000233199600022
PM 15889995
DA 2020-12-15
ER

PT J
AU Machado, CM
   Boas, LSV
   Mendes, AVA
   da Rocha, IF
   Sturaro, D
   Dulley, FL
   Pannuti, CS
AF Machado, CM
   Boas, LSV
   Mendes, AVA
   da Rocha, IF
   Sturaro, D
   Dulley, FL
   Pannuti, CS
TI Use of Oseltamivir to control influenza complications after bone marrow
   transplantation
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE influenza; Oseltamivir; pneumonia; BMT; respiratory virus
ID NEURAMINIDASE INHIBITOR OSELTAMIVIR; RESPIRATORY VIRUS-INFECTIONS
AB Influenza infection can be severe in bone marrow transplant (BMT) recipients. Although yearly epidemics occur worldwide, and a higher risk of complication is expected in these patients, few studies have addressed the impact of the new neuraminidase inhibitors in the prognosis of influenza after BMT. Influenza A or B infections were found in 39 of the 66 patients (59%) showing a positive nasal wash by DFA. Influenza A was diagnosed in 18 patients and influenza B in 23 patients; two patients were infected by influenza A and B with 84- and 90-day intervals between episodes, respectively. Of the 41 episodes (61%) of influenza A or B, 25 infections occurred during the spring and summer months. Oseltamivir was introduced within 48 h of symptoms appearing. Only two patients (5.1%) developed influenza pneumonia, and no patient died of influenza. A total of 22 patients (56.4%) acquired influenza before day + 180 when preventive vaccination strategies are precluded owing to poor immunogenicity of the vaccine during this period. Oseltamivir proved to be safe and appears to have played an important role in the outcome of influenza infection in this population. The therapeutic and/or prophylactic benefits of Oseltamivir in BMT recipients remain to be demonstrated in randomized, prospective trials.
C1 Inst Med Trop Sao Paulo, HCFMUSP, LIM 52, Virol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Discipline Hematol, Fundacao Pro Sangue Hemoctr Sao Paulo,BMT Program, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
RI Dulley, Frederico Luiz/H-7063-2013; Pannuti, Claudio/B-7649-2012
CR Bowden Raleigh A., 1997, American Journal of Medicine, V102, P27, DOI 10.1016/S0002-9343(97)00007-7
   COUGH RB, 1997, AM J MED, V102, P2
   DYKEWICZ CA, 2000, MMWR-MORBID MORTAL W, V49, P1
   ENGELHARD D, 2001, BONE MARROW TRANSPL, V28, P775
   Englund JA, 1996, J CLIN MICROBIOL, V34, P1649, DOI 10.1128/JCM.34.7.1649-1653.1996
   GANDHI MK, 1993, BONE MARROW TRANSPL, V11, P1
   Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240
   Ljungman P, 2001, BONE MARROW TRANSPL, V28, P479, DOI 10.1038/sj.bmt.1703139
   Machado CM, 2003, BONE MARROW TRANSPL, V31, P695, DOI 10.1038/sj.bmt.1703900
   McClellan K, 2001, DRUGS, V61, P263, DOI 10.2165/00003495-200161020-00011
   Pauksen K, 2000, CLIN INFECT DIS, V30, P342, DOI 10.1086/313663
   Shek Lynette Pei-Chi, 2003, Paediatr Respir Rev, V4, P105, DOI 10.1016/S1526-0542(03)00024-1
   Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016
   WHIMBEY E, 1994, BONE MARROW TRANSPL, V13, P437
NR 14
TC 85
Z9 89
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUL
PY 2004
VL 34
IS 2
BP 111
EP 114
DI 10.1038/sj.bmt.1704534
PG 4
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 834CF
UT WOS:000222388500003
PM 15094755
OA Bronze
DA 2020-12-15
ER

PT J
AU Machado, CM
AF Machado, CM
TI Reimmunization after bone marrow transplantation - current
   recommendations and perspectives
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article; Proceedings Paper
CT 1st Symposium on Advances in Medical Research
CY MAR 21-22, 2003
CL SAO PAULO, BRAZIL
DE bone marrow transplantation; vaccination; autologous; allogeneic;
   toxoid; polysaccharide
ID INFLUENZAE TYPE-B; INACTIVATED VARICELLA VACCINE; PNEUMOCOCCAL VACCINE;
   CONJUGATE VACCINE; IMMUNE-RESPONSE; ALLOGENEIC BMT; CELL
   TRANSPLANTATION; DONOR IMMUNIZATION; ANTIBODY-RESPONSE; RECIPIENTS
AB Autologous and allogeneic bone marrow transplantation (BMT) recipients lose immune memory of exposure to infectious agents and vaccines accumulated through a lifetime and therefore need to be revaccinated. Diphtheria toxoid, tetanus toxoid, pertussis vaccine (children <7 years old), Haemophilus influenzae type b conjugate, 23-valent pneumococcal polysaccharide, inactivated influenza vaccine, inactivated polio vaccine and live-attenuated measles-mumps-rubella vaccine are the currently recommended vaccines to be included in a vaccination program after BMT. For most of them, the best time to vaccinate, the number of vaccine doses and/or the duration of immunity after vaccination have not been established. Vaccination protocols vary greatly among BMT centers, suggesting that the lack of sufficient data has not permitted the formulation of reliable recommendations. The use of other vaccines and the perspectives for different vaccination protocols are analyzed in this review.
C1 Univ Sao Paulo, Fac Med, Lab Virol, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Disciplina Hematol, Div Transplante Medula Ossea, BR-05403000 Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Fac Med, Lab Virol, Inst Med Trop Sao Paulo, LIM-52,Av Dr Eneas C Aguiar,470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
CR AVANZINI MA, 1995, J CLIN IMMUNOL, V15, P137, DOI 10.1007/BF01543105
   BARRA A, 1992, J INFECT DIS, V166, P1021, DOI 10.1093/infdis/166.5.1021
   DYKEWICZ CA, 2000, MMWR-MORBID MORTAL W, V49, P1
   ENGELHARD D, 1991, BONE MARROW TRANSPL, V8, P295
   ENGELHARD D, 1993, BONE MARROW TRANSPL, V11, P1
   GUINAN EC, 1994, TRANSPLANTATION, V57, P677, DOI 10.1097/00007890-199403150-00009
   HAMMARSTROM V, 1993, SUPPORT CARE CANCER, V1, P195, DOI 10.1007/BF00366446
   Hata A, 2002, NEW ENGL J MED, V347, P26, DOI 10.1056/NEJMoa013441
   Henning KJ, 1997, JAMA-J AM MED ASSOC, V277, P1148, DOI 10.1001/jama.277.14.1148
   ILAN Y, 1993, HEPATOLOGY, V18, P246, DOI 10.1016/0270-9139(93)90003-6
   LIVOLTI S, 1994, BONE MARROW TRANSPL, V14, P225
   LJUNGMAN P, 1994, BLOOD, V84, P657
   LJUNGMAN P, 1989, J INFECT DIS, V159, P610, DOI 10.1093/infdis/159.4.610
   LJUNGMAN P, 1995, BONE MARROW TRANSPL, V15, P455
   Ljungman P, 1999, BONE MARROW TRANSPL, V23, P635, DOI 10.1038/sj.bmt.1701641
   LJUNGMAN P, 1991, BONE MARROW TRANSPL, V7, P89
   LJUNGMAN P, 1990, J INFECT DIS, V162, P496, DOI 10.1093/infdis/162.2.496
   LORTAN JE, 1992, CLIN EXP IMMUNOL, V88, P512
   LUM LG, 1986, J CLIN IMMUNOL, V6, P389, DOI 10.1007/BF00915378
   LUM LG, 1987, BLOOD, V69, P369
   Machado CM, 2002, BLOOD, V99, P83, DOI 10.1182/blood.V99.1.83
   MACHADO CM, 1996, 9 INT S INF IMM HOST
   MACHADO CM, 2002, 12 INT S INF IMM HOS
   Molrine DC, 1996, BLOOD, V87, P3012, DOI 10.1182/blood.V87.7.3012.bloodjournal8773012
   Molrine DC, 2003, BLOOD, V101, P831, DOI 10.1182/blood-2002-03-0832
   NAGLER A, 1995, BONE MARROW TRANSPL, V15, P475
   Nakano T, 1996, ACTA PAEDIATR JAPON, V38, P212
   Parkkali T, 1997, BONE MARROW TRANSPL, V20, P663, DOI 10.1038/sj.bmt.1700959
   Parkkali T, 1997, BONE MARROW TRANSPL, V19, P933, DOI 10.1038/sj.bmt.1700768
   Parkkali T, 1996, BONE MARROW TRANSPL, V18, P961
   Parkkali T, 1996, APMIS, V104, P383, DOI 10.1111/j.1699-0463.1996.tb00731.x
   PAUKSEN K, 1992, BONE MARROW TRANSPL, V9, P427
   Pauksen K, 2000, CLIN INFECT DIS, V30, P342, DOI 10.1086/313663
   Redman RL, 1997, J INFECT DIS, V176, P578, DOI 10.1086/514077
   Sauerbrei A, 1997, BONE MARROW TRANSPL, V20, P381, DOI 10.1038/sj.bmt.1700909
   Singhal S, 1999, BONE MARROW TRANSPL, V23, P637, DOI 10.1038/sj.bmt.1701640
   SOMANI J, 1995, AM J MED, V98, P389, DOI 10.1016/S0002-9343(99)80319-2
   Spoulou V, 2000, J INFECT DIS, V182, P965, DOI 10.1086/315798
   Vance E, 1998, BONE MARROW TRANSPL, V22, P735, DOI 10.1038/sj.bmt.1701424
   Wilson ME, 2001, INFECT DIS CLIN N AM, V15, P231, DOI 10.1016/S0891-5520(05)70277-4
   WINSTON DJ, 1983, ARCH INTERN MED, V143, P1735, DOI 10.1001/archinte.143.9.1735
NR 41
TC 20
Z9 21
U1 0
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD JAN
PY 2004
VL 37
IS 1
BP 151
EP 158
DI 10.1590/S0100-879X2004000100021
PG 8
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 802XQ
UT WOS:000220196600021
PM 14689057
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Machado, CM
   Boas, LSV
   Mendes, AVA
   Santos, MFM
   da Rocha, IF
   Sturaro, D
   Dulley, FL
   Pannuti, CS
AF Machado, CM
   Boas, LSV
   Mendes, AVA
   Santos, MFM
   da Rocha, IF
   Sturaro, D
   Dulley, FL
   Pannuti, CS
TI Low mortality rates related to respiratory virus infections after bone
   marrow transplantation
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE respiratory virus; BMT; immunofluorescence; RSV; influenza;
   parainfluenza; mortality rate
ID STEM-CELL TRANSPLANTATION; SYNCYTIAL VIRUS; IMMUNOCOMPROMISED ADULTS;
   TRACT INFECTIONS; CHILDREN; RECIPIENTS; IMMUNOFLUORESCENCE;
   BRONCHIOLITIS; DIAGNOSIS; DISEASES
AB Respiratory viruses (RVs) frequently cause severe respiratory disease in bone marrrow transplant (BMT) recipients. To evaluate the frequency of RV, nasal washes were collected year-round from BMT recipients with symptoms of upper respiratory tract infection (URI). Direct immunofluorescence assay was performed for respiratory syncytial virus (RSV), influenza (Flu) A and B, adenovirus and parainfluenza (Paraflu) virus. Patients with RSV pneumonia or with upper RSV infection, but considered at high risk for developing RSV pneumonia received aerosolized ribavirin. Oseltamivir was given to patients with influenza. A total of 179 patients had 392 episodes of URI. In all, 68 (38%) tested positive: RSV was detected in 18 patients (26.4%), Flu B in 17 (25%), Flu A in 11 (16.2%) and Paraflu in 7 (10.3%). A total of 14 patients (20.6%) had multiple RV infections or coinfection. RSV pneumonia developed in 55.5% of the patients with RSV-URI. One of the 15 patients (6.6%) with RSV pneumonia died. Influenza pneumonia was diagnosed in three patients (7.3%). RSV and influenza infections peaked in fall-winter and winter-spring months, respectively. We observed decreased rates of influenza and parainfluenza pneumonia and low mortality because of RSV pneumonia. The role of antiviral interventions such as aerosolized ribavirin and new neuraminidase inhibitors remains to be defined in randomized trials.
C1 USP, Inst Trop Med, Virol Lab, BR-09500900 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Discipline Hematol, Fdn Pro Sangue Hemoctr Sao Paulo,BMT Program, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Av Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
RI Pannuti, Claudio/B-7649-2012; Dulley, Frederico Luiz/H-7063-2013
CR Andreoletti L, 2000, J MED VIROL, V61, P341, DOI 10.1002/1096-9071(200007)61:3&lt;341::AID-JMV10&gt;3.0.CO;2-0
   Bowden Raleigh A., 1997, American Journal of Medicine, V102, P27, DOI 10.1016/S0002-9343(97)00007-7
   Cintra OAL, 2001, J MED VIROL, V65, P408, DOI 10.1002/jmv.2049
   COUGH RB, 1997, AM J MED, V102, P2
   DEARRUDA E, 1991, J INFECT DIS, V164, P252, DOI 10.1093/infdis/164.2.252
   ENGLUND JA, 1988, ANN INTERN MED, V109, P203, DOI 10.7326/0003-4819-109-3-203
   Englund JA, 1996, J CLIN MICROBIOL, V34, P1649, DOI 10.1128/JCM.34.7.1649-1653.1996
   Ghosh S, 2000, BONE MARROW TRANSPL, V25, P751, DOI 10.1038/sj.bmt.1702228
   GHOSH S, 2002, INT J INFECT DIS S2, V6, P23
   HARRINGTON RD, 1992, J INFECT DIS, V165, P987, DOI 10.1093/infdis/165.6.987
   Ljungman P, 2001, BONE MARROW TRANSPL, V28, P479, DOI 10.1038/sj.bmt.1703139
   Lord A, 2000, J MED VIROL, V62, P405, DOI 10.1002/1096-9071(200012)62:4&lt;405::AID-JMV2&gt;3.0.CO;2-8
   Lujan-Zilbermann J, 2001, CLIN INFECT DIS, V33, P962, DOI 10.1086/322628
   Madhi SA, 2002, EUR J CLIN MICROBIOL, V21, P499, DOI 10.1007/s10096-002-0754-9
   Madhi SA, 2000, J PEDIATR-US, V137, P78, DOI 10.1067/mpd.2000.105350
   NASCIMENTO JP, 1991, REV I MED TROP, V33, P287, DOI 10.1590/S0036-46651991000400008
   Ong GM, 2001, J HOSP INFECT, V49, P122, DOI 10.1053/jhin.2001.1044
   Straliotto Selir M., 2002, Rev. Soc. Bras. Med. Trop., V35, P283, DOI 10.1590/S0037-86822002000400002
   Vieira Sandra E., 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P125, DOI 10.1590/S0036-46652001000300002
   WHIMBEY E, 1995, CLIN INFECT DIS, V21, P376, DOI 10.1093/clinids/21.2.376
   WHIMBEY E, 1994, BONE MARROW TRANSPL, V13, P437
   Whimbey E, 1996, CLIN INFECT DIS, V22, P778, DOI 10.1093/clinids/22.5.778
   Whimbey Estella, 1997, American Journal of Medicine, V102, P10, DOI 10.1016/S0002-9343(97)80004-6
NR 23
TC 75
Z9 80
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2003
VL 31
IS 8
BP 695
EP 700
DI 10.1038/sj.bmt.1703900
PG 6
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 672AA
UT WOS:000182497000010
PM 12692610
OA Green Published, Bronze
DA 2020-12-15
ER

PT J
AU Mendes, AVA
   Benard, G
   Pereira, CB
   Kallas, EG
   Duarte, AJS
   Pannuti, CS
   Dulley, FL
   Machado, CM
AF Mendes, AVA
   Benard, G
   Pereira, CB
   Kallas, EG
   Duarte, AJS
   Pannuti, CS
   Dulley, FL
   Machado, CM
TI Different kinetics in anti-cytomegalovirus immunity reconstitution
   evaluated by lymphocyte proliferation and IFN-gamma production in
   allogeneic and autologous bone marrow transplantation
SO ACTA HAEMATOLOGICA
LA English
DT Article
DE bone marrow transplantation; CD8; cytomegalovirus; IFN-gamma; immune
   reconstitution; lymphoproliferative response
ID BLOOD STEM-CELL; CMV DISEASE; T-CELLS; GANCICLOVIR; RECIPIENTS;
   INFECTION; INTERFERON; FIBROBLASTS; RESPONSES; PARACOCCIDIOIDOMYCOSIS
AB Allogeneic bone marrow transplantation (ALLOBMT) is associated with an increased risk of cytomegalovirus (CMV) morbidity compared to autologous BMT (AUTOBMT). To investigate this, we evaluated AUTOBMT and ALLOBMT patients regarding anti-CMV immune reconstitution at 1 and 4 months after BMT and on the day after first CMV antigenemia detection. Intermittent ganciclovir preemptive therapy was prompted by antigenemia of greater than or equal to2 cells. One month after transplant, AUTOBMT recipients already displayed larger CD8+ T cell numbers than ALLOBMT recipients, but comparably small CD4+ T cell numbers. Most AUTOBMT patients had positive CMV antigen (CMV-Ag)-induced lymphoproliferation (86%) and IFN-gamma secretion (86%), whereas this was infrequently seen in ALLOBMT patients (20 and 10%, respectively). This early AUTOBMT immune reconstitution was associated with a lower frequency of CMV reactivation up to +4 months in AUTOBMT (21%) than ALLOBMT patients (91%). At +4 months, most ALLOBMT recipients had also recovered CMV-Ag immune responses. At first antigenemia detection, all 3 AUTOBMT recipients already displayed anti-CMV immune functions and 2 cleared the infection without therapy, whereas of the 10 ALLOBMT recipients only 1 had positive lymphoproliferation. In the latter group, none had IFN-gamma secretion or cleared the infection without therapy. Thus, differences in anti-CMV immune reconstitution may help to explain the contrasting rates of CMV morbidity between ALLOBMT and AUTOBMT patients. Copyright (C) 2002 S. Karger AG, Basel.
C1 Univ Sao Paulo, Sch Med, Virol Lab, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Lab Clin & Expt Allergy & Immunol, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Immunol Lab, Discipline Infect Dis, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Fundacao Pro Sangue Hemoctr Sao Paulo, Discipline Hematol,BMT Program, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
RI Dulley, Frederico Luiz/H-7063-2013; Pannuti, Claudio/B-7649-2012;
   Duarte, Alberto J S/D-4382-2012; Benard, Gil/D-9414-2013; Kallas, Esper
   G/C-9539-2012
OI Kallas, Esper/0000-0003-2026-6925
CR Benard G, 1997, J INFECT DIS, V175, P1263, DOI 10.1086/593694
   Benard G, 2001, CYTOKINE, V13, P248, DOI 10.1006/cyto.2000.0824
   Bilgrami S, 1999, BONE MARROW TRANSPL, V24, P69, DOI 10.1038/sj.bmt.1701827
   Boeckh M, 1996, BLOOD, V88, P4063, DOI 10.1182/blood.V88.10.4063.bloodjournal88104063
   BOLAND GJ, 1992, CLIN EXP IMMUNOL, V88, P506
   BORYSIEWICZ LK, 1983, EUR J IMMUNOL, V13, P804, DOI 10.1002/eji.1830131005
   BOWDEN RA, 1990, TRANSPLANTATION, V50, P38, DOI 10.1097/00007890-199007000-00008
   Bruggeman CA, 1995, SCAND J INFECT DIS, P43
   Dai ZH, 2000, J IMMUNOL, V165, P3031, DOI 10.4049/jimmunol.165.6.3031
   de Vries E, 2000, BONE MARROW TRANSPL, V25, P267, DOI 10.1038/sj.bmt.1702141
   DUNCOMBE AS, 1990, BLOOD, V76, P1046
   EINSELE H, 1995, BLOOD, V86, P2815
   GAST GC, 1985, BLOOD, V6, P428
   Ghanekar SA, 2001, CLIN DIAGN LAB IMMUN, V8, P628, DOI 10.1128/CDLI.8.3.628-631.2001
   GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303
   Gor D, 1998, BONE MARROW TRANSPL, V21, P597, DOI 10.1038/sj.bmt.1701139
   GRUNDY JE, 1993, IMMUNOLOGY, V78, P405
   GRUNDY JE, 1993, IMMUNOLOGY, V78, P413
   Holmberg LA, 1999, BLOOD, V94, P4029, DOI 10.1182/blood.V94.12.4029.424k21_4029_4035
   Humar A, 1999, J INFECT DIS, V179, P484, DOI 10.1086/314602
   Kallas EG, 1998, IMMUNOL LETT, V64, P63, DOI 10.1016/S0165-2478(98)00080-7
   Krause H, 1997, BONE MARROW TRANSPL, V19, P1111, DOI 10.1038/sj.bmt.1700801
   LI CR, 1994, BLOOD, V83, P1971, DOI 10.1182/blood.V83.7.1971.1971
   LJUNGMAN P, 1986, BLOOD, V68, P108
   LJUNGMAN P, 1985, TRANSPLANTATION, V40, P515, DOI 10.1097/00007890-198511000-00009
   LJUNGMAN P, 1993, BRIT J HAEMATOL, V83, P118, DOI 10.1111/j.1365-2141.1993.tb04641.x
   Ljungman P, 1996, SCAND J INFECT DIS, P59
   Ljungman P, 1995, SCAND J INFECT DIS, P87
   Machado CM, 2000, BONE MARROW TRANSPL, V26, P413, DOI 10.1038/sj.bmt.1702526
   MEYERS JD, 1980, J INFECT DIS, V142, P816, DOI 10.1093/infdis/142.6.816
   Pannuti CS, 1996, AM J OPHTHALMOL, V122, P847, DOI 10.1016/S0002-9394(14)70381-2
   Podlech J, 1998, J GEN VIROL, V79, P2099, DOI 10.1099/0022-1317-79-9-2099
   QUINNAN GV, 1982, NEW ENGL J MED, V307, P7, DOI 10.1056/NEJM198207013070102
   REUSSER P, 1991, BLOOD, V78, P1373
   Reusser P, 1997, BLOOD, V89, P3873, DOI 10.1182/blood.V89.10.3873.3873_3873_3879
   SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501
   THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706
   Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947
   WINSTON DJ, 1979, MEDICINE, V58, P1, DOI 10.1097/00005792-197901000-00001
NR 39
TC 8
Z9 8
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5792
EI 1421-9662
J9 ACTA HAEMATOL-BASEL
JI Acta Haematol.
PY 2002
VL 107
IS 4
BP 187
EP 194
DI 10.1159/000058313
PG 8
WC Hematology
SC Hematology
GA 563MT
UT WOS:000176260000001
PM 12053145
DA 2020-12-15
ER

PT J
AU Machado, CM
   Goncalves, FB
   Pannuti, CS
   Dulley, FL
   de Souza, VAUF
AF Machado, CM
   Goncalves, FB
   Pannuti, CS
   Dulley, FL
   de Souza, VAUF
TI Measles in bone marrow transplant recipients during an outbreak in Sao
   Paulo, Brazil
SO BLOOD
LA English
DT Article
ID RUBELLA VACCINE; VITAMIN-A; T-CELL; MUMPS; CHILDREN; IMMUNITY; BLOOD
AB In 1997, a measles outbreak was identified in Sio Paulo. Between February and December, 20 185 cases were confirmed. From April to July 1997, a seroepidemiologic survey was conducted to identify the recipients of bone marrow (BM) transplants who were susceptible to measles and the occurrence of measles in this population. A total of 156 patients were screened by enzyme immunoassay (EIA). Patients with IgG titers more than 100 mIU/mL were considered immune. Measles reimmunization records were also reviewed. Thirty-two vaccinated patients underwent serologic evaluation. Six of 22 patients (27.3%) within 3 years after vaccination lost measles immunity, in contrast to 7 of 10 patients (70%) vaccinated longer than 3 years previously (P=.049). Among the 122 nonvaccinated patients, 41 (33.6%) were susceptible to measles: 4 of 47 patients (8.5%) within the first year after BM transplantation (BMT), and 37 of the 75 patients (49.3%) after the first year after BMT (P<.001). Eight recipients acquired measles, confirmed by serology (EIA). High-avidity IgG antibodies were observed in the acute phase of measles, suggesting a secondary immune response. Measles interstitial pneumonia was observed in one patient. Seven patients had mild symptoms. Exanthema was present in all patients. All but one patient had fever and nonproductive cough. Koplik spots could be observed in 5 patients. Measles can be mild in BM transplant recipients. Exanthema is frequently present but not often typical. Immunity to measles decreases after day +365 after BMT. Additional studies are needed to evaluate the safety of measles vaccine after the first year of BMT, mostly during outbreaks.
C1 Univ Sao Paulo, Sch Med, Inst Med Trop Sao Paulo, Virol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Discipline Hematol, Sao Paulo, Brazil.
   Fundacao Pro Sangue Hemoctr Sao Paulo, BMT Program, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), IMTSP, FMUSP, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
RI Pannuti, Claudio/B-7649-2012; Dulley, Frederico Luiz/H-7063-2013
CR [Anonymous], 1987, WKLY EPIDEMIOL REC, V62, P133
   BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294
   Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P189
   CHAN M, 1990, BMJ-BRIT MED J, V301, P1230, DOI 10.1136/bmj.301.6763.1230
   ERDMAN DD, 1991, J CLIN MICROBIOL, V29, P1466, DOI 10.1128/JCM.29.7.1466-1471.1991
   GRIFFIN DE, 1996, VIROLOGY, P1267
   HIDAKA Y, 1994, SCAND J INFECT DIS, V26, P725, DOI 10.3109/00365549409008642
   KAPLAN LJ, 1992, JAMA-J AM MED ASSOC, V267, P1237, DOI 10.1001/jama.267.9.1237
   King SM, 1996, BONE MARROW TRANSPL, V17, P633
   LJUNGMAN P, 1994, BLOOD, V84, P657
   LJUNGMAN P, 1989, J INFECT DIS, V159, P610, DOI 10.1093/infdis/159.4.610
   LJUNGMAN P, 1995, BONE MARROW TRANSPL, V15, P455
   Lum L G, 1987, Prog Clin Biol Res, V244, P449
   MUSTAFA MM, 1993, CLIN INFECT DIS, V16, P654, DOI 10.1093/clind/16.5.654
   Nakano T, 1996, ACTA PAEDIATR JAPON, V38, P212
   Pauksen K, 1995, BONE MARROW TRANSPL, V16, P807
   Pauksen K, 1996, BONE MARROW TRANSPL, V18, P969
   Singhal S, 1999, BONE MARROW TRANSPL, V23, P637, DOI 10.1038/sj.bmt.1701640
   SOUZA VAI, 1994, 8 INT S INF IMM HOST
   Souza Vanda Akico Ueda Fick De, 1997, Journal of Medical Virology, V52, P275
   1988, MORB MORTAL WKLY REP, V47, P1
   1996, MORB MORTAL WKLY REP, V45, P603
NR 22
TC 42
Z9 47
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JAN 1
PY 2002
VL 99
IS 1
BP 83
EP 87
DI 10.1182/blood.V99.1.83
PG 5
WC Hematology
SC Hematology
GA 506PK
UT WOS:000172980800016
PM 11756156
DA 2020-12-15
ER

PT J
AU Machado, CM
   Menezes, RX
   Macedo, MCA
   Mendes, AVA
   Boas, LSV
   Castelli, JB
   Dulley, FL
   Pannuti, CS
AF Machado, CM
   Menezes, RX
   Macedo, MCA
   Mendes, AVA
   Boas, LSV
   Castelli, JB
   Dulley, FL
   Pannuti, CS
TI Extended antigenemia surveillance and late cytomegalovirus infection
   after allogeneic BMT
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE antigenemia; CMV; BMT; extended surveillance; late CMV disease
ID BONE-MARROW TRANSPLANT; PP65 ANTIGENEMIA; PREEMPTIVE GANCICLOVIR;
   PERIPHERAL-BLOOD; DISEASE; RISK; RECIPIENTS; PNEUMONIA; THERAPY; ASSAY
AB Late CMV disease remains a major concern in allogeneic BMT recipients. Few surveillance data are available on the occurrence of CMV infection and recurrences after day +100. We evaluated the occurrence of antigenemia (AG) recurrences until day +365 in 76 patients who received pre-emptive ganciclovir (GCV) therapy prompted by AG greater than or equal to2 positive cells. Sixty-two episodes of AG recurrences were detected in 33 of the 52 patients who had positive AG. Survival analysis showed a 45.4% probability of AG recurrence on day +100, 64.8% on day +180 and 71.2% on day +365. The median time for AG recurrences was 113 (35 to 343) days. Thirty-five of the 62 episodes (56.4%) occurred after day +100. More than 70% of the patients responded to a 2-week course of GCV and no CMV disease was observed shortly after discontinuation of GCV. The Cox proportional model showed a significant effect of AG recurrences on patient's follow-up only when the patient developed chronic GVHD (P = 0.012). Extended surveillance favored early introduction of GCV and late CMV pneumonia occurred in only one of the 76 patients (1.3%). AG recurrences are frequent after day +100 and extended surveillance until day +365 is recommended for patients who develop chronic GvHD.
C1 Inst Med Trop Sao Paulo, Virol Lab, LIM 52, HCFMUSP, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Discipline Hematol, Fundacao Pro Sangue Hemoctr Sao Paulo,BMT Program, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Discipline Med Informat, LIM 01,HCFMUSP, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, INCOR HC, Dept Pathol, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
RI Castelli, Jussara B/I-4798-2013; Dulley, Frederico Luiz/H-7063-2013;
   Pannuti, Claudio/B-7649-2012
OI Castelli, Jussara B/0000-0002-8414-4161; 
CR BOECKH M, 1992, BLOOD, V80, P1358
   Boeckh M, 1999, BLOOD, V93, P1781, DOI 10.1182/blood.V93.5.1781
   Boeckh M, 1996, BLOOD, V88, P4063, DOI 10.1182/blood.V88.10.4063.bloodjournal88104063
   EINSELE H, 1995, BLOOD, V86, P2815
   Einsele H, 2000, BONE MARROW TRANSPL, V25, P757, DOI 10.1038/sj.bmt.1702226
   HALWACHS G, 1993, TRANSPLANTATION, V56, P338, DOI 10.1097/00007890-199308000-00016
   Humar A, 1998, CLIN INFECT DIS, V26, P606, DOI 10.1086/514569
   Krause H, 1997, BONE MARROW TRANSPL, V19, P1111, DOI 10.1038/sj.bmt.1700801
   LI CR, 1994, BLOOD, V83, P1971, DOI 10.1182/blood.V83.7.1971.1971
   Ljungman P, 1995, SCAND J INFECT DIS, P87
   Machado CM, 2000, BONE MARROW TRANSPL, V26, P413, DOI 10.1038/sj.bmt.1702526
   Mori T, 2000, BONE MARROW TRANSPL, V25, P765, DOI 10.1038/sj.bmt.1702227
   Nguyen Q, 1999, CLIN INFECT DIS, V28, P618, DOI 10.1086/515146
   Pannuti CS, 1996, AM J OPHTHALMOL, V122, P847, DOI 10.1016/S0002-9394(14)70381-2
   SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501
   SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0
   Stocchi R, 1999, BONE MARROW TRANSPL, V23, P705, DOI 10.1038/sj.bmt.1701629
   Therneau T.M., 2000, MODELING SURVIVAL DA
   THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706
   Trenschel R, 2000, BONE MARROW TRANSPL, V25, P665, DOI 10.1038/sj.bmt.1702216
   VANDERBIJ W, 1988, J MED VIROL, V25, P179, DOI 10.1002/jmv.1890250208
   VLIEGER AM, 1992, BONE MARROW TRANSPL, V9, P247
   ZAIA JA, 1991, TRANSPL P, V23, P1
   Zaia JA, 1997, J INFECT DIS, V176, P782, DOI 10.1086/517301
NR 24
TC 25
Z9 26
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD DEC
PY 2001
VL 28
IS 11
BP 1053
EP 1059
DI 10.1038/sj.bmt.1703282
PG 7
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 504PF
UT WOS:000172864500009
PM 11781616
OA Bronze
DA 2020-12-15
ER

PT J
AU Machado, C
   Garcia, AB
   Calado, RT
   Falcao, RP
AF Machado, C
   Garcia, AB
   Calado, RT
   Falcao, RP
TI Age-related changes of P-glycoprotein function in normal human
   peripheral blood lymphocytes and in bone marrow CD34+cells.
SO BLOOD
LA English
DT Meeting Abstract
C1 Univ Sao Paulo, Dept Clin Med, Sch Med, BR-14049 Ribeirao Preto, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 16
PY 2001
VL 98
IS 11
MA 83
BP 23A
EP 23A
PN 1
PG 1
WC Hematology
SC Hematology
GA 491WY
UT WOS:000172134100084
DA 2020-12-15
ER

PT J
AU Machado, CM
   Dulley, FL
   Boas, LSV
   Castelli, JB
   Macedo, MCA
   Silva, RL
   Pallota, R
   Saboya, RS
   Pannuti, CS
AF Machado, CM
   Dulley, FL
   Boas, LSV
   Castelli, JB
   Macedo, MCA
   Silva, RL
   Pallota, R
   Saboya, RS
   Pannuti, CS
TI CMV pneumonia in allogeneic BMT recipients undergoing early treatment or
   pre-emptive ganciclovir therapy
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE CMV; pneumonia; BMT; antigenemia; extended surveillance; IVIg
ID CYTOMEGALO-VIRUS PNEUMONIA; BONE-MARROW TRANSPLANTATION; INTRAVENOUS
   IMMUNE GLOBULIN; ANTIVIRAL THERAPY; PERIPHERAL-BLOOD; DISEASE;
   PROPHYLAXIS; EBMT
AB The incidence, treatment and outcome of CMV interstitial pneumonia (CMV-IP) were reviewed in 139 consecutive allogeneic BRIT patients undergoing extended CMV antigenemia surveillance and two different ganciclovir (GCV) strategies to control CMV infection. Nineteen cases of CMV-IP were reviewed, 16 of 63 patients (25.4%) who received early GCV treatment (ET) and three of 76 patients (3.9%) who received preemptive (PE) GCV therapy. In the ET group, the median time for occurrence of CMV-IP was 55 (range 36 to 311) days, Two patients had three episodes of CMV-IP recurrences after day +100, CMV-IP-related death occurred in two patients (15.4%). In the PE group, 41 patients received pre-emptive GCV therapy prompted by the appearance of positive antigenemia greater than or equal to 2 cells. The median time for the occurrence of CMV-IP was 92 (range 48 to 197) days, Response to therapy was observed when GCV was introduced within 6 days of antigenemia positivity. The use of IVIg in association with GCV did not play a major role in response to therapy. The median time for occurrence of CMV-IP was delayed during PE strategy and the cost-effectiveness of CMV surveillance after day +100 should be investigated in this population.
C1 Fdn Pro Sangue Hemoctr Sao Paulo, BMT Program, Discipline Hematol, Sao Paulo, Brazil.
   Inst Med Trop Sao Paulo, Virol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, INCORHC, Dept Pathol, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
RI Castelli, Jussara B/I-4798-2013; Dulley, Frederico Luiz/H-7063-2013;
   Pannuti, Claudio/B-7649-2012
OI Castelli, Jussara B/0000-0002-8414-4161; 
CR BOECKH M, 1992, BLOOD, V80, P1358
   Boeckh M, 1996, BLOOD, V88, P4063, DOI 10.1182/blood.V88.10.4063.bloodjournal88104063
   BOECKH M, 1997, 6 INT CMV WORKSH OR
   EINSELE H, 1995, BLOOD, V86, P2815
   EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777
   FRANK I, 1988, ANN INTERN MED, V109, P769, DOI 10.7326/0003-4819-109-10-769
   GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303
   HALWACHS G, 1993, TRANSPLANTATION, V56, P338, DOI 10.1097/00007890-199308000-00016
   LI CR, 1994, BLOOD, V83, P1971, DOI 10.1182/blood.V83.7.1971.1971
   Ljungman P, 1998, BONE MARROW TRANSPL, V21, P473, DOI 10.1038/sj.bmt.1701113
   LJUNGMAN P, 1993, BONE MARROW TRANSPL, V12, P399
   LJUNGMAN P, 1995, SCAND J INFECT DIS S, V99, P87
   MACHADO CM, 1999, 39 ICACC SAN FRANC C
   REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783
   SHEPP DH, 1985, ANN INTERN MED, V103, P368, DOI 10.7326/0003-4819-103-3-368
   ZAIA JA, 1991, TRANSPL P, V23, P1
NR 16
TC 61
Z9 64
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD AUG
PY 2000
VL 26
IS 4
BP 413
EP 417
DI 10.1038/sj.bmt.1702526
PG 5
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 345WB
UT WOS:000088837200008
PM 10982288
OA Bronze
DA 2020-12-15
ER

PT J
AU Pallotta, RS
   Barbosa, JAL
   Macedo, MCMA
   Saboya, R
   Silva, RL
   Machado, CM
   Castelli, JB
   Jamra, M
   Chamone, DAF
   Dulley, FL
AF Pallotta, RS
   Barbosa, JAL
   Macedo, MCMA
   Saboya, R
   Silva, RL
   Machado, CM
   Castelli, JB
   Jamra, M
   Chamone, DAF
   Dulley, FL
TI Mycobacteria infection in bone marrow transplant recipients.
SO BLOOD
LA English
DT Meeting Abstract
C1 Fundacao Pro Sangue, Hemoctr Sao Paulo, BMT Program, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RI Dulley, Frederico Luiz/H-7063-2013; Castelli, Jussara B/I-4798-2013
OI Castelli, Jussara B/0000-0002-8414-4161
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1998
VL 92
IS 10
SU 1
MA 4450
BP 336B
EP 337B
PN 2
PG 2
WC Hematology
SC Hematology
GA 141AX
UT WOS:000077121401475
DA 2020-12-15
ER

PT J
AU Saboya, R
   Pallotta, RS
   Macedo, MCMA
   Silva, RL
   Machado, CM
   Jamra, M
   Chamone, DAF
AF Saboya, R
   Pallotta, RS
   Macedo, MCMA
   Silva, RL
   Machado, CM
   Jamra, M
   Chamone, DAF
TI Risk factors for bacterial and fungal infections in bone marrow
   transplant recipients.
SO BLOOD
LA English
DT Meeting Abstract
C1 Hemoctr Sao Paulo, Fundacao Prosangue, BMT Program, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1998
VL 92
IS 10
SU 1
MA 4458
BP 338B
EP 338B
PN 2
PG 1
WC Hematology
SC Hematology
GA 141AX
UT WOS:000077121401483
DA 2020-12-15
ER

PT J
AU Silva, RL
   Pallotta, RS
   Saboya, R
   Macedo, MCMA
   Machado, CM
   Castelli, JB
   Jamra, M
   Chamone, DAF
   Dulley, FL
AF Silva, RL
   Pallotta, RS
   Saboya, R
   Macedo, MCMA
   Machado, CM
   Castelli, JB
   Jamra, M
   Chamone, DAF
   Dulley, FL
TI Epstein-Barr virus infection in bone marrow transplantation recipients.
SO BLOOD
LA English
DT Meeting Abstract
C1 Hemoctr Sao Paulo, Fundacao Prosangue, BMT Program, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
RI Castelli, Jussara B/I-4798-2013; Dulley, Frederico Luiz/H-7063-2013
OI Castelli, Jussara B/0000-0002-8414-4161; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1998
VL 92
IS 10
SU 1
MA 4459
BP 338B
EP 338B
PN 2
PG 1
WC Hematology
SC Hematology
GA 141AX
UT WOS:000077121401484
DA 2020-12-15
ER

PT J
AU Machado, CM
   Macedo, MCA
   Medeiros, RSS
   Massumoto, C
   Silva, ACM
   Castelli, JB
   Silva, RL
   Ostronoff, M
   Dulley, FL
AF Machado, CM
   Macedo, MCA
   Medeiros, RSS
   Massumoto, C
   Silva, ACM
   Castelli, JB
   Silva, RL
   Ostronoff, M
   Dulley, FL
TI Primary Pneumocystis carinii prophylaxis with aerosolized pentamidine
   after bone marrow transplantation
SO ACTA HAEMATOLOGICA
LA English
DT Article
ID TOXOPLASMIC ENCEPHALITIS; PNEUMONIA; RECIPIENTS; CHEMOPROPHYLAXIS;
   INFECTION
C1 Univ Sao Paulo, Sch Med, INCOR HC Dept Pathol, Sao Paulo, Brazil.
   Pro Sangue Hemocentro Fdn & Discipline Hematol, BMT Program, Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
RI Castelli, Jussara B/I-4798-2013; Dulley, Frederico Luiz/H-7063-2013
OI Castelli, Jussara B/0000-0002-8414-4161; 
CR CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106
   COHEN OJ, 1991, ARCH INTERN MED, V151, P1205, DOI 10.1001/archinte.151.6.1205
   DEROUIN F, 1992, CLIN INFECT DIS, V15, P267, DOI 10.1093/clinids/15.2.267
   DULLEY FL, 1994, BLOOD, V84, pA334
   EDELSTEIN H, 1990, CHEST, V98, P1366, DOI 10.1378/chest.98.6.1366
   HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602
   HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604
   JULESELYSEE KM, 1990, ANN INTERN MED, V112, P750, DOI 10.7326/0003-4819-112-10-750
   LEONG GS, 1990, NEW ENGL J MED, V323, P769
   LINK H, 1993, BONE MARROW TRANSPL, V11, P403
   MEYERS J, 1988, CLIN APPROACH INFECT, P546
   NOSKIN GA, 1991, REV INFECT DIS, V13, P525
   OPRAVIL M, 1995, CLIN INFECT DIS, V20, P531, DOI 10.1093/clinids/20.3.531
   RAVIGLIONE MC, 1990, REV INFECT DIS, V12, P1127
   RAVIGLIONE MC, 1990, LANCET, V335, P180
   SLAVIN MA, 1994, BONE MARROW TRANSPL, V13, P549
   *USPHS IDSA, 1995, MMWR-MORBID MORTAL W, V44, P1
NR 17
TC 15
Z9 16
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5792
J9 ACTA HAEMATOL-BASEL
JI Acta Haematol.
PY 1998
VL 99
IS 1
BP 54
EP 56
DI 10.1159/000040719
PG 3
WC Hematology
SC Hematology
GA YW866
UT WOS:000071981900014
PM 9490570
DA 2020-12-15
ER

PT J
AU Machado, CM
   Souza, VAUF
   Goncalves, FB
   daRocha, IF
   Diomede, BB
   Massumoto, CM
   Dzik, C
   Sobrinho, J
   Macedo, MCMA
   Silva, RL
   Pallotta, RS
   Saboya, R
   Pannuti, CS
   Chamone, DAF
   Dulley, FL
AF Machado, CM
   Souza, VAUF
   Goncalves, FB
   daRocha, IF
   Diomede, BB
   Massumoto, CM
   Dzik, C
   Sobrinho, J
   Macedo, MCMA
   Silva, RL
   Pallotta, RS
   Saboya, R
   Pannuti, CS
   Chamone, DAF
   Dulley, FL
TI Measles in BMT recipients during an outbreak in Sao Paulo, Brazil.
SO BLOOD
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,INST MED TROP SAO PAULO,FDN PRO SANGUE,HEMOCTR SAO PAULO,BMT PROGRAM,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,INST MED TROP SAO PAULO,VIROL LAB,SAO PAULO,BRAZIL.
RI Dulley, Frederico Luiz/H-7063-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1997
VL 90
IS 10
SU 1
BP 2417
EP 2417
PN 1
PG 2
WC Hematology
SC Hematology
GA YG424
UT WOS:A1997YG42402413
DA 2020-12-15
ER

PT J
AU Machado, CM
   Barbosa, MAS
   daRocha, IF
   Diomede, BB
   Massumoto, CM
   Chamone, DAF
   Dulley, FL
AF Machado, CM
   Barbosa, MAS
   daRocha, IF
   Diomede, BB
   Massumoto, CM
   Chamone, DAF
   Dulley, FL
TI Blood cultures obtained from long-term central venous catheters versus
   peripheral vein puncture in febrile BMT recipients.
SO BLOOD
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DISCIPLINE HEMATOL,BMT PROGRAM,FUNDACAO PRO SANGUE HEMOCENTRO SAO PAULO,SAO PAULO,BRAZIL.
RI Dulley, Frederico Luiz/H-7063-2013
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1997
VL 90
IS 10
SU 1
BP 4418
EP 4418
PN 2
PG 1
WC Hematology
SC Hematology
GA YG425
UT WOS:A1997YG42501727
DA 2020-12-15
ER

PT J
AU Silva, RL
   Sperandio, FA
   Machado, CM
   Massumoto, CM
   Imamura, R
   Macedo, MCMA
   Loterio, HA
   Dizik, C
   Pallotta, RS
   Saboya, R
   Chamone, DAF
   Dulley, FL
AF Silva, RL
   Sperandio, FA
   Machado, CM
   Massumoto, CM
   Imamura, R
   Macedo, MCMA
   Loterio, HA
   Dizik, C
   Pallotta, RS
   Saboya, R
   Chamone, DAF
   Dulley, FL
TI Sinusitis in bone marrow transplant patients.
SO BLOOD
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,BMT PROGRAM,FUNDACAO PRO SANGUE HEMOCENTRO SAO PAULO,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DISCIPLINE HEMATOL,SAO PAULO,BRAZIL.
RI Imamura, Rui/B-8968-2014; Dulley, Frederico Luiz/H-7063-2013
OI Imamura, Rui/0000-0002-0161-7518; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1997
VL 90
IS 10
SU 1
BP 4437
EP 4437
PN 2
PG 1
WC Hematology
SC Hematology
GA YG425
UT WOS:A1997YG42501746
DA 2020-12-15
ER

PT J
AU Machado, CM
   Boas, LSV
   Dulley, FL
   Macedo, MC
   Massumoto, C
   Castelli, JB
   Medeiros, RS
   Silva, RL
   Pannuti, CS
AF Machado, CM
   Boas, LSV
   Dulley, FL
   Macedo, MC
   Massumoto, C
   Castelli, JB
   Medeiros, RS
   Silva, RL
   Pannuti, CS
TI Antigenemia guided ganciclovir therapy in allogeneic BMT recipients:
   Pre-emptive or early treatment of established CMV disease?
SO BLOOD
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,DISCIPLINE HEMATOL,HEMOCTR SAO PAULO,FDN PROSANGUE,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DISCIPLINE INFECT DIS,SAO PAULO,BRAZIL.
RI Castelli, Jussara B/I-4798-2013; Dulley, Frederico Luiz/H-7063-2013
OI Castelli, Jussara B/0000-0002-8414-4161; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1996
VL 88
IS 10
SU 1
BP 1684
EP 1684
PN 1
PG 1
WC Hematology
SC Hematology
GA VT983
UT WOS:A1996VT98301684
DA 2020-12-15
ER

PT J
AU Massumoto, CM
   Machado, C
   Macedo, MCA
   Medeiros, R
   Silva, RL
   Chamone, DAF
   Dulley, F
AF Massumoto, CM
   Machado, C
   Macedo, MCA
   Medeiros, R
   Silva, RL
   Chamone, DAF
   Dulley, F
TI Fusarium sp infection in bone marrow transplantation.
SO BLOOD
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,DISCIPLINE HEMATOL,FDN PRO SANGUE,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,HEMOCTR SAO PAULO,SAO PAULO,BRAZIL.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1996
VL 88
IS 10
SU 1
BP 3779
EP 3779
PN 2
PG 1
WC Hematology
SC Hematology
GA VT986
UT WOS:A1996VT98601040
DA 2020-12-15
ER

PT J
AU Medeiros, RSS
   Soussain, C
   Ostronoff, M
   Machado, C
   Macedo, MC
   Massumoto, C
   Silva, RL
   Dzik, C
   DorjhiacLlacer, P
   Chamone, DAF
   Dulley, F
AF Medeiros, RSS
   Soussain, C
   Ostronoff, M
   Machado, C
   Macedo, MC
   Massumoto, C
   Silva, RL
   Dzik, C
   DorjhiacLlacer, P
   Chamone, DAF
   Dulley, F
TI Extension of Pneumocystis carinii prophylaxis to low grade non Hodgkin's
   lymphoma treated with fludarabine before autologous bone marrow
   transplantation (ABMT).
SO BLOOD
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,DISCIPLINE HEMATOL,SAO PAULO,BRAZIL.
   FUNDACAO PRO SANGUE,HEMATOCTR,SAO PAULO,BRAZIL.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1996
VL 88
IS 10
SU 1
BP 3780
EP 3780
PN 2
PG 1
WC Hematology
SC Hematology
GA VT986
UT WOS:A1996VT98601041
DA 2020-12-15
ER

PT J
AU Silva, RL
   Soussain, C
   Massumoto, C
   Macedo, MCA
   Medeiros, RSS
   Dzik, C
   Rocha, IF
   Silva, ACM
   Loterio, HA
   Diomede, BB
   Franca, GG
   Ostronoff, M
   Machado, CM
   DorlhiacLlacer, P
   Chamone, DAF
   Dulley, F
AF Silva, RL
   Soussain, C
   Massumoto, C
   Macedo, MCA
   Medeiros, RSS
   Dzik, C
   Rocha, IF
   Silva, ACM
   Loterio, HA
   Diomede, BB
   Franca, GG
   Ostronoff, M
   Machado, CM
   DorlhiacLlacer, P
   Chamone, DAF
   Dulley, F
TI Autologous peripheral blood stem cells transplantation (APSBcT) as an
   outpatient basis. Experience of a Brazilian center.
SO BLOOD
LA English
DT Meeting Abstract
C1 FUNDACAO PROSANGUE HEMOCTR,BMT PROGRAM,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DISCIPLINE HEMATOL,BR-05508 SAO PAULO,BRAZIL.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1996
VL 88
IS 10
SU 1
BP 3878
EP 3878
PN 2
PG 1
WC Hematology
SC Hematology
GA VT986
UT WOS:A1996VT98601139
DA 2020-12-15
ER

PT J
AU daRocha, IF
   Machado, CM
   Ostronoff, M
   Diomede, B
   Ferraz, PD
   Massumoto, C
   Macedo, MCMA
   Medeiros, RSS
   Silva, AC
   DorlhiacLlacer, PE
   Chamone, DAF
   Dulley, F
AF daRocha, IF
   Machado, CM
   Ostronoff, M
   Diomede, B
   Ferraz, PD
   Massumoto, C
   Macedo, MCMA
   Medeiros, RSS
   Silva, AC
   DorlhiacLlacer, PE
   Chamone, DAF
   Dulley, F
TI Intra lumen prophylactic aminoglycoside in Hickman catheters of bone
   marrow transplant (BMT) outpatients.
SO BLOOD
LA English
DT Meeting Abstract
C1 FUNDACO PROSANGUE HEMOCTR,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DISCIPLINE HEMATOL,BR-05508 SAO PAULO,BRAZIL.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1995
VL 86
IS 10
SU 1
BP 836
EP 836
PG 1
WC Hematology
SC Hematology
GA TH910
UT WOS:A1995TH91000837
DA 2020-12-15
ER

PT J
AU Machado, CM
   Silva, RL
   Lazzaro, J
   Ostronoff, M
   Boas, LSV
   Macedo, MCMA
   Zambon, E
   Massumoto, C
   Medeiros, R
   Pannuti, CS
   Silva, AC
   daRocha, IF
   DorlhiacLlacer, PE
   Chamone, DAF
   Dulley, F
AF Machado, CM
   Silva, RL
   Lazzaro, J
   Ostronoff, M
   Boas, LSV
   Macedo, MCMA
   Zambon, E
   Massumoto, C
   Medeiros, R
   Pannuti, CS
   Silva, AC
   daRocha, IF
   DorlhiacLlacer, PE
   Chamone, DAF
   Dulley, F
TI Radiological findings subsequent to the appearance of positive CMV
   antigenemia in BMT recipients.
SO BLOOD
LA English
DT Meeting Abstract
C1 FDN PROSANGUE HEMOCTR,DISCIPLINE HEMATOL,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,INST TROP MED,BR-05508 SAO PAULO,BRAZIL.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1995
VL 86
IS 10
SU 1
BP 846
EP 846
PG 1
WC Hematology
SC Hematology
GA TH910
UT WOS:A1995TH91000847
DA 2020-12-15
ER

PT J
AU Machado, CM
   daRocha, IF
   Diomede, B
   Ferraz, PD
   Macedo, MCMA
   Ostronoff, M
   Zambon, E
   Massumoto, C
   Medeiros, RSS
   Silva, AC
   DorlhiacLlacer, PE
   Chamone, DAF
   Dulley, F
AF Machado, CM
   daRocha, IF
   Diomede, B
   Ferraz, PD
   Macedo, MCMA
   Ostronoff, M
   Zambon, E
   Massumoto, C
   Medeiros, RSS
   Silva, AC
   DorlhiacLlacer, PE
   Chamone, DAF
   Dulley, F
TI Effectiveness of hepatitis B vaccination in bone marrow transplant
   recipients.
SO BLOOD
LA English
DT Meeting Abstract
C1 FDN PROSANGUE HEMOCTR,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DISCIPLINE HEMATOL,BR-05508 SAO PAULO,BRAZIL.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1995
VL 86
IS 10
SU 1
BP 847
EP 847
PG 1
WC Hematology
SC Hematology
GA TH910
UT WOS:A1995TH91000848
DA 2020-12-15
ER

PT J
AU Machado, CM
   Massumoto, C
   Boas, LSV
   Pannuti, CS
   Macedo, MCMA
   Ostronoff, M
   Zambon, E
   Medeiros, RSS
   daRocha, IF
   Silva, AC
   DorlhiacLlacer, PE
   Chamone, DAF
   Dulley, F
AF Machado, CM
   Massumoto, C
   Boas, LSV
   Pannuti, CS
   Macedo, MCMA
   Ostronoff, M
   Zambon, E
   Medeiros, RSS
   daRocha, IF
   Silva, AC
   DorlhiacLlacer, PE
   Chamone, DAF
   Dulley, F
TI Cytomegalovirus antigenemia in autologous bone marrow transplant
   recipients (ABMT).
SO BLOOD
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,FDN PRO SANGUE HEMOCTR,BR-05508 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DISCIPLINE HEMATOL,BR-05508 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,INST TROP MED,VIROL LAB,BR-05508 SAO PAULO,BRAZIL.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1995
VL 86
IS 10
SU 1
BP 3809
EP 3809
PG 1
WC Hematology
SC Hematology
GA TH910
UT WOS:A1995TH91003809
DA 2020-12-15
ER

PT J
AU Medeiros, RSS
   Ostronoff, M
   Machado, C
   Silva, RL
   Macedo, MCMA
   Massumoto, C
   Zambon, E
   Laterio, HA
   Racha, IF
   DorlhiacLlacer, PE
   Chamone, DAF
   Dulley, F
AF Medeiros, RSS
   Ostronoff, M
   Machado, C
   Silva, RL
   Macedo, MCMA
   Massumoto, C
   Zambon, E
   Laterio, HA
   Racha, IF
   DorlhiacLlacer, PE
   Chamone, DAF
   Dulley, F
TI Effect of prophylaxis to Toxoplasma gondii and Pneumocystis carinii
   after bone marrow transplantation (BMT).
SO BLOOD
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,DISCIPLINE HEMATOL,FDN PRO SANGUE HEMOCTR,BR-05508 SAO PAULO,BRAZIL.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1995
VL 86
IS 10
SU 1
BP 3819
EP 3819
PG 1
WC Hematology
SC Hematology
GA TH910
UT WOS:A1995TH91003819
DA 2020-12-15
ER

PT J
AU DULLEY, FL
   MACHADO, CM
   NOKUI, Y
   ZAMBON, E
   MACEDO, MCMA
   SILVA, ACM
   BOEHRINGER, B
   OSTRONOFF, M
   MASSUMOTO, C
   CHAMONE, DF
AF DULLEY, FL
   MACHADO, CM
   NOKUI, Y
   ZAMBON, E
   MACEDO, MCMA
   SILVA, ACM
   BOEHRINGER, B
   OSTRONOFF, M
   MASSUMOTO, C
   CHAMONE, DF
TI TOXOPLASMOSIS IN BONE-MARROW TRANSPLANT RECIPIENTS RELATED TO THE CHANGE
   OF PNEUMOCYSTIS-CARINII PROPHYLAXIS
SO BLOOD
LA English
DT Meeting Abstract
C1 HEMOCTR SAO PAULO,F PRO SANGUE,BMT PROGRAM,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DEPT HEMATOL,SAO PAULO,BRAZIL.
RI Dulley, Frederico Luiz/H-7063-2013
NR 0
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1994
VL 84
IS 10
SU 1
BP A334
EP A334
PG 1
WC Hematology
SC Hematology
GA PR754
UT WOS:A1994PR75401318
DA 2020-12-15
ER

PT J
AU MACEDO, MCMA
   DULLEY, FL
   OSTRONOFF, M
   MACHADO, CM
   SILVA, ACM
   MASSUMOTO, C
   BOEHRINGER, B
   ZAMBON, E
   LOTERIO, H
   DORLHIACLLACER, PE
   CHAMONE, DF
AF MACEDO, MCMA
   DULLEY, FL
   OSTRONOFF, M
   MACHADO, CM
   SILVA, ACM
   MASSUMOTO, C
   BOEHRINGER, B
   ZAMBON, E
   LOTERIO, H
   DORLHIACLLACER, PE
   CHAMONE, DF
TI GANCICLOVIR VS GANCICLOVIR PLUS GM-CSF AS PROPHYLAXIS FOR CMV INFECTION
   IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
SO BLOOD
LA English
DT Meeting Abstract
C1 SAO PAULO UNIV,DEP HEMATOL,FUNDACAO HEMOCTR,SAO PAULO,BRAZIL.
RI Dulley, Frederico Luiz/H-7063-2013
NR 0
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1994
VL 84
IS 10
SU 1
BP A713
EP A713
PG 1
WC Hematology
SC Hematology
GA PR754
UT WOS:A1994PR75402834
DA 2020-12-15
ER

PT J
AU MACHADO, CM
   OSTRONOFF, M
   SILVA, ACM
   MACEDO, MCMA
   BOEHRINGER, B
   ZAMBON, E
   NUKUI, Y
   MASSUMOTO, C
   DORLHIACLLACER, PE
   CHAMONE, DF
   DULLEY, FL
AF MACHADO, CM
   OSTRONOFF, M
   SILVA, ACM
   MACEDO, MCMA
   BOEHRINGER, B
   ZAMBON, E
   NUKUI, Y
   MASSUMOTO, C
   DORLHIACLLACER, PE
   CHAMONE, DF
   DULLEY, FL
TI PRIMARY PNEUMOCYSTIS-CARINII PROPHYLAXIS WITH AEROSOLIZED PENTAMIDINE
   AFTER BONE-MARROW TRANSPLANTATION
SO BLOOD
LA English
DT Meeting Abstract
C1 UNIV SAO PAULO,SCH MED,BMT PROGRAM,FUNDACAO PRO SANGUE,HEMOCTR SAO PAULO,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,SCH MED,DEPT HEMATOL,SAO PAULO,BRAZIL.
RI Dulley, Frederico Luiz/H-7063-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO
PI PHILADELPHIA
PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 1994
VL 84
IS 10
SU 1
BP A714
EP A714
PG 1
WC Hematology
SC Hematology
GA PR754
UT WOS:A1994PR75402835
DA 2020-12-15
ER

PT J
AU MACEDO, MCMA
   DULLEY, FL
   OSTRONOFF, M
   MACHADO, CM
   ZAMBON, E
   MATSUMOTO, C
   DORLHIACLLACCER, P
   CHAMONE, DF
AF MACEDO, MCMA
   DULLEY, FL
   OSTRONOFF, M
   MACHADO, CM
   ZAMBON, E
   MATSUMOTO, C
   DORLHIACLLACCER, P
   CHAMONE, DF
TI EFFECTIVENESS OF AMPHOTERICIN-B IN LIPID EMULSION FOR TREATING FUNGAL
   SEPTICEMIA IN GRANULOCYTOPENIC PATIENTS
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
ID PHARMACOKINETICS; TOXICITY; INVITRO
C1 UNIV SAO PAULO,SCH MED,DEPT HEMATOL & HEMOTHERAPY,SAO PAULO,BRAZIL.
RP MACEDO, MCMA (corresponding author), UNIV SAO PAULO,SCH MED,DEPT HEMATOL,BONE MARROW TRANSPLANT PROGRAM,SAO PAULO,BRAZIL.
RI Dulley, Frederico Luiz/H-7063-2013
CR CHAVANET P, 1992, PATHOL BIOL, V40, P507
   CHAVANET PY, 1992, BRIT MED J, V305, P921, DOI 10.1136/bmj.305.6859.921
   JANKNEGT R, 1992, CLIN PHARMACOKINET, V23, P279, DOI 10.2165/00003088-199223040-00004
   JULIANO RL, 1987, MOL PHARMACOL, V31, P1
   KAN VL, 1991, J INFECT DIS, V164, P418, DOI 10.1093/infdis/164.2.418
   SZOKA FC, 1987, ANTIMICROB AGENTS CH, V31, P421, DOI 10.1128/AAC.31.3.421
NR 6
TC 7
Z9 9
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD AUG
PY 1994
VL 19
IS 2
BP 366
EP 367
DI 10.1093/clinids/19.2.366
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA PB655
UT WOS:A1994PB65500041
PM 7986930
DA 2020-12-15
ER

PT J
AU MACHADO, CM
   FINK, MCD
   BOAS, LSV
   SUMITA, LM
   WEINBERG, A
   SHIGUEMATSU, K
   SOUZA, IC
   CASANOVA, LD
   PANNUTI, CS
AF MACHADO, CM
   FINK, MCD
   BOAS, LSV
   SUMITA, LM
   WEINBERG, A
   SHIGUEMATSU, K
   SOUZA, IC
   CASANOVA, LD
   PANNUTI, CS
TI CYTOMEGALOVIRUS PERINATAL INFECTION IN A PUBLIC HOSPITAL OF SAO-PAULO
   CITY - A PROSPECTIVE-STUDY
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA Portuguese
DT Article
ID VIRUS INFECTION; BREAST-MILK; FOLLOW-UP; INFANCY; EPIDEMIOLOGY;
   PNEUMONITIS
AB In order to demonstrate the occurrence of CMV perinatal infection in a middle socioeconomic class population, the authors conducted a 8-month prospective study in 37 children, not infected congenitally, born in a public hospital of Sao Paulo city, Prevalence of CMV-IgG antibodies in mothers, detected by immunoenzimatic assay (ELISA), was 92.7%. Survival analysis showed that the risk of acquiring CMV perinatal infection diagnosed by virus isolation in human fibroblasts was 30.9%. When the diagnostic method was detection of IgM class antibodies by indirect immunofluorescence the risk was 8.1% (p < 0.05). Milk samples inoculated in human fibroblasts failed to demonstrate the presence of virus. The infected children did not present any signal of disease in a 4-month follow-up.
C1 ESCOLA PAULISTA MED SCH,DEPT DOENCAS INFECCIOSAS & PARASITARIAS,BR-04023 SAO PAULO,BRAZIL.
   HOSP SERVIDOR PUBL ESTADUAL FRANCISCO MORATO OLIVEIRA,SERV NEONATOL,SAO PAULO,SP,BRAZIL.
RP MACHADO, CM (corresponding author), INST MED TROP SAO PAULO,VIROL LAB,AV DR ENEAS CARVALHO AGUIAR 470,BR-05403 SAO PAULO,SP,BRAZIL.
RI Pannuti, Claudio/B-7649-2012; Fink, Maria Cristina/M-8718-2015
CR ALFORD CA, 1985, ALA J MED SCI, V22, P169
   BERQUO ES, 1960, BIOESTATISTICA
   BOAS LSV, 1987, 23 C SOC BRAS MED TR, P115
   BRASFIELD DM, 1987, PEDIATRICS, V79, P76
   CHANDLER SH, 1985, J INFECT DIS, V152, P249, DOI 10.1093/infdis/152.2.249
   CHIANG CL, 1982, INTRO STOCHASTIC PRO
   DWORSKY M, 1983, PEDIATRICS, V72, P295
   DWORSKY M, 1982, J PEDIATR-US, V101, P440, DOI 10.1016/S0022-3476(82)80081-4
   GEHRZ RC, 1982, CLIN EXP IMMUNOL, V47, P27
   GRANSTROM ML, 1978, SCAND J INFECT DIS, V10, P257, DOI 10.3109/inf.1978.10.issue-4.01
   GRANSTROM ML, 1977, ARCH DIS CHILD, V52, P354, DOI 10.1136/adc.52.5.354
   HO M, 1978, DM-DIS MON, V24, P4
   HO M, 1982, CYTOMEGALOVIRUS BIOL, P32
   KUMAR ML, 1984, J PEDIATR-US, V104, P674, DOI 10.1016/S0022-3476(84)80942-7
   KUMAR ML, 1984, J PEDIATR-US, V104, P669, DOI 10.1016/S0022-3476(84)80941-5
   LEINIKKI P, 1978, SCAND J INFECT DIS, V10, P165, DOI 10.3109/inf.1978.10.issue-3.02
   LEVINSOHN EM, 1969, P SOC EXP BIOL MED, V132, P957, DOI 10.3181/00379727-132-34345
   MELISH ME, 1973, AM J DIS CHILD, V126, P190, DOI 10.1001/archpedi.1973.02110190168011
   MONTGOMERY R, 1970, PEDIATRICS, V49, P524
   PANNUTI CS, 1983, THESIS U SAO PAULO
   PECKHAM CS, 1987, ARCH DIS CHILD, V62, P780, DOI 10.1136/adc.62.8.780
   REYNOLDS DW, 1973, NEW ENGL J MED, V289, P1, DOI 10.1056/NEJM197307052890101
   REYNOLDS DW, 1979, DIAGNOSTIC PROCEDURE, P72
   Siegel S., 1975, ESTATISTICA NAO PARA
   STAGNO S, 1975, J INFECT DIS, V132, P568, DOI 10.1093/infdis/132.5.568
   STAGNO S, 1980, NEW ENGL J MED, V302, P1073, DOI 10.1056/NEJM198005083021908
   STAGNO S, 1977, NEW ENGL J MED, V296, P1254, DOI 10.1056/NEJM197706022962203
   STAGNO S, 1980, PEDIATRICS, V65, P251, DOI 10.1542/peds.65.2.251
   STAGNO S, 1982, Clinical Obstetrics and Gynecology, V25, P563, DOI 10.1097/00003081-198209000-00014
   STERN H, 1968, BMJ-BRIT MED J, V1, P665, DOI 10.1136/bmj.1.5593.665
   WEINBERG A, 1986, J IMMUNOL, V137, P3310
   WHITLEY RJ, 1976, J PEDIATR-US, V89, P16, DOI 10.1016/S0022-3476(76)80919-5
NR 32
TC 5
Z9 7
U1 0
U2 0
PU INST MEDICINA TROPICAL
PI SAO PAULO
PA AV DR ENEIAS C AGUIAR CAIXA POSTAL 2921, SAO PAULO, BRAZIL
SN 0036-4665
J9 REV I MED TROP
PD MAR-APR
PY 1991
VL 33
IS 2
BP 159
EP 166
DI 10.1590/S0036-46651991000200012
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FR381
UT WOS:A1991FR38100012
PM 1668902
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

EF